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1. INTRODUCTION 
Definition 
Hydrocephalus is a hydrodynamic disorder of the cerebrospinal fluid that leads to an increase in 
the volume occupied by this fluid in the central nervous system. 
Other conditions may mimic it, i.e. cerebral atrophy or focal destructive lesions, if a loss of 
cerebral tissue leaves vacant space that is passively filled with cerebrospinal fluid. These 
conditions are not the result of altered hydrodynamics and are thus excluded from the group. 
Incidence 
The worldwide incidence of hydrocephalus is unknown and varies according to the health care 
from country to country. Congenital hydrocephalus has a quoted incidence of three per one 
thousand live births. 
Approximately one hundred thousand shunts are implanted per year in developed counties. 
The incidence of hydrocephalus has a bimodal distribution curve, with one peak in infancy, related 
to the various forms of congenital malformations and another peak in adult years, mostly related to 
so-called normal pressure hydrocephalus. Adult hydrocephalus represents about forty percent of 
the total number of cases. In children the average revision rate for a valve is approximately twice 
that in adults. Thus an estimate of the number of new paediatric hydrocephalic patients treated 
each year is about twenty thousand worldwide. This figure is, happily, decreasing. 
2. CEREBROSPINAL FLUID PHYSIOLOGY 
Cerebrospinal fluid production 
Eighty percent of cerebrospinal fluid is ultra-filtered and actively secreted by the choroid plexus 
into the ventricles at the level of the non-tight junction of the capillary endothelial wall (McComb 
1983). The plexus is a very secure blood brain barrier. The fluid secretion rate is continuous and 
stable under normal conditions (twenty one millilitres per hour in adults and children). There are 
no specific data on neonates, but the plexus is relatively bigger in this age group (Welch 1975). 
Other functions of the plexus include active transportation of solutes and purification processes. 
Chronic increases in intra-cranial pressure (as occurs in hydrocephalus) reduce cerebrospinal fluid 
formation and may cause atrophy of the plexus. 
The other twenty per cent of cerebrospinal fluid is produced by the ependyma. 
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Cerebrospinal fluid flow 
From its ventricular origin, cerebrospinal fluid flows in a bi-directional manner, that is, with both 
retrograde and anterograde direction. It is pulsatile and dependent on the cardiac pulsation and 
central nervous system displacement. 
Cerebrospinal fluid resorption 
The fluid is resorbed, passively, at the arachnoid villi in the venous sinuses, depending on pressure 
gradients between subarachnoid space and the sinus. There appears to be both a vacuolar transport 
system and some lymphatic drainage responsible for this process. The resorption rate is a linear 
function of pressure above a pressure threshold that is equal to the venous sinus pressure 
(approximately five centimetres of water in the supine adult). There is also some evidence for the 
potential role of the central canal of the spinal cord in children in this resorption process. 
Intra-cranial Pressure 
Intra-cranial pressure, defined as the cerebrospinal fluid hydrostatic pressure, results from the 
active secretion of cerebrospinal fluid and the resistances that oppose its flow and passive 
resorption in the venous system. It thus represents the equilibrium point where resorption equals 
secretion and is directly related to venous sinus pressure and passively follows its variations. This 
explains the postural changes noted. In the recumbent, resting child and adult, pressures are about 
twelve centimetres of water. In the newborn and during infancy, values are less and are quoted as 
starting at two to four centimetres of water in neonates (Welch 1980). 
3. DIAGNOSIS 
The clinical picture will depend on age of patient, the nature and degree of the underlying 
pathology and the speed of onset of the hydrodynamic disturbance and the associated neurological 
and endocrine disturbances. 
Suspicion should be high in the presence of known associated conditions. 
During infancy, an abnormally rapid head growth is the most common sign (NeUhaus 1968). It 
always occurs in hydrocephalus occurring before the age of two years, irrespective of the cause. 
Macrocrania is another important sign and may be accompanied by features of raised intra-cranial 
pressure. In infants this includes a bulging anterior fontanelle, disjunction of the sutures, thin, 
shiny scalp with visible veins and the setting sun eye phenomenon. 
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Sixth and third nerve palsies may also be seen and carry the potential risk of amblyopia by . 
disturbing binocular vision 
Signs of acute intra-cranial hypertension are more frequent in older children with rigid skulls. 
Chronic intra-cranial hypertension in addition may cause developmental delays, headaches, 
memory loss and behavioural changes. Later signs include motor disturbance and endocrine 
imbalances. 
Differential diagnoses of hydrocephalus include: non-pathological big heads (familial 
macrocrania), normal rapid skull growth of the premature infant, chronic subdural causing intra-
cranial hypertension. 
Investigations: 
Transfontaneller ultrasound examination across an open anterior fontanelle can visualise 
ventricular dilation, but cannot ascertain the cause (Bejar 1980). 
Computerised tomogram (CT) scanning can illustrate the ventricular dilation, the topography and 
the concurrent dilation of the subarachnoid spaces (Albanese 1982). The total number of scans 
through the ocular globes should be limited to decrease the risk of cataract formation. 
Magnetic Resonance Imaging (MRI) Scanning is the examination of choice. It provides greater 
morphological definition. It also allows a pathophysiological approach to understanding the 
underlying hydrodynamic disorder through analysis of the cerebrospinal fluid flow (cine-phase 
contrast studies). 
Chronic intra-cranial pressure monitoring can also be done, non-invasively in infants, through the 
anterior fontanelle, or invasively in older children. 
Other investigations occasionally of use include Doppler assessment of cerebral blood flow, 
lumbar puncture and angiography. 
4. MANAGEMENT: 
If the pathology manifests before closure of the cranial sutures, the condition presents with an 
increase in intra-cranial voluine and treatment is semi-elective. When the sutures are closed, raised 
intra-cranial pressure may compromise cerebral perfusion and treatment is then urgent. 
Management is still today guided by individual neurosurgical preference. The development of 
implantable shunt devices was a major breakthrough in treatment (Nulsen 1951) but has led to a 
whole new range of problems, i.e. the management of shunt complications (McLaurin 1982). This 
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has lead to commercial competition and a wide array of implantable devices. There is also a need 
for associated forms of treatment to complement the use of implantable devices. 
Medical treatment to decrease cerebrospinal fluid volume: 
Acetazolamide and frusemide decrease cerebrospinal fluid formation and isosorbide increases its 
resorption. These agents can be used as a temporary measure whilst awaiting either the insertion 
of a shunt or the resolution of the underlying pathology. They are ineffective in the long-term 
management of hydrocephalus and may induce metabolic complications. 
External drainaee of cerebrospinal fluid: 
External drainage may be achieved by a ventricular catheter or by repeated cerebrospinal fluid 
taps performed with subcutaneous ventricular access. These are also temporary measures whilst 
awaiting the resolution of the underlying condition or the insertion of a shunt when sepsis has 
cleared. This treatment requires close observation and carries the risk of contamination. 
These measures save a significant number of patients from a permanent shunt. They also allow 
time for clearing of clot or debris in patients who will receive a shunt. 
Alternatives to shuntine: 
Alternatives exist mainly when there is an obstacle within the ventricles, including the outlet of 
the fourth (aqueductal stenosis, posterior fossa tumour, arachnoid cysts). These treatments should 
be considered first, even if they are less straightforward than simple shunt insertion. 
Treatment of underlying cause is the best therapeutic strategy. Treatment of hypervitaminosis A, 
resection of a mass, correction of a malformation etc. A promising example is the use of 
thrombolytics in cases of post haemorrhagic hydrocephalus. Urokinase instilled into the ventricles 
appears to reduce the requirement for shunt placement (Hudgins 1994). Unfortunately normal 
fluid flow is not always established due to secondary alterations and multifactorial aetiology. 
Historically some patients were "shunted" prior to receiving "aetiological treatment" to control 
intra-cranial pressures pre-op, but this practice has been abandoned since the realisation that it 
induces shunt dependency in patients who would otherwise no longer be hydrocephalic. 
Membrane fenestration is an alternative to treatment of the underlying cause. In cases of alteration 
of cerebrospinal fluid flow in the posterior fossa or aqueduct stenosis, this can establish an 
alternative route for flow toward the subarachnoid spaces (Hoffman 1981). This is usually 
performed endoscopically via a coronal burr-hole and perforations can be made by laser, 
coagulation, radiofrequency or balloon catheter techniques (Heilman 1991). 
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Shunts: 
At present seventy five percent of cases of hydrocephalus require a shunt (DiRocco 1987), the 
other twenty five percent can be managed by other means. The aim is to establish a 
communication between the cerebrospinal fluid (ventricular or lumbar) and a drainage cavity 
(peritoneum, right atrium, pleura). The choice of cavities varies with each case, depending on age, 
aetiology and previous sepsis. The peritoneal cavity is the preferred drainage site in children, 
because it enables the implantation of an important length of drainage catheter to allow for growth 
and predisposes to less severe infectious complications than does the use of the right atrium. 
The perfect shunt does not exist. Careful consideration and planning is necessary before 
committing a patient to a lifelong relationship with an imperfect device. Shunt selection is 
influenced both by attempts to prevent skin complications and by hydrodynamic requirements. 
Shunt selection is, in reality, remarkably anecdotal and may be driven by cost, personal 
experience, marketing techniques etc. 
Numerous differing shunts exist, but they can be classified, from the hydrodynamic point of view, 
into two categories. 
Shunts consist of proximal tubing, a valve system and distal tubing. Other components may be 
added. Components are made of silicone elastomer with barium impregnation, polycarbonate, 
polyethylene, polysulfone and various metals. Antibiotics may in the future be impregnated into 
the shunt matrix. A multicentre prospective trial is presently in progress in South Africa. 
The proximal tube components may vary in size, stiffness, length and shape and tip characteristics 
(flanged or not). 
The valve varies in location, profile, pressure-flow characteristics (pressure regulating, siphon 
resistive or flow regulating). 
The distal tubing is coated. A pure platinum cured silicone outer wall seems less prone to 
promoting calcification than does barium-impregnated tubing. At least twenty-five centimetres has 
to be inserted to allow for growth and to allow for lengthening procedures without adverse 
sequelae. 
The connections between elements vary in shape, mode of securing, size and material used. 
Reservoirs are rarely used today due to the risk of contamination. 
Shunt characteristics, including configuration, hydrodynamic properties and material amount to a 
compromise between ease of insertion and risk of disconnection, risk of early or late obstruction, 
expense and ease and cost of manufacture. 
The surgical technique influences the risk of contamination. Other factors include operating 
theatre "traffic", timing of surgery, number of procedures performed per day. 
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Post-operative care of patients with shunts: 
High care nursing should be considered for all small babies or any with patient with problems. 
Special care should be given to prevention of skin problems leading to shunt contamination and 
avoidance of pressure over the valve system. 
5. ANAESTHESIA FOR SHUNT INSERTION: 
Ventriculoperitoneal shunt insertion involves the positioning of an inert, silicone drain from the 
lateral ventricle to the peritoneal cavity under general anaesthesia. There are three stages; the first 
two involve incisions over scalp and abdomen for drain placement and the third is to tunnel a 
conduit for the connecting catheter from the scalp incision to the abdomen. This runs 
subcutaneously and allows the flow of cerebrospinal fluid from ventricle to the peritoneal cavity 
where the cerebrospinal fluid is absorbed 
ANAESTHESIA 
General goals for the anaesthetist 
One of the fundamental principles of providing good anaesthetic care is that the Anaesthetist 
should attempt to maintain his patient's tissue metabolism in spite of the threat posed to this by 
both the underlying pathophysiology and the clinical interventions. In order to achieve this, a 
stable physiological environment is required; in particular, tissue perfusion, oxygenation, substrate 
supply, attenuation of the stress response and temperature control are basic goals. 
It is well recognised that this clinical "Holy Grail" is not always possible, but with developing 
knowledge, improving techniques and the availability of new drugs with specific pharmacological 
profiles, the Anaesthetist is better placed to achieve these ends. 
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Specific 2oals in this scenario 
Principles of good anaesthetic practice in this particular situation include peri-operative attention 
to any associated anomalies, anaesthesia for the small child, optimisation and maintenance of 
cerebral perfusion pressure, attenuation of the stress response to minimise autonomic, 
neuroendocrine, metabolic, catabolic and immunosuppressive sequelae, and finally rapid recovery 
with no respiratory depression or interference with neurological assessment post operatively. 
Thus good anaesthetic care should include general anaesthesia, positive pressure ventilation, 
attention to cerebral perfusion, local anaesthesia to the scalp and abdominal sites and adequate 
analgesia to cover the subcutaneous tunnelling phase, without causing post-operative respiratory 
depression or delayed recovery. 
Present day practice- room for improvement 
Intra-operative pain management of the third, tunnelling, stage has, however, always been felt to 
be suboptimal. This is both because of a poor historical understanding of the nature of paediatric 
pain and because of a fear of the side effects of opioids in small children. 
Whilst analgesia is provided by infiltration with local anaesthetic and vasoconstrictor for the scalp 
and abdominal sites, subcutaneous tunnelling, which is possibly the most painful part and is 
performed towards the end of the procedure (about twenty to thirty minutes in straightforward 
cases), is performed without specific analgesia, for fear of post operative respiratory depression 
and delayed recovery. This is especially critical in the presence of a potentially depressed level of 
consciousness due to intra-cranial pathology and in sick neonates with a poorly developed 
respiratory drive. The usual practice is to briefly increase the concentration of inspired volatile 
agent. This has the inherent problem, however, of being difficult to titrate to effect, because of 
exponential wash-in and wash-out curves of both anaesthetic circuit and patient. This means 
extreme difficulty with manipulating brain isoflurane levels to coincide with isolated events. It 
may thus lead to either inadequate cover and I or unacceptable cardiovascular depression and may 
therefore compromise cerebral perfusion in a patient whose cerebral perfusion pressure is already 
at risk. 
It is also inherently inappropriate to use an anaesthetic agent when an analgesic is required. 
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Previous misconceptions about the nature of paediatric pain 
Popular dogma in the not too distant past has suggested that neonates, infants and young children 
do not feel pain, as do adults; their responses were thought to be "decorticate in nature", with little 
associated stress response. 
Aynsley-Green and Anand have both written that even small premature babies do have the 
neurophysiological and anatomical development to fed and respond to painful stimuli. Anand was 
the first to suggest that unattenuated pain and stress worsens outcome and that preventing pain and 
stress improves outcome. 
There is now overwhelming evidence to show that all of the neurophysiological components 
required for pain perception begin to develop by the seventh week of gestation and are 
significantly developed by mid gestation in the human foetus (Fitzgerald) and are functionally 
active by the time that viable preterm birth occurs. 
Fitzgerald & Gibson, in 1994, proposed that pain may be experienced by babies in a heightened 
fashion due to a lack of descending inhibition and because immature nociceptors are less specific, 
have lower thresholds and have larger receptive fields and because there is immature synaptic 
processing by small children and neonates. 
A further point to make is that metabolic stability is that much harder to achieve in the newborn 
for many reasons. These include a greater surface area to volume ratio, necessitating greater heat 
production; a larger brain to body weight .ratio, with increased obligatory glucose requirements; 
the need to maintain somatic growth; much smaller reserves of fat, carbohydrate and protein; the 
metabolic adaptation to extra-uterine life and enteral nutrition and the maturation of metabolic 
enzymes and the other chemical mechanisms controlling these systems. 
Anand has succinctly and clearly stated that hormonal and metabolic changes are greater in 
magnitude and shorter in duration in term infants than in adults undergoing similar surgery. 
Immature enzyme activity and decreased lipid stores increase tissue breakdown in preterm infants 
post operatively. 
Pain may also cause many other harmful pathophysiological changes. Endorphin release may 
cause changes in blood pressure and respiratory demands; thus energy expenditure may increase. 
Pain is also known to cause changes in regional blood flow, respiratory parameters and 
oxygenation. 
In addition, unattenuated stress predisposes to catabolism and immunocompromise. Ward showed 
both depressed circulating concentrations of lymphocytes and impaired "in vitro" lymphocyte 
function in infants and children undergoing a stress response post operatively. Shunt infection 
being a common and serious complication of the procedure and is thought to usually involve 
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bacteria that infect intra-operatively (the association between poor control of the stress response 
and shunt infection is a theoretical one and very little work has been published specifically on this 
matter.) 
Anand states that acute or chronic pain and stress in the preterm neonate may also be associated 
with a resulting prolonged period of hyperalgesia (also Andrews), with an increased incidence of 
early intraventricular haemorrhage, with ischaemic changes leading to periventricular 
leukomalacia and may in fact cause long term neurobehavioural and developmental sequelae. It 
may delay social milestones and feeding. Grunau suggests that long-term effects may include an 
increased incidence of non-specific somatic complaints later in life. 
Overall, appropriate treatment of pain can be said to be essential for humanitarian reasons, for 
attenuation of the stress response with a reduction in incidence of all the autonomic, catabolic, 
hypermetabolic, endocrine and immunosuppressive sequelae. It is also essential for optimising 
neurophysiological development, for improvement in outcome by preventing organ failure and to 
decrease cost by allowing fewer complications, earlier mobilisation and earlier discharge. 
In the case of shunt insertion in sick, young neurosurgical patients, intra-operative pain control is 
essential to provide a stable haemodynamic environment, thus minimising the risks of surges of 
blood pressure. Such uncontrolled surges in the context of immature cerebral autoregulation 
predispose to intraventricular haemorrhage with all the associated mortality and morbidity 
(Mullart, 1994) 
The above, coupled with the knowledge that the response can indeed be modified by opioid 
administration (Anand, Lancet 1987) has caused general and widespread changes in practice and 
has promoted clinical and pharmaceutical interest and research. Anand and Hickey compared 
halothane and morphine with high dose sufentanil for anaesthesia and post-operative analgesia in 
neonatal cardiac surgery. They demonstrated that high dose opioids can virtually eliminate the 
stress response and may improve post-operative recovery in the critically ill infant. 
Anand and McGrath in 1993 wrote the first edition of "Pain in Neonates". They stated that 
because of the huge improvements in the understanding of the basic sciences, they felt optimistic 
that "clinical management of pain associated with the care of newborns and young infants is at the 
threshold of dramatic change". 
Huge improvements in understanding and scientific advances in the field of neonatal analgesia 
have, however, not been matched by changes in practice, which are only really just beginning to 
occur. 
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Bush and Harkins discuss the literature that summarises the previously held and inappropriate 
principles and practice of paediatric pain relief. 
Daneers of providine inadeguate analeesia in this particular case scenario 
Thus the tunnelling phase of shunt insertion, if uncovered by adequate analgesia such as in present 
practice, may predispose to a sudden uncontrolled rise in blood pressure and because of immature 
cerebral autoregulation, intra-cranial pressure. This is in the setting of an already compromised 
cerebral perfusion pressure and can predispose the patient to intraventricular haemorrhage and 
cerebral ischaemia, as well as to the generalised effects of an unattenuated stress response, such as 
postoperative catabolism and immunocompromise. Mullart states that fluctuations in cerebral 
blood flow, cerebral blood volume and cerebral venous pressure appear to play a role in the 
development of intraventricular haemorrhage with potentially catastrophic consequences. 
Measurine Pain and Stress the very youne 
In general terms, the very young have a different experience of and response to pain. Pain is 
subjective and young children are unable to communicate their experience of it. Thus methods for 
measuring both pain and the response to analgesics must be tailored to suit the different age 
groups. The criteria used for assessing pain in the very young can be classified as behavioural, 
physiological and biochemical. 
In the awake baby, an assessment of behavioural responses can be used both clinically and for 
research purposes. These behavioural responses include facial expression, crying characteristics, 
motor responses, body position and sleep patterns. Unfortunately stress of any other origin, such 
as hunger, can also elicit these signs. 
Many different pain measurement tools have been described and all vary in their reliability, 
validity, feasibility, sensitivity and specificity. The factors influencing the choice of tool used in 
any given situation include the patient gestational age, behavioural and disease state, the 
environment, the clinician and the attending nurse and whether it is for research or clinical use. 
Experienced paediatric nurses are better at using these tools than are trainees (Manne, 1992) and 
appropriate training is required to optimise their potential. Pain measurement tools and scores 
assign a numerical value to just one of seven described dimensions and are used with other 
markers of pain in the overall approach to pain assessment. Behavioural tools are obviously of no 
use in the unconscious anaesthetized patient, so in this scenario, use is made of physiological or 
biochemical markers. 
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Physiological signs of pain and stress include changes in cardiovascular parameters, respiratory 
rate, intracranial pressure, palmar sweating, oxygenation, vagal tone and skin colour. Researchers 
disagree, however, about which, if any, markers are the best to study pain and stress. 
Lindh used neonatal heart rate and variability of rate to assess pain in a study to assess the efficacy 
ofEMLA (eutectic mixture of local anaesthetic) for venepuncture and found significant changes in 
the untreated group. 
Finke used heart rate, blood pressure and a behavioural analysis to assess post-operative pain. He 
concluded that post-operatively, at least, not only was it very difficult to attain a reliable and 
accurate cardiorespiratory assessment, but the parameters also correlated poorly with well-
established behavioural scores. 
These physiological changes also occur, to confuse the picture further, with other sources of stress, 
such as hunger or the need for handling. 
Biochemical end-points that have been used to assess pain include changes in plasma cortisol, 
catecholamines, growth hormone, endorphin, insulin and glucose. These markers generally have 
limited use clinically because of the expense and logistics of such tests but they may be useful 
research tools to assess the efficacy of new analgesic or sedation regimes. 
Duncan used plasma glucose, cortisol and adrenaline to assess the stress response in infants 
undergoing cardiac surgery and showed changes in these parameters that correlated well with 
physiological signs of stress. These changes were also shown to be attenuated with the use of high 
dose fentanyl. He showed that a balanced anaesthetic containing fentanyl twenty-five to fifty 
micrograms.kg-1 is sufficient to obtund haemodynamic responses to the pre-bypass phase of 
surgery. Higher doses of fentanyl (one hundred and one hundred and fifty micrograms. kg-1) 
offered little advantage over fifty micrograms.kg-1, and risked hypotension. 
Okur showed that significant changes in plasma cortisol and growth hormone occur in neonates 
during the first forty-eight hours post-operatively. 
Gunnar pointed out, however, that these changes in plasma cortisol are unreliable markers of 
stress, that marked changes in these levels can occur, without any evidence of stress occurring and 
in the absence of physiological markers of stress. 
Protonotariou published an article suggesting that the inflammatory cytokines are valuable 
research tools for assessing perinatal stress and early infant immunodevelopment. 
Hara suggested that plasma antioxidants and free fatty acids are good markers of neonatal 
oxidative stress 
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Quinn used changes in plasma catecholamine levels to assess stress in ventilated preterm infants. 
He found that certain modes of ventilation were associated with lower adrenaline levels and an 
improved outcome. 
Peters reviewed the literature about the use of adrenocortical axis to assess stress in term and 
preterm babies. He remarked on the conflicting evidence about the reliability and validity of 
cortisol levels as an indicator. 
Most of these biochemical markers, with the exception of the catecholamines, show a lag in their 
rise and fall following a painful event. Their time course is hours or days, thus their usefulness in 
the assessment of response to isolated moments of stress is limited. Catecholamines, however, rise 
and fall in seconds and have a half-life of about one minute. They may therefore be of more use in 
the assessment of responses to an acute painful stimulus such as subcutaneous intra-operative 
tunnelling. Such short half-lives mean, however, that great care is required in the method used to 
take and test blood samples. Important aspects of sampling and measuring catecholamines include 
the accurate timing of sample, the choice of an appropriate site for sampling, the immediate 
spinning down and separation of plasma and the immediate cooling and storage of the sample at 
-70° Celsius. Subsequent careful thawing and calibration of the liquid chromatogram is required, 
as is a skilled interpretation of the resulting chromatogram. Any flaw in the sampling, spinning, 
cooling, storage, thawing and testing of the catecholamines can lead to gross inaccuracies in the 
final analysis. 
Dangers of opioids in small children 
Postoperative drowsiness hinders early neurological assessment. In addition, postoperative 
respiratory depression may raise intra-cranial volume by causing hypercapnia or make artificial 
ventilation, with all its cerebrovascular sequelae, necessary. This is crucial in this situation where 
further disturbances in intra-cranial volumes and pressures (in those patients with closed cranial 
sutures and fontanelles) may cause critical decompensation and cerebral ischaemia. 
There has also been an understandable, if excessive, fear of the use of opioids in small children in 
the past, because of other side effects such as addiction, tolerance, withdrawal and hypotension. 
Powerful analgesia in the form of an opioid will inevitably increase the risk of post operative 
respiratory depression as all currently manufactured opioids cause a dose dependant respiratory 
depression due to their effects on the "mu2" receptors (reclassified and renamed "OP3", since 
1997) (Dhawan et al). 
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The neonate and infant are thought to be at greater risk of side effects for many different 
physiological and pharmacological reasons that will be discussed in chapter two. Premature 
babies, i.e. those born before thirty-five weeks of post conceptual age and "x-premies", i.e. babies 
of less than fifty-six weeks post conceptual age that were born prematurely, are even more at risk 
than term neonates. 
Opiates have even greater potential to cause problems if any pre-operative depression of 
consciousness exists. 
Most paediatric anaesthetists will use alternative means of analgesia wherever possible (local or 
field blocks), because of the high risk of respiratory depression that small children exhibit to 
opioid administration, but when opioids are necessary, post operative high care monitoring is 
provided. This is expensive and labour intensive as well. 
Current recommendations for the use of "traditional" opioids in children and small babies vary 
between institutions, but generally include avoiding the use of fentanyl in infants less than one 
month of age and morphine in infants less than two months (Kart) unless post operative high care 
facilities are available for respiratory monitoring and support. 
Most authorities have traditionally been more inclined to be guided by the post conceptual age, 
recommending post operative high care for all ex-preterm infants of up to fifty or even sixty 
weeks post conceptual age, that receive opioids. This age limit can increase further in the presence 
of other complicating factors. These postoperative facilities are expensive and in high demand. 
All currently available opioid agonists have similar pharmacodynamic profiles, i.e. they cause a 
dose dependent respiratory depression. This respiratory depression can be minimised by careful 
consideration of drug, dose, dose interval, mode of administration, etc. given the patient's 
individual setting. 
Remifentanil 
Remifentanil is a new opioid with a totally different pharmacokinetic profile that may prove to be 
of use, during the tunnelling phase, to provide titratable analgesia without causing prolonged 
respiratory depression. 
Remifentanil is a 4-anilidopiperidine derivative and is a selective "mu" receptor agonist with an 
analgesic potency similar to fentanyl and twenty to thirty times that of alfentanil (Glass). It does 
not significantly bind to non-opioid receptor groups. 
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Its pharmacology will be discussed fully in chapter three. The literature suggests that its closest 
rival, alfentanil, has several kinetic and dynamic differences that make it a less appropriate agent 
for analgesia of short duration in young children in this setting. 
The purpose of the study is to assess the use of remifentanil in this context and to review the 
relevant literature. 
6.0UTCOME of HYDROCEPHALUS 
Historically the prognosis has been poor, with mortality rates up to eighty percent (Y ash on 1965). 
Shunts and medical care have improved and today's figures are much better. 
The prognosis today depends on the causative lesion rather than the hydrocephalus itself (Dennis 
1981 ). The outlook for any one individual with hydrocephalus is quite variable and depends on a 
number of factors including the diagnostic category, age, associated abnormalities, complications 
and treatment (Boynton 1986). 
The psychomimetric effects of hydrocephalus are poorly understood. The most commonly 
reported clinical finding is an uneven development of cognitive function, with verbal intelligence 
higher than non-verbal. 
The "site of alteration" of the cerebrospinal fluid circulation has been reported to influence 
intellectual outcome and non-verbal intelligence. 
Prenatal hydrocephalus has a poorer prognosis. Seventy percent have an Intelligence Quotient 
lower than eighty (Tardieu 1981). 
The thickness of the cortical mantle, assessed pre-operatively, has been reported to correlate with 
prognosis (Young 1973). 
Treatments have resulted in functional recovery, without a real understanding of anatomical 
correlation. Thus the goal of normalisation of radiological images is probably too simplistic to be 
accepted (Gruber 1983). 
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1. INTRODUCTION 
During the last few decades it has become apparent that infants and children are very different 
from adults in their disposition to and response to drugs. Adult studies always precede studies on 
the young. These studies on children are then often slow or incomplete: ethical considerations and 
a lack of micromethods for drug analyses hinder detailed trials in small children. Developmental 
neurophysiological and neuroanatomical studies are only starting to understand basic concepts 
such as opioid receptor development. 
Opioid analgesics are the gold standard for pain relief for neonates, infants and children as well as 
adults, although much may be achieved by the use of regional analgesic techniques. The young 
individual, however, appears to be even more at risk from the most serious side effect of opioids, 
respiratory depression. 
2. OPIOID PHYSIOLOGY: 
The opioid analgesics act on receptor sites and effector mechanisms usually acted on by a family 
of neurohormones known as the endogenous opioids. Here is a classification table of these 
endogenous opioids: 
Precursor polypeptides 
1. Proenkephalin A .................... . 
2. Proopimelanocortin (POMC) ........... . 
Endogenous opioids 
Metenkephalin (Enkephalin group) 
gammaMSH 
ACTH 
betaLPH ... beta endorphin 
betaMSH 
3. Prodynorphin ....................................... Dynorphin A (1-17). Dynorphin A 
Dynorphin B 
Neoendorphin 
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Function of the endo2enous opioid peptides: 
These opioid peptides are widely distributed in the central nervous system. They are involved in 
many different, sometimes overlapping control systems including those modulating pain, affective 
behaviour, motor control, autonomic nervous system modulation and neuroendocrine function. 
They are also found in the adrenal medulla and in certain exocrine glands. It is now widely 
believed that in addition to the above peptides, morphine and codeine also occur naturally 
(Lambert). 
Physioloa of receptors 
Receptors have traditionally been classified into Mu, Kappa and Delta types, all with subclasses, 
with differing selectivity profiles, pharmacological profiles and distributions in the body. Drugs 
acting on them may be "receptor- selective" at one dose but may affect additional receptors at 
higher doses. The receptors have, however, been renamed by the "IUPHAR", the International 
Union ofPharmacologists, as OP1 (delta), OP2 (kappa) and OP3 (mu) in 1997 (Dhawan). 
The mu receptor is the most important receptor clinically. Both beta-endorphin and enkephalin 
have a very high affinity for the mu receptor and morphine may also be a natural ligand. The 
receptor can be irreversibly blocked by beta funaltrexamine. 'Mu1' receptors are located 
supraspinally and modulate analgesia, respiratory depression, mioisis, euphoria, dependence, 
drowsiness and gastrointestinal effects. 'Mu2' receptors are located spinally and modulate spinal 
analgesia, respiratory depression and gastrointestinal effects. 
Kappa receptors can be subdivided into kappa 1, 2 and 3. Dynorphin A acts on kappa 1 receptors 
as a natural ligand. Kappa 1 receptor group subdivisions include both spinal (modulating 
analgesia) and supraspinal (modulating neuroendocrine function). Kappa 2 receptors have been 
proposed, but as yet remain unidentified and Kappa 3 receptors are supraspinal and modulate 
analgesia. 
Kappa receptor activation may produce analgesia and dysphoria. It also causes less respiratory 
depression and less mioisis than mu receptor activation. 
Encephalins act as the natural ligand of delta receptors, which may be spinal and supraspinal 
Sigma receptors have been described. If they do exist, their actions are unclear as yet. 
Structurally the receptor walls contain seven trans-membrane spanning regions, with intracellular 
loops connecting with inhibitory "G" proteins for signal processing. Extracellular loops contain 
unique ligand binding domains. 
The receptor effector mechanism acts by three different intracellular processes. Firstly, activation 
of membrane or cytosolic enzyme systems including: adenylate cyclase (leading to decreased 
cyclic adenine monophosphate production), phospholipase A2 (leading to the production of 12 
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lipoxygenase metabolites) and neuronal nitric oxide synthetase (leading to increased nitric oxide 
synthesis). Secondly activation of receptor operated potassium channels and thirdly suppression 
of voltage gated calcium channels 
The above cellular processes all then cause an increased depolarisation threshold for the neurone, 
a shorter duration of action potential and a reduced release of neurotransmitters (especially 
substance P and glutamate). 
Stimulatory effects of opioids may be due to either disinhibition or second messenger release via 
the release of adenosine and dopamine (these processes involve adenyl cyclase, phosphinositide 
hydrolysis and calcium increases). 
3. OPIOID PHARMACOLOGY 
Opioids may be classified by four different classification systems. Firstly by mode of synthesis, 
i.e. synthetic, semi-synthetic or synthetic. Secondly by their chemical structure, i.e. morphinans, 
phenypiperidines, methadones, etc. Thirdly, by receptor activity, i.e. mu, delta, kappa. Fourthly by 
pharmacological action, i.e. agonist, antagonist or mixed actions. 
Opioid Pharmacodynamics - <Mainly Mu Effects) 
Opioid analgesia is selective in nature (i.e. the other sensory modalities remain intact); it has a 
psychological component and is best used for dull, visceral pain (it is less effective for bone pain, 
biliary pain or neuropathic pain). 
Mul receptors involved in analgesia exist at many sites, i.e. the terminals of primary afferents 
where they may cause inhibition of neurotransmitter release (including substance P). Mul 
receptors are also involved with postsynaptic inhibition of substance P in interneurones. They 
exist in the dorsal horn, they cause inhibition of the spinothalamic tract output, they exist in the 
periaqueductal grey in the medulla, in the nucleus raphe magnus, the locus coeruleus, they can 
cause enhanced activity of descending bulbospinal pathways and are active in undefined other 
supraspinal sites. 
Opioid euphoria is caused by the activation of dopaminergic neurones in the ventral tegmentum 
(kappa stimulation, however, inhibits the release of dopamine) 
Opioid sedation is caused by the activation of the locus coeruleus. 
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Opioid respiratory depression (mu2) is due to a direct effect on the brainstem respiratory centre; it 
occurs early (maximum effect occurs between five to ten minutes post intravenous injection or 
thirty to ninety minutes post intramuscular injection); it can last up to five hours. It decreases 
respiratory rate more than tidal volume and is responsible for almost all opiate related deaths. It 
occurs faster with the more lipid soluble agents and characteristically, patients will breathe if 
instructed to ("Ondine's curse"). The hypoxic drive remains intact but there is a decreased carbon 
dioxide responsiveness (this is, however, less profound with kappa agonists or with certain mixed 
agonist or antagonists). 
Opioid effects on the cardiovascular system are multiple. Orthostatic hypotension occurs due to an 
increase in venous pooling and to a decrease in the systemic vascular resistance and to an 
inhibition of the baroreceptor reflex with a centrally mediated sympatholysis (via the 
paraventricular nucleus of the hypothalamus). This effect occurs less with fentanyl and sufentanil. 
It is also mediated by histamine release. In addition, vagotonia is mediated via opioid receptors in 
the vagal nucleii. Deceased oxygen consumption, left ventricular end diastolic pressure and 
cardiac work result from the above. Cerebral circulation is indirectly affected by an increase in 
arterial carbon dioxide. 
Neuroendocrine effects are due to actions on the hypothalamus. These include a resetting of the 
central thermostat (which may lead to a decreased core temperature) and an inhibition of the 
release of gonadotrophin releasing hormone, corticotrophin release factor, etc. It also includes an 
increase in prolactin secretion and finally kappa agonists inhibit antidiuretic hormone. 
Ocular effects include miosis. This is caused by both mu and kappa effects, via excitation of the 
parasympathetic nervous system. It is subject to tolerance and is associated with an increased 
accommodative power and a decreased intraocular pressure. 
Excitatory effects by opioids on the central nervous system effects include convulsions. This may 
be caused by an inhibition of gamma amino butyric acid, causing excitation of hippocampal 
pyramidal cells. It may be reversed by naloxone. 
Cough suppression is caused by a direct effect on the medullary cough centre and is unrelated to 
opioid respiratory depressant effects. 
Opioids have an effect on the gastrointestinal system. Nausea and vomiting are caused by a direct 
stimulation of the chemoreceptor trigger zone. It is uncommon in the recumbent patient, but 
occurs in up to forty percent of ambulatory patients (fifteen percent actually vomit). Other 
gastrointestinal effects include achlorhydria, decreased gastric motility, increased antral tone, 
prolonged small bowel transit with decreased small bowel secretions, delayed absorption, 
increased resting intramural and intraluminal tone, periodic spasms, an increased amplitude of non 
-propulsive spasms and an increased absorption of water, with drying of faeces. Increased anal 
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sphincter tone, a decreased reflex relaxation and an inattention to normal sensory stimuli can lead 
to constipation. 
Opioid related contraction of sphincter of Oddi can cause an increased pressure in the common 
bile duct for between fifteen minutes and two hours. Either trinitrate or naloxone can reverse this. 
Opioids may cause tone and amplitude of ureteric contractions to increase. This may be 
overridden, however, by opioid effects on anti diuretic hormone). 
Opioids may cause inhibition of the bladder voiding reflex, an increase of external sphincter tone 
and an increase in bladder volume. 
Opioids may decrease the tone and frequency of contractions of the uterus. 
Opioids may cause dilation of cutaneous vessels (especially in the upper body), sweating, pruritus 
and urticaria. 
Opioids may cause inhibition of lymphocyte rosette formation. Beta-endorphin effects may be 
chemotactic; they may increase precursor cells and may increase the cytotoxic activity of 
monocytes. Certain immune cells produce "pro-opio melanocortin" and pro-enkephalin. The 
possibility of a new "epsilon" receptor responsible for these immunological phenomena has been 
postulated. 
Opioid induced muscular rigidity is thought to be due to activation of spinal pathways. 
Tolerance to the effects of opioids can be classified as: innate (genetic), pharmacokinetic (changes 
in distribution or metabolism), pharmacodynamic (receptor density changes) or learned 
(behavioural). All opioids, it is said, can be discontinued without withdrawal, given an appropriate 
weaning programme. Proposed mechanisms for the development of tolerance are an increased 
coupling of opioid receptors to stimulatory G proteins (Gs), an activation of "NMDA" receptors 
via protein kinase C and calmodulin dependant increases of cytosolic calcium. NMDA agonists 
and inhibitors prevent development of tolerance to morphine; glutamate, glycine and nitric oxide 
appear to be involved in this process. Tolerance does not involve the same pathways as pain; thus 
there is the potential for development of new agents that cause analgesia without inducing 
tolerance. Tolerance, physical dependence and the potential for withdrawal syndromes are closely 
linked. Norton wrote that in neonates withdrawal is called the" opioid abstinence syndrome" and 
is characterised by irritability, restlessness, insomnia, muscle twitches, and movement disorders. 
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Opioid Pharmacokinetics 
Opioids may be readily absorbed through gastrointestinal tract (including the rectum); lipid 
soluble agents are readily absorbed nasally, buccally and transdermally. First pass metabolism is 
responsible for a significantly decreased bioavailability of orally administered opioid. Opioids are 
also absorbed subcutaneously and intramuscularly. 
Distribution has been described by a hi-exponential function composed of a rapid initial 
distribution phase followed by a more slow elimination phase. However some authors suggest a 
tri-exponential model. Morphine is one-third protein bound. There is a decreased volume of 
· distribution in the elderly. Tissue concentration of morphine is low twenty-four hours post 
administration. Blood brain barrier passage depends on lipid solubility. Epidural administration 
may cause twelve to twenty fom hours of analgesia (rostral spread of opioid in the cerebrospinal 
fluid can lead to respiratory depression. This is less of a feature with lipid soluble agents). 
The main metabolic product from liver metabolism is morphine 6 glucuronide ("M6G" is twice as 
potent as morphine systemically and one hundred times as potent spinally). The elimination half-
life of morphine is two hours (morphine 6 glucuronide's half-life is longer). Morphine 3 
glucuronide is an intermediate, inactive product and sulphation of morphine also occurs to a 
limited extent, possibly more so in children. 
Morphine is excreted by the kidney, as "morphine 6 glucuronide". 
4. OTHER RECENT DEVELOPMENTS IN THE LITERATURE: 
Opioids have been much discussed in the literature recently. Quite apart from reviews of 
remifentanil's pharmacology and predictions of its clinical applications, several other issues 
related to opioids have been published. 
In 1992, Evans reported the possible existence of the delta receptor. 
The evidence for the existence of mu receptor subtypes mul and mu2 has been through 
pharmacological studies (mul modulating analgesia and mu2 respiratory depression). This theory 
is not as yet supported by any cloning studies. Thus the possibility of a mechanism such as "post 
receptor translation" of the two sub functions has recently been postulated (Lambert 1998). 
Standifer, using antisense oligonucleotide technology, proposed the existence of a morphine 6 
glucuronide receptor. 
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Henderson has identified a new receptor - transmitter system, the "orphan opioid receptor I 
orpanin fq", which, it is proposed, is bound by the endogenous peptide nociceptin. It is not bound 
by conventional opioids; nocistatin may reverse its effects. It has a fifty percent homology to other 
opioid receptors. It is called "ORLl" (opioid receptor like) and it mediates analgesia and other 
opioid effects (Darland). 
Zadina and Hackler discovered the endomorphin peptides 1 and 2 in 1997. It appears that they 
possess a similar mode of action to the other opioids (calcium entry, cAMP (cyclic adenosine 
monophosphate) effects) and their clinical significance is presently being investigated. 
Research has produced new drugs such as the plasma esterase metabolised remifentanil (see 
Chapter 3) and the peripherally acting opioid antagonists such as methylnaltrexone (Foss). 
Novel routes of opioid administration have been much written about. Intranasal administration can 
be used for lipid soluble agents, which are well absorbed by this route. It has the advantage of 
avoiding first pass metabolism First pass metabolism is the metabolism of enterally administered 
substances by the liver before their release into the systemic circulation and can account for a 
significantly decreased bioavailability of that substance at it's target site. Formulations include 
powdered, dissolved and aerosol forms. Uses include premedication, postoperative analgesia and 
trauma unit analgesia. It is as effective as intravenous administration for severe postoperative pain 
but side effects include a bitter taste and nasal irritation. It is thought, however, not to be as 
satisfactory a mode of administration as patient controlled analgesia. Inhalational administration 
may stimulate opioid receptors in the lung. It is thought to decrease the sense of dyspnoea in 
chronic obstructive pulmonary disease and is good for palliative care. Side effects include a bitter 
taste, nasal pruritis and there may be significant individual variability in absorption. The electrical 
encouragement of transdermal absorption is termed iontophoresis. After deposition of drug at the 
electrode of the same charge a current then promotes passage to superficial and deep tissues. The 
passage across the skin depends on drug, the electrode and the current characteristics. Fentanyl has 
been administered by this route. It is a faster and more controllable mode than transdermal alone 
but it requires equipment and supervision. Peripheral opioid receptors respond to intra-articularly 
administered opioid and this may be put to use post-arthroscopy. 
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5. EFFECTS OF DISEASE STATES ON MORPHINE ACTIONS 
The pharmacology of opioids may be influenced by the clinical state of the child; severe illness 
may influence the pattern of opioid receptors and also their affinity for morphine. 
In renal failure, morphine 6 glucuronide accumulates leading to prolonged action. 
In head injury, additional increased intracranial pressure due to hypercarbia may exacerbate the 
problem by causing an increased intracerebral blood volume. Neurological observations may also 
be misleading due to sedation and miosis. 
In asthma, cough reflexes may be inhibited, secretions dried, histamine released and respiratory 
depression may occur. 
In hypovolaemia and shock states, hypotension may occur due to the multiple cardiovascular 
effects, as outlined above. 
Interactions with other drugs may occur, i.e. phenothiazines, monoamine oxidase inhibitors, 
tricyclics, (additive depressant effect, hypotension, respiratory depression) and amphetamines 
(euphoria, analgesia). 
In liver disease, the effects of the drug may be increased due to underlying changes in liver blood 
flow, enzyme activity and protein binding. Cirrhosis itself involves cardiovascular changes such as 
arteriovenous shunts, plasma volume increases, cardiac output increases, peripheral pooling of 
blood and nutritional changes such as hypoalbuminaemia. Hepatitis by itself causes enzyme 
activity changes. 
6. THERAPEUTIC USES OF OPIOIDS 
Opioids main clinical use is for analgesia. It is particularly suited for the relief of moderate to 
severe, visceral pain 
Sub-analgesic doses of opioids can be used for cough suppression. 
Opioid effects on gastrointestinal secretions and motility mean that they are useful for the 
management of diaorrhea, problematic ileostomy drainage and dysentery. 
Opioid's effects on the systemic vascular resistance, the venous tone, oxygen consumption and 
psychological affect make it useful in the management of left ventricular failure 
Opioid's dampening of systemic responses to pain, together with the cardiovascular stability 
associated with their administration makes them a useful agent for anaesthesia. 
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7. PHARMACOLOGY OF MORPHINE IN THE VERY YOUNG 
Kinetics 
Studies suggest that a large interindividual variability exists, up to ten-fold (Chay and Duffy) in 
the kinetics of morphine in neonates. 
Oral absorption is dependent on the gastric pH and the gastric emptying time. At birth the gastric 
pH is neutral because of the presence of alkaline amniotic fluids. At day 1 it falls to a pH of 1-3, 
but this is poorly maintained, until 3 years of age, when the gastric mucosa and the acid producing 
mechanisms mature. This means that both acid labile and acidic drugs are absorbed more and 
alkaline drugs absorbed less in the small infant. Gastric emptying is "slow and linear" in infants 
less than six months of age, compared to "fast and exponential" in the adult. 
Intramuscular absorption of drug is less predictable in neonates due to vasomotor instability, a 
smaller muscular mass, less subcutaneous fat and a higher proportion of body water than adults. 
Transdermal absorption depends on the epidermal stratum corneum thickness and the state of skin 
hydration. These factors cause transdermal absorption of opioids to be unpredictable in small 
infants. 
The distribution of opioid administered to the newborn varies to that seen in the adult or older 
child. Protein binding is lower, due to lower albumen and alpha 1 glycoprotein levels, lower 
affinity of foetal albumen for drugs and competition for binding sites (i.e. by bilirubin). About 
eighty percent of the drug is unbound to plasma proteins. Body water is seventy five percent of 
neonatal body weight, versus sixty percent in the adult, with a larger extracellular component 
(forty versus twenty percent). There is less fat (fifteen versus twenty percent) and less muscle 
(twenty five percent) than in the adult. Thus drug volumes of distribution tend to be higher in the 
neonate. Greene suggests that the cerebrospinal fluid morphine concentration is approximately 
equivalent to the concentration of unbound morphine in plasma. This may cause a significant 
increase in the "free" morphine that is then able to penetrate the brain. This may explain the 
observation made by Way of increased brain levels of morphine in the newborn and morphine's 
more profound respiratory depressant effects. Glare, however, feels that this may be of limited 
clinical significance, as the percentage protein binding in preterm, term neonates and infants 
(twenty percent) may not be much different to adults (twenty to thirty five percent) that 
discrepancies in free morphine plasma concentration is too small, given the individual variation in 
morphine kinetics. Gulati showed that the cerebrospinal fluid to plasma ratio of morphine is 
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substantially higher in preterm infants than full term babies. This probably reflects immaturity of 
the blood brain barrier. 
The neonatal brain's blood supply represents approximately thirty four percent of the cardiac 
output, compared with only fifteen percent for the adult brain, thus a greater proportion of 
systemically administered opioid will be rapidly delivered to the neonatal brain. There is evidence 
of an increased choroid plexus relative size and an increased choroidal delivery of and transport of 
opioids into the fourth ventricle and associated respiratory centre (immature blood brain barrier). 
Hepatic metabolism is present but much less developed and slower in the neonate. In addition to 
the decreased enzymatic activity, the neonatal liver blood flow is reduced, further decreasing 
metabolism. Phase 1 and phase 2 reactions show differing maturation profiles. Many of the 
metabolic reactions are catalysed in the liver by microsomal mixed function oxidases that require 
the cytochrome P450 system, nicotinamide adenine dinucleotide (NADPH) and oxygen. The 
cytochrome system is very immature at birth and does not reach adult levels until the first month 
or two of life. However, the P450 system can be induced by various drugs and substrates and 
matures even in babies of very low gestational age. Pharmacokinetic data from different studies 
varies somewhat but is consistent in its demonstration of changes with age. Koren found that the 
half-life of morphine in neonates was fourteen hours and terminal half-life· was twenty-five hours. 
The corresponding values in older children and adults are two hours only for both half-lives. Lynn, 
however, found morphine elimination half-life values of seven hours in the neonate and four hours 
in older infants. Clearance values were calculated at six and twenty four ml I min I kg respectively. 
These findings are consistent with immaturity of hepatic conjugation of morphine in the newborn. 
Higher plasma and tissue opioid concentrations thus result in the newborn for a given dose or 
infusion rate, so particular care is required with their clinical use. 
Metabolism is even less developed in the premature baby. Kart states that the majority of preterm 
neonates are capable of glucuronidating morphine and that birth weight, gestational and postnatal 
ages influence the glucuronidation capability. He states that the volume of distribution is unrelated 
to age at 2.8 1 I kg at all ages, but that half-life and clearance are age-dependant. Bhat et al showed 
that preterm neonates have longer elimination half-lives than older neonates (ten versus 6.7 hours) 
and have a delayed clearance of morphine (3.4 vs. 15.5ml I kg I hr). Barret states that half-life is 
dependent on gestational age; whereas Lynn feels postnatal age is the more relevant and 
determines how premature and full term infants metabolise drugs. Differing ideas exist on the age 
at which infant metabolism approaches that of adults, opinions varying from two to six months 
after birth. 
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As an additional explanation for this increased half-life, some studies suggest that premature 
neonates may be able to conjugate morphine to morphine 3 glucuronide more easily than to 
morphine 6 glucuronide, whereas term babies can do both as readily. The prol~nged action of a 
single dose of morphine in the neonate is probably explained purely on its limited metabolic 
capacity, rather than the production of high levels of active metabolite (M6G I Morphine ratios are 
lower in neonates than in older children). This lower metabolic capacity thus leads to a lower 
elimination rate. Other studies, however, contradict this and state that the ratio of M6G I M3G 
increases with decreasing birth weight, indicating that the formation of M6G, the active analgesic 
metabolite, increases with decreasing birth weight (McRorie). Another feature peculiar to 
premature babies is their use of sulphation as an alternative metabolic pathway. This route 
subsequently diminishes later in life. A further consideration is that neonates may also perform 
desulphation and deglucuronidation processes faster than the sulphation and glucuronidation 
processes themselves. Also, glucuronidation may occur in the neonatal intestine or kidney. 
Terminal elimination half-lives may be much longer in all groups (up to twenty five hours in older 
children) due to both redistribution from the peripheral tissue to the plasma and the enterohepatic 
circulation. When morphine is continuously infused, plasma concentrations are three times greater 
and elimination half-lives seven times longer in neonates than older patients. In addition, 
enterohepatic circulation may cause a further rise in plasma levels even after the infusion has been 
stopped. 
The preterm infant has fewer glomeruli than the term neonate, who has "adult" numbers. At birth, 
the glomerular filtration rate and the tubular secretion processes are reduced. Maturation processes 
are complex and take six to twelve months for various renal functions to reach adult values. It 
seems that renal excretion of unchanged morphine occurs more in neonates than in adults (fifteen 
versus ten percent). As renal function develops rapidly during the first few days of life, postnatal 
age may be the important factor determining the excretion of unchanged morphine and 
metabolites. 
It is clear that some neonates even from the age of two weeks have a morphine half-life 
resembling adult morphine half-life, while others do not reach adult values before the age of two 
months. Other studies have found that clearance reaches adult values of twenty ml I min I kg also 
by the age of two months. Hence it seems reasonable, states Kart, to assume that pharmacok.inetic 
data is comparable to adult values by the age of two months post delivery, bearing in mind in 
some babies this state is achieved after as little as two weeks. 
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Dynamics 
Kart has stated that no dose response curve for morphine analgesia in neonates, infants or children 
has been established. Various workers including the Cape Town surgical team of Millar, Rode and 
Cywes have quoted different figures for the minimum effective plasma concentration. This is due 
not only to different sensitivities towards morphine in neonates, infants and children, but also to 
variations in pain perceptions as well. Differing sensitivity to morphine may be different because 
of differing opioid receptor occurrence, distribution, location or affinity for morphine. Another 
problem with defining an effective plasma concentration is that the measured plasma 
concentration may not be directly related to the concentration at the receptor site and local 
concentrations at the receptor site could vary without any detectable variations in plasma. The 
immature blood brain barrier of neonates and infants might also influence the distribution and 
effect of morphine. 
Morphine depresses the carbon dioxide responsiveness curve more in neonates than in adults. It is 
more of a respiratory depressant than pethidine due to its greater solubility in the central nervous 
system. It is thought that the neonatal nervous system has altered numbers and an increased ratio 
of mu2 to mul opioid receptors, both centrally and peripherally, thus favouring respiratory 
depression over analgesia as a response to a given dose of opioid. Thus higher concentrations of 
opioids may be required to provide analgesia to neonates. In neonatal rats there is a good 
correlation between the number of high affinity mul receptors and pain relief and the number of 
low affinity mu2 receptors and respiratory depression. Rats that are two days old have fewer high 
affinity binding sites than adult rats and are less sensitive to morphine's analgesic effects, despite 
having higher brain concentrations of the opioid, while showing a similar degree of respiratory 
depression. 
Anand and Hickey (1987), however, are unconvinced by this theory of increased sensitivity to the 
side effects of opioids and Tyler also disputes the commonly held view that neonates have an 
increased sensitivity to the respiratory depressant effects of opioids. Kart also feels that neonates 
are not more susceptible to respiratory depression than older children. Kart concludes that despite 
shortcomings in our knowledge of the pharmacokinetics of morphine, it can be considered safe to 
administer it to neonates, infants and children, adjusting the initial regimens according to the 
analgesic effect and the incidence of side effects. Moorse states that respiratory depression is 
rarely a clinical problem in term babies taken off the ventilator one hour after stopping a morphine 
infusion. If it does occur, naloxone can be administered. If it should occur in a preterm baby, 
respiratory support should be continued rather than risk the use of naloxone, which may cause a 
massive rebound stress response. 
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Other effects 
Hypotension may occur in dehydrated babies. Histamine release may occur, causing hypotension, 
bradycardia and flushing. Children with chronic lung disease may be at risk of the effects of 
airway narrowing. 
Gastrointestinal motility is decreased and abdominal distension. Consequently feeding may be 
compromised. 
Neonates who have become tolerant to opioids may need weaning off their regimes gradually to 
avoid withdrawal syndromes. These syndromes may manifest as irritability, restlessness, muscle 
twitches and movement disorders. Withdrawal may occur after as little as 48 hours of morphine 
infusion, but _is rarely a clinical problem when managed appropriately. 
Neuraxially administered morphine is reported to cause nausea or vomiting in up to 46 percent of 
children, urinary retention in up to 30 percent, pruritus in up to 57 percent and respiratory 
depression in up to 25 percent. 
Lynn and Nespeca found that a plasma level of 20 nanograms I ml, at steady state, was the 
threshold above which most children aged 2 - 570 days developed respiratory depression (using 
strict criteria for the diagnosis of respiratory depression). In this particular study the susceptibility 
to respiratory depression was found to occur at equal morphine concentrations in neonates, infants 
and children. Nichols also found, in a concurrent study, that the tendency to respiratory depression 
following intrathecal administration of morphine was the same for all children, regardless of age, 
aged four months to fifteen years. He found that respiratory depression was maximum at six hours, 
but still present at eighteen hours. Attia found similar results for epidurally administered 
morphine, at a dose of0.05 mg I kg, with signs of respiratory depression still present at 22 hours. 
Kart concludes that respiratory depression can occur hours after administration, by any route, of 
morphine but severe respiratory depression needing treatment is rarely described (he quotes one 
case only of fatality- Gourlay- following morphine use). This indicates that awareness of the risk 
and proper monitoring of respiratory parameters can prevent lethal situations. 
Glenski found an increased frequency of side effects but no increase in duration of action if the 
epidural dose was above 0.1 mg I kg. Other workers have found a decreased duration of action 
with doses less than this, but with no reduction in incidence of side effects. 
What are the acute or long-term effects of the administration of opioids on the developing nervous 
system? This is especially relevant now with the increasing tendency to use powerful opioids 
routinely, often for long periods, in the neonatal intensive care unit. Zadina in animal studies on 
rats showed that administration of beta-endorphin and morphine during the perinatal period results 
in increased sensitivity to thermal pain that can endure until adulthood. Thus it is not possible to 
be entirely confident that current empirical practice is without major adverse consequences on 
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normal neurophysiological development. Anand (1998) has also stressed the clinical and 
physiological consequences of opiate use on the developing neural system. It is certainly felt that 
excessive use of opiates sometimes occurs, particularly in the United Kingdom, creating a whole 
new set of problems. 
8. THE PHARMACOLOGY AND USE OF OTHER OPIOIDS IN THE VERY YOUNG 
Many compounds are similar pharmacologically to morphine. None are superior in terms of 
analgesic effect. Patients all have individual responses to individual compounds. 
Kinetic studies for pethidine are incomplete but it has been suggested that during the first two days 
of life more pethidine than norpethidine is excreted; by three days of age, the reverse is true, 
indicating rapid activation of the enzymes responsible for pethidine metabolism after birth. 
Pasternack showed that pethidine causes less respiratory depression than morphine or fentanyl as 
it penetrates the neonatal blood brain barrier less, but it is rarely used in this age group as it causes 
greater sedation and it's metabolite norpethidine has the potential to cause delayed respiratory 
depression. Pethidine does, however, have the ability to prevent or stop post-operative shivering in 
the older child. 
The pharmacokinetics of methadone in children are indistinguishable from adults with an 
elimination half-life of 19 hours and a clearance of 5.4 ml I min I kg. Methadone has been used as 
an analgesic only relatively recently. A high plasma level can be achieved from a single 
intravenous dose. This may prove to be a convenient way of providing prolonged analgesia. 
Indeed some have recommended it as an alternative to the use of continuous opioid infusions (a 
"poor mans" patient controlled analgesia). 
Little literature exists on codeine's kinetics in children, per se. Codeine is a useful analgesic and 
antitussive in children. In equipotent doses, codeine's effectiveness as a respiratory depressant and 
analgesic approaches that of morphine. It also shares a similar side effect profile. Codeine should 
never be administered intravenously; serious complications such as cardiovascular collapse due to 
histamine release have been reported. 
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The fentanyls are highly bound to alpha 1 acid glycoproteins in the plasma, which are reduced in 
the newborn (Singleton). The kinetics of fentanyl appears to be similar in premature and term 
babies. In neonates, the plasma fentanyl concentration is lower, the volume of distribution is 
larger, the elimination half-life is longer, total body clearance greater than in older children and 
adults, both initially after a bolus and at steady state during an infusion. This T1 I 2 value ranges 
from 6 to 32 hours (compared to the 2 to 3 hours in the older child). These kinetic values vary 
between individuals, however, especially in the newborn. Late rebounds in plasma levels may 
reflect drug release from adipose stores. The prolonged elimination half-life has important clinical 
implications; i.e. repeated doses will cause accumulation of analgesic and respiratory depressant 
effects. However the greater clearance may produce lower plasma concentrations and allow 
tolerance of more drug without respiratory depression. Context-sensitive half-time, the time taken 
for a drug concentration at it's target site to fall to one half after cessation of it's administration - is 
dependant on many factors pertaining to both patient and dose administration. More than 90 
percent of the drug is metabolised by the liver. Increased intra-abdominal pressure, as commonly 
occurs in neonates, can triple the elimination half-life, by reducing liver blood flow. Plasma 
clearance is slower in the first week of life. Clinically its action is short lived so must be 
administered by frequent intermittent boluses or by continuous infusion. 
Fentanyl has a high therapeutic index and is effective at dampening stress responses at low doses. 
It is also excellent at blocking nociceptive stimuli with concomitant haemodynamic stability 
(Anand 1987) and is used in high doses for cardiac anaesthesia. Hickey showed that fentanyl 
blocks increases in pulmonary vascular resistance in stressed normoxic neonates, hence its use by 
continuous infusion in neonates with pulmonary hypertension requiring extracorporeal membrane 
oxygenation. It significantly reduces baroreceptor responses of neonates without affecting heart 
rate or blood pressure. Baroresponse slopes are reduced and shifted to the left, suggesting that 
fentanyl affects the central nervous system without altering the ratio of parasympathetic to 
sympathetic tone. It causes significant chest wall rigidity in children. This is due to effects on 
stimulatory pathways in the spinal cord. It occurs more in the full term than in the premature 
neonate. This can be overcome by the concomitant use of relaxants, by infusing the drug slowly or 
by using bolus doses of no more than 3 micrograms I kg. Hypotension may occur in dehydrated 
babies. Respiratory depression is significant. Tolerance develops after long-term administration, 
more rapidly than tolerance to morphine. Physical dependence is a risk particularly in newborns 
given very high dose fentanyl infusions following repair of congenital heart disease (Arnold 
1991). 
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Sufentanil is commonly used for neonatal cardiac surgery. It is ten times as potent as fentanyl. 
Greeley showed that as with other opioids, sufentanil is more rapidly metabolised and eliminated 
in 2 to 3 week old neonates than in neonates less than 1 week of age. This metabolism is by 
0 - demethylation and N - dealkylation. The volume of distribution is only half the value in 
infants as in adults. A shorter elimination half-life shortens the duration of anaesthesia. Henderson 
states that it can be administered intranasally in doses of 1.5 to 3.0 micrograms I kg and produce 
effective analgesia and sedation within ten minutes. Sufentanil has a mildly negatively inotropic 
effect on infant hearts. It reduces serum catecholamine levels. It also decreases lung compliance, 
limiting its use in spontaneously breathing neonates. Anand and Hickey (1992) showed its great 
advantage in its ability to maintain superb metabolic and haemodynamic stability. 
Alfentanil is very short acting and may be used for short procedures. Alfentanil is a quarter as 
potent as fentanyl, is more highly protein bound (90 percent) to alpha-1-acid glycoprotein and is 
less lipid soluble than fentanyl. This causes a more rapid onset and shorter duration of action than 
fentanyl. Alfentanil has a rapid onset and offset in neonates (Meistelman). Preterm infants have a 
volume of distribution of 0.5 L I Kg, an elimination half-life of 321 minutes and a clearance of 0.9 
ml I kg I min. The prolonged half-life in premies probably reflects the slower clearance at this age. 
Thus repeated doses are not required as frequently in premies. It is metabolised in the liver by 
oxidative dealkylation. This enzyme system is likely to be immature in the premature baby, hence 
the prolonged clearance figures. There is, as with other opioids, great interindividual variability in 
their pharmacokinetic data. Roure showed that the elimination half-life is 30 percent shorter in 
neonates than in adults. It reduces lung compliance. Alfentanil may be used for short painful 
procedures in neonates. 
Remifentanil is the newest opioid available for clinical use. It's unique mode of metabolism means 
that it does not accumulate or have a prolonged action. The time from discontinuation of an 
infusion to wakefulness and spontaneous ventilation is 8- 10 minutes. Neonatal data show that it 
possesses an elimination half-life of 4.4 +I - 1.3 minutes and a clearance of 80 + I- 23 ml I kg I 
min (Davis 1997). The dose of remifentanil in the neonate has not yet been reported. A summary 
of the literature available about this new drug is presented in chapter three. 
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9. CLINICAL GUIDELINES 
The variations in the kinetics and dynamics of morphine in neonates, infants and children have 
contributed to the historical opinion that morphine is unsafe to use in children due to the risk of 
severe side effects. However, even though there is significant variation in morphine handling 
among children and within the same child, the meta - analysis performed by Kart et al of the 
kinetic values for morphine reveal that it is possible to establish an overall course for the 
development of morphine pharmacokinetics and based on this knowledge recommended regimens 
for morphine administration have been established. Thus guidelines based on kinetic data are 
useful, but they must be used carefully and doses titrated according to dynamic effect. 
Kart's paper sets out to describe age appropriate dosage regimes. He believes that opioid 
administration to a neonate or infant of less than two months of age needs to be done in a 
monitored setting. This is in line with Y aster and Maxwell's conclusions in Schecter's grand 
review of childhood pain. Remifentanil's unique kinetic profile may now, however, mean that an 
opioid can possibly be administered to even a small baby without necessitating the expense and 
extra workload of postoperative admission to a high care unit. 
Present practice is that young babies receiving opioids need to be carefully monitored. In South 
Africa this means a high care area. Nursing care on general wards is not sufficient. 
At the Red Cross Children's Hospital, any child of less than 50 weeks post conceptual age 
receiving an opioid goes to a high care unit. In the case of other postnatal problems, this limit may 
increase to 60 weeks. Premature babies or neonates may require ventilation. 
Other units may recommend high care monitoring for any child receiving an opioid up to the age 
of six months, or even older if there are additional problems. 
Lynn, however, states that high care is required only for babies up to 48 weeks of post conceptual 
age, providing they are otherwise healthy 
Yaster, in 1993, recommended that the use of any opioid in children less than 2 months old 
must be limited to a monitored setting, while those children older than 2 months may safely be 
monitored as older children or adults, on a general ward. Guidelines will also depend on the child, 
the illness, the agent used, and the route of administration and general logistics. 
Perhaps with increasing experience of the intra-operative use of remifentanil in the very young, 
the requirement for such labour intensive and expensive post-operative care facilities will not as 
definite. 
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1. THE SEARCH FOR THE IDEAL ANALGESIC 
Lynn states that the search for the ideal analgesic to use in children and infants remains an 
elusive goal. The properties of an ideal compound would include potent analgesia capable 
of blunting the hormonal and catabolic responses to the stress of surgery or painful 
procedures and a rapid onset with minimal effects on haemodynamic and other variables. 
This ideal agent would have minimal undesired effects on ventilation, gastrointestinal 
motility, and bladder function and would not induce pruritus. Any metabolic by-products 
should be inert, with metabolism unaffected by renal or hepatic impairment or immaturity. 
No tolerance or dependence would occur. 
This ideal is far from being achieved, thus the search for the ideal pharmaceutical product 
continues and meanwhile we optimise our use of available agents, using our knowledge of 
their kinetics and dynamics, by modifying dosage, mode and timing of administration, etc., 
in the different patient groups. 
Side effects may, however, be unavoidable with the opioid analgesics, since the same 
family of receptors that mediate analgesia also mediate ventilatory depression, nausea, 
constipation and urinary retention. So an opioid whose dose, plasma level and site effect 
can be titrated to maximum therapeutic effect with minimal undesirable effects becomes 
the best we can achieve. 
Fentanyl has historically been regarded as being more cardiovascularly stable than 
morphine and pethidine; the more recent alfentanil is faster and more titratable than 
fentanyl and the even more recent sufentanil' s faster offset time and cardiovascular stability 
after a large bolus dose makes it suitable for use in "fast-tracking" post cardiac surgery. 
However all of these undergo accumulation in peripheral compartments after repeated or 
continuous dosing leading to a protracted decline in drug concentration on termination of 
the administration. Remifentanil appears, according to initial evaluations, to be most 
modifiable of all. 
It has been registered in Europe and the USA for a few years and has recently been 
registered here in South Africa in 1999. 
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2. REMIFENTANIL KINETICS- A COMPARISON WITH OTHER OPIOIDS 
Remifentanil is a novel member in the family of the 4-anilidopiperidine opioid analgesics, a 
group that also includes the traditional agents fentanyl, alfentanil and sufentanil. 
Remifentanil is the first in a newly developed class of synthetic, selective, mu-opioid 
agonists whose unique metabolism by blood and tissue esterases yields an ultrashort 
elimination half-life in adults (Glass). This imparts brevity of action, precise and rapidly 
titratable effects, non-cumulative effects and rapid recovery after cessation of 
administration. Its pharmacological effects otherwise essentially parallel other opioids in 
this class. It is a hydrochloric salt, a methyl ester derivative of a 4-anilidopiperidine 
propanoic acid. It contains the same basic structure as fentanyl, sufentanil and alfentanil but 
with the addition of a propanoic acid methyl ester group at position 1 of the piperidine ring. 
It does not significantly bind to non-opioid receptor groups. 
It exhibits a linear and dose independent pharmacokinetic profile; its distribution can be 
described by either a 2 or 3-compartment model, although the third compartment is small 
(less than five percent) and only relevant after infusions lasting more than one hour. 
Seventy per cent of a dose of remifentanil is bound to plasma proteins of which two-thirds 
is alpha 1 acid glycoprotein. Traditional opioids show a higher degree of binding (> 90 
percent). The lipid solubility of remifentanil is lower than that of sufentanil or fentanyl, but 
is similar to that of alfentanil. Intravenous remifentanil, 1 to 2 f.Lg per kg, shows a hi-
exponential or tri-exponential decline in plasma concentrations (alfentanil shows a tri-
exponential decline). Continuous remifentanil infusions lasting more than one hour 
conform more to a three-compartment model. Although the distribution of remifentanil into 
the second compartment is very rapid, distribution into the third compartment is quite 
limited and accounts for less than 5 percent of the total exposure. This is in marked contrast 
with the kinetic profile of traditional opioids, particularly when they are administered for 
prolonged periods when significant accumulation can occur in the third compartment. 
Subsequent problems with toxicity following discontinuation of these older drugs may then 
occur because of redistribution from these tissues. The volume of distribution (V d) in the 
steady state in adults is 24 - 40 Litres (0.39L I Kg) and is dose independent. The V d of 
alfentanil is 0.52 L I Kg and is dose dependent. This low Vd also sets remifentanil apart 
from other opioids and together with its' esterase metabolism is responsible for the rapid, 
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titratable offset that is remifentanil' s hallmark. It is significantly faster and more titratable 
than all other opioids, including alfentanil. This difference is, however, less marked when 
purely a bolus dose is used. The central compartment Vd is 5.7 - 8.0 L, with a mean 
residence time ofbetween 5.7- 7.7 minutes. 
The time required for equilibration of peak blood concentration and peak effect (Tl I 2 keo) 
is similar for both remifentanil and alfentanil (1.6 vs. 0.96 min) (Egan and Minto) thus 
accounting for its rapid onset and rapid pharmacodynamic response to changes in plasma 
concentration. Egan based this on the effect site concentration I EEG 
(electroencephalogram) relationship and Glass found similar figures (1.3 minutes for 
remifentanil), based on analgesic measurements. This is due to remifentanil's relatively low 
lipid solubility. Sufentanil and fentanyl both show slower equilibration between plasma and 
effect compartment. 
Remifentanil is metabolised to effectively inactive products, which are excreted mainly by 
the kidney. Metabolism is independent of plasma cholinesterase activity (Stiller). 
Remifentanil is de-esterified by non-specific plasma and tissue esterases, with consequent 
liberation of a carboxylic acid metabolite, which is 4600-fold less potent than the pare1:1t 
drug. Remifentanil is also N-dealkylated, albeit negligibly. 
Metabolism of remifentanil is temperature dependent, thus infusion rates need adjusting 
during hypothermic cardiopulmonary bypass, this causing a 20 percent decrease in 
clearance (Russell and Royston). Bodyweight, age or gender does not influence total 
clearance of remifentanil, however obese patients have less central clearance. Thus ideal 
body weights should be used for dose calculations in obese patients, rather than actual 
weight. 
Terminal half-lives do not adequately reflect the overall concentration decay curves for 
drugs with complex three-compartment kinetics. Hence the use of the term: "context 
sensitive half time". The "Context Sensitive Half Time" of a compound with three-
compartment distribution is initially very short, as the drug is removed from the central 
compartment by both distribution and metabolism. There may be little difference in this 
value between traditional opioids and remifentanil. However the context sensitive half time 
of the traditional opioids, including alfentanil, increases with duration of infusion, whereas 
this does not occur with remifentanil. Alfentanil has a CSHT of 55 minutes after a 3-hour 
infusion (Egan) compared with 4 minutes for remifentanil, whatever the duration of 
infusion. 
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The ester linkage is cleaved by tissue and blood esterases, giving a very short elimination 
half-life (Egan). This occurs at its propionic methyl ester group to yield the carboxylic acid 
metabolite (88 percent of the dose is recovered in the urine in this form). It is not 
metabolised by the liver. Remifentanil has an elimination half-life of 8 - 10 minutes. 
Alfentanil also has a short elimination half-life but accumulates after prolonged infusions. 
Computer simulations based on pharmacokinetic parameters allow us to graphically show 
how blood concentrations of a drug decline after infusions of variable duration. Here is 
such a table with the values ofthe context sensitive halftimes: 
INFUSION 100 MIN 200MIN 300 MIN 
DURATION 
Remifentanil 3 3 3 
Alfentanil 45 55 58 
Sufentanil 20 25 35 
Fentanyl 220 262 -
(Egan 1996) 
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This data has been obtained from adults and shows that the offset of remifentanil is 
independent of duration of infusion and that it is unique in this. It has a distribution phase 
half-life of 0.94 minutes and a rapid onset of action (1.3 min half time for equilibration 
between plasma and effect compartment). It has a clearance from the central compartment 
of 2.9 L I min (41.2 ml I min I kg), compared to 9.0 ml I min I kg for alfentanil. It has a 
mean terminal elimination half-life of 10 minutes, compared to the 57.8 minutes of 
alfentanil. This high clearance and low steady state volume of distribution results in a faster 
decline in blood concentration of remifentanil compared to alfentanil. 
After discontinuation of a three-hour infusion, time to spontaneous ventilation is 4 minutes, 
time to extubation is 4.2 - 7 minutes, time to respond to verbal commands is 3 - 4.6 minutes 
and time to the requirement for an analgesic is 21 minutes. 
It is said, however, that for infusions of short duration, i.e. < 10 minutes, the kinetic 
differences between remifentanil and alfentanil are not that readily apparent. 
Remifentanil' s kinetics appear to be consistent between individuals of different ages and 
pathophysiological states. Kharash suggested there was a large individual variation in 
alfentanil' s pharmacokinetics due to individual variability in cytochrome P450 A34 
enzyme activity. 
3. REMIFENTANIL DYNAMICS. a comparison with other opioids 
With the exception of remifentanil's nearly 20 fold greater potency, the dynamics of 
remifentanil and alfentanil are quite similar. Higher potency has several dynamic 
implications including the potential for a longer onset time, by the "law of mass action" 
(bombardment of target receptor with fewer drug molecules) and the potential for a shorter 
duration of action, due to the presence of fewer molecules to eliminate. This definitely 
appears to be true for duration of action, but although statistically significant, the difference 
in onset time is probably clinically unimportant. 
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Remifentanil, like alfentanil, produces a dose dependent increase in analgesia. The onset of 
action of analgesia is similar to that of alfentanil and Glass' early studies suggested a peak 
analgesic effect at 1 - 3 minutes after intravenous administration, with a maximum PaC02 
seen at 5 minutes (return to baseline at 20 minutes versus 30 minutes with alfentanil), using 
twice the recommended bolus dose. It has a potency similar to fentanyl and 20 - 30 times 
that of alfentanil based on various clinical end points, including analgesic effects (Glass). 
Its offset is 10 times as rapid as alfentanil following a 3-hour infusion in Kapilas' study on 
30 healthy volunteers. Remifentanil facilitates better control of intraoperative 
haemodynamic responses than alfentanil (Monk) and is approximately 15 times as potent as 
alfentanil in blunting the catecholamine response to surgical stimuli. Herreods showed that 
patients with poor left ventricular function undergoing coronary artery bypass graft surgery 
receiving remifentanil showed superior attenuation of stress response to maximum sternal 
spread than patients receiving fentanyl. 
Cerebrovacular responsiveness to increasing PaC02 levels is maintained during a 
remifentanil infusion, with cerebral blood flow increasing with increasing PaC02 levels 
(Baker). In addition, reduction in cerebral blood flow in response to hypocapnia is not 
affected by remifentanil. Forde agreed with these findings in 1998. 
Thus there is no evidence of remifentanil causing raised intracranial pressure (Guy). 
Equally Hindman found that single doses of remifentanil or alfentanil did not produce any 
clinically significant changes in intracranial pressure. He did, however, show that at higher 
doses cerebral perfusion pressure decreases in parallel with a decrease in mean arterial 
pressure. He found that mean arterial pressures do not decrease more than 20 percent from 
the baseline. 
Remifentanil, used as a sole induction agent induces and maintains a stable electro 
encephalographic state (> 50 percent reduction in spectral edge frequency) without 
evidence of seizure activity. A dose of 4- 6 )lg I kg without premedication, produces a loss 
of consciousness in 60 percent of patients. However, because of a high incidence of apnoea 
and muscle rigidity it is not recommended for use as a sole induction agent. The EEG 
effects closely parallel its arterial concentration. Its' rapid recovery profile makes it useful 
for neuroanaesthesia, i.e. for early assessment post operatively. Patients can be extubated 
and then coma scales and the neurological picture can be assessed very early. 
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It causes a reduction in the minimum alveolar concentration value of anaesthetic volatile 
agents when used in combination. It has a sparing effect on hypnotics and sedatives and its' 
unique kinetic profile facilitates 'real time' management of intraoperative stress. Schraag 
was keen to point out his findings that when he used middle latency auditory evoked 
potentials, remifentanil appeared to give no quantitative contribution to the suppression of 
the potentials during propofol anaesthesia. Thus, he concluded, remifentanil might in fact 
contribute to a misleading clinical suggestion of adequate anaesthesia. Remifentanil does 
produce, however, a dose dependent reduction in auditory and somatosensory evoked 
responses during isoflurane anaesthesia. 
Remifentanil does not cause histamine release, but does cause a significant decline in heart 
rate and blood pressure over time. Glass quoted a 15 - 20 percent fall in blood pressure and 
a moderate degree of bradycardia. These changes are readily attenuated by intravenous 
anticholinergic premedication and are easily reversed by adrenergic agents (Pitts). This fall 
in blood pressure and heart rate is exaggerated when remifentanil is combined with 
propofol. The hypotension is exaggerated even more in the presence of hypovolaemia. 
Berghmanns demonstrated, by using transoesophageal echocardiographic analyses, that the 
pathophysiological mechanism underlying the hypotension associated with the use of 
remifentanil was related to a reduction in left ventricular preload and afterload without a 
change in contractile state. 
Alfentanil is said to have unpredictable effects on the cardiovascular system and may cause 
changes in the pulmonary vascular resistance. Alfentanil may cause a rise in pulmonary 
vascular resistance that may result in a reversal of the transitional circulation back to the 
foetal state in neonates. 
Like alfentanil, remifentanil produces a dose dependent respiratory depression with the 
peak effect on PaC02 and Pa02 occurring 5 minutes after a single intravenous bolus dose 
(Glass and Hardmann). Complete recovery from the respiratory depressant effects appears 
to occur in 15 minutes (Schlugman) and Amins' study showed that spontaneous recovery of 
ventilatory function is faster after cessation of a remifentanil infusion than an alfentanil 
infusion (20 minutes vs. 30 minutes). Infusions of remifentanil of< 0.5 microgram/kg/min 
do appear to permit spontaneous ventilation during isoflurane or propofol anaesthesia. 
CHAPTER 3 - REMIFENT ANIL 9 
Its' rapid elimination from the central compartment, coupled with its' limited distribution 
into peripheral compartments, means that recurrent respiratory depression does not occur. 
This is in marked comparison to the traditional opioids. Mahla reported this unpredictable 
and significant problem with the use of alfentanil. 
Recovery of respiratory function is rapid on cessation of the infusion, in line with its' 
overall recovery profile. 
Glass, in 1992, showed that following a 4-hour infusion, recovery of respiratory function 
occurred in 8 minutes in patients receiving a rernifentanil infusion and 61 minutes in 
patients receiving an alfentanil infusion. 
Dershwitz reported his use of rernifentanil in total intravenous anaesthesia, with propofol, 
for procedures of varying duration. He found the recovery profile (time to spontaneous 
ventilation I time to response to voice I time to extubation) very rapid. He also found that 
analgesia was required soon after the infusion was stopped. He also noted the bradycardia 
and the hypotension that has been widely acknowledged. 
A relatively high incidence of rigidity has been reported when remifentanil is used alone at 
high doses to induce anaesthesia. The mechanism is thought to involve opioid receptors in 
the brainstem and basal ganglia. The rigidity is reversed by naloxone. Remifentanil in 
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lower doses, patiicularly in combination with hypnotic agents, does not usually produce 
clinically significant muscle rigidity (1 percent incidence) and even then, did not interfere 
with ventilatory support. 
Remifentanil causes other typical 'mu' side effects of nausea, vomiting, pruritus, etc. Its 
brevity of action not only ensures a rapid resolution of these adverse effects, but also 
necessitates early establishment of postoperative analgesia. 
Bi2 Studies comparing remifentanil to alfentanil 
Cartwright et al published a big study comparing the two agents in patients undergoing day 
case surgery, with the agent being discontinued just prior to the end of surgery. They found 
that the remifentanil group experienced significantly fe~er stress responses and required 
less rescue analgesia intraoperatively, in adults. Psychonletric functioning and mental 
agility showed better recovery in the remifentanil group. They did, however, find that 
general recovery profiles were faster in the alfentanil group: times to spontaneous 
ventilation, response to verbal commands, adequate respiratory rate, extubation were all 
faster in the alfentanil group. However the times were all low (i.e. time to spontaneous 
ventilation, five minutes versus eight minutes). Intra-operative hypotension and 
postoperative shivering were higher in the remifentanil group. 
Davis and Lermann found that fewer remifentanil recipients required naloxone for 
respiratory depression and that recovery occurred at a comparable time to children 
receiving alfentanil infusions (they looked at orientation, extubation, discharge to the ward 
and ambulation) in children undergoing elective strabismus surgery. The remifentanil 
patients had greater postoperative pain and showed a lower incidence of postoperative 
hypoxaemia. Nausea and vomiting and haemodynamic parameters were similar in the two 
groups. Davis states in this paper that the quoted infusion rate of 1 micrograms I kg I 
minute may, in fact, be too much in this age group. 
Other studies confirm these findings and add that postoperative analgesia is required earlier 
in the patients who received remifentanil. 
Shuttler, however, found little difference in the recovery profile between the two groups, in 
a large double blind study on patients undergoing major abdominal surgery. He did find 
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that time to extubation was more predictable and less variable in the remifentanil group. 
His large study also found that remifentanil was better than alfentanil at blunting 
haemodynamic responses intra-operatively. He found a similar overall incidence of side 
effects in both groups, with more hypotension and bradycardia in the remifentanil group. 
This was easily controlled by dose titration. 
4. EFFECTS OF ORGAN DISEASE 
Dershwitz and Hoke found that kinetics are not altered significantly by liver disease and 
Shlugman showed the same for renal impairment, although patients with either disease did 
appear to show an increased sensitivity to the respiratory depressant effects of the opioid. 
The significance of this is unclear given the brevity of action of the drug. 
Steady state concentrations of the metabolite are much higher in-patients with renal 
impairment. This, however, has very little clinical significance because of its low potency. 
The metabolite is 30% extracted by the dialysis process. 
Both "ageing" and " obesity", however, do alter the kinetics of the drug. Patients over 65 
years of age are sufficiently sensitive to warrant a 50% reduction in the dose 
recommendations. There is a small decrease in both clearance and volume of distribution 
with increasing age. Dosages for obese patients should be based on their " ideal body 
weight" and not their " actual total body weight". 
5. ADMINISTRATION 
Recommended regimes include a bolus dose of 1 microgram per kilogram slowly over at 
least 30 seconds, followed by an infusion rate of 0.2 - 0.5 Jlg I kg I min. Kinetic data 
suggests that on commencing or changing the rate of infusion, 80 percent of the steady state 
blood concentration is reached within 5 - 8 minutes. 
Intubation responses are only effectively prevented at an infusion rate of 1 Jlg I kg I min. 
Woods recently tried doses of2 J...lg I kg to ablate responses to intubation but found that the 
subsequent duration of apnoea was significantly longer than in those receiving only 1 J...lg I 
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kg. Haemodynamic stability can be achieved intraoperatively with a background infusion 
rate of 0.21-lg I kg I min, with increases of up to 0.51-lg I kg I min during periods of 
stimulation. 
Paventi suggested that infusion rates of at least 0.5 1-lg I kg I min are required to completely 
dampen the catecholamine response to laparoscopic cholecystectomy. 
Postoperative analgesia appears to be achieved at an infusion rate of 0.1 1-lg I kg I min (with 
0.025!-lg increments as required), higher rates causing respiratory depression. This regime 
has been found to provide better post operative analgesia than 0.15 mg I kg of morphine 
given 20 minutes prior to the end of surgery followed by intermittent bolus doses. 
Recovery profiles are independent of the infusion rate. 
6. CLINICAL USES AND FINDINGS 
The following have been approved by Control Councils in Europe and North America as 
appropriate indications for use: 
1. Analgesia during induction and maintenance of general anaesthesia 
2. Postoperative analgesia under close supervision in post-anaesthesia or intensive care 
setting 
3. Analgesia during monitored anaesthesia care. 
Remifentanil decreases the Minimum Alveolar Concentration (MAC) of isoflurane, but 
demonstrates a ceiling effect; i.e. very high plasma levels do not decrease the MAC further. 
It also decreases the amount of propofol required for a given stimulus. 
Much work has and is being done to define the place of this drug in modem anaesthesia. 
McAtamney et al have shown that it is effective in dampening the stress response to 
endotracheal intubation. Valenti has suggested its' usefulness for consCious sedation, but 
acknowledged its' poor amnesic effects. Boccara has highlighted its' potential as an adjunct 
"patient controlled analgesic" in conjunction with local field block for hernia surgery. 
Stuart also tested it and found it to be effective for "patient maintained analgesia" for day 
case gynaecological laparoscopy. Gustorff has recently suggested that it may have a place 
in the testing of chronic neuropathic pain for opioid responsiveness. 
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7. COMPARISON WITH OTHER SEDATIVES 
It has also been used and recommended for sedation and analgesia during local and 
regional blocks. Greater patient comfort, less sedation and therefore more co-operation 
have been found but the risk of respiratory depression has been emphasised (Lauwers). 
8. TOLERABILITY 
Typical mu opioid side effects occur. At recommended doses common events (i.e. with 
greater than a 1 percent incidence) include bradycardia, hypotension and skeletal muscle 
rigidity. Muscle rigidity is reduced when remifentanil is administered concurrently with a 
hypnotic induction agent. 
Respiratory depression occurs more commonly (7 percent incidence) when remifentanil is 
administered for postoperative analgesia than when given during induction or maintenance 
of general anaesthesia (less than 1 percent incidence). 
During monitored anaesthesia at recommended dose common adverse events include 
(greater than 18 percent incidence) nausea, vomiting, pruritus and headache. These events 
can be decreased by the concomitant administration of midazolam 2 mg (higher doses of 
midazolam increase the incidence of respiratory depression- GlaxoWellcome Inc). 
Postoperative shivering, nausea, vomiting and fever have also been reported (greater than 5 
percent incidence). 
Other side effects (1-5 percent incidence) after discontinuation of remifentanil have 
included respiratory depression, dizziness, visual disturbance, hypotension, headache, 
shivering and pruritus. 
Excessive doses of remifentanil increase the incidence of these adverse events, especially 
muscle rigidity and bradycardia. Tachycardia and hypertension have, however, been 
reported at these higher doses. 
Tolerance to the effects of remifentanil has been shown, by Vinik, to occur rapidly in 
humans not undergoing constant painful stimuli. He found that a constant-rate infusion 
resulted in a 75 percent reduction of analgesic effect after a three-hour period. Thus, he 
concludes, tolerance is profound, of rapid onset and needs considering when setting up 
target-controlled infusions. 
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9. REMIFENTANIL IN NEUROSURGERY 
There are negligible direct cerebrovascular effects following remifentanil administration. 
This is particularly desirable in neuroanaesthesia, as neurosurgical patients may be 
susceptible to changes in cerebral blood volume, cerebrovascular tone and intracranial 
pressure, resulting from an increased cerebral blood flow. Neurosurgical patients are 
particularly vulnerable to damage from increased cerebral blood flow due to their 
diminished intra-cranial compliance. This can lead to brain herniation or decreased 
perfusion and ischaemia. 
Guy also suggested that remifentanil was a good analgesic agent for use during elective 
craniotomy (1997). 
Coles showed that total intravenous anaesthesia using a propofol infusion together with a 
remifentanil infusion allowed good haemodynamic conditions for craniotomy and this 
regime showed faster recovery than propofol and either alfentanil or fentanyl infusions. 
Maintenance requirements of propofol were less in the remifentanil group. 
Surnmors has suggested that the use of remifentanil during acoustic neuroma surgery 
decreases propofol requirements and therefore speeds recovery from anaesthesia. 
It is vital that there is no postoperative delay in recovery or respiratory depression leading to 
hypercarbia and increased intracranial blood volume. 
10. REMIFENT ANIL IN PAEDIATRICS 
Little work has, as yet, been done on the use of remifentanil in paediatrics. This is the first 
big study including neonates and preterm babies. 
In early studies Davis suggested that in a child over age of two years of age the 
pharmacology of remifentanil is comparable to that of an adult. He found clearances of 
58.7 ml I kg I min, volumes of distribution of 0.2 L I Kg and elimination half lives of 5 min 
in 1 0 children aged 2 - 12 years, but further work is needed to assess the kinetics and 
dynamics of the drug and to assess the activity of esterases in infants. He and Lermann used 
remifentanil in children undergoing squint surgery. Davis subsequently wrote, in an 
abstract based on a study of six neonates, that the pharmacokinetic parameters appeared 
similar in neonates and older children. 
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Robinson recently published a paper stating that remifentanil was a good alternative to 
suxamethonium or alfentanil for providing good intubating conditions in children aged two 
to twelve and showed that both remifentanil and alfentanil caused a similar degree of 
attenuation of the stress response to intubation, with a similar recovery time to spontaneous 
ventilation. 
Wee wrote a case report on the successful use of a combined remifentanil intravenous 
infusion and an epidural ropivacaine infusion in a term neonate at risk of transient 
myasthenia gravis, for repair of bladder extrophy. He noted the hypotension and 
bradycardia that he feels is marked in neonates, particularly on bolus administration. 
More recently Eck published a case report about its' use in three infants with complex 
. medical problems and suggested that although it is known that the pharmacological profile 
of remifentanil has not been published in infants, and that other opioid kinetics have 
generally been found to be different in neonates and young infants compared with older 
children, it seems that it does have a short duration of action in this age group, even after a 
prolonged infusion, and therefore may prove to be particularly useful in certain patients of 
this age group. 
Grundmann compared haemodynamic and recovery profiles between children receiving 
propofol and remifentanil "total intravenous anaesthesia" (TIVA) and children receiving 
desflurane and nitrous oxide. He found a significantly lower perioperative heart rate and 
less postoperative agitation in the "TIVA" group. All but one of the recovery landmarks 
(i.e. extubation, eye opening, Aldrete score > 9) were similar, but the "TIV A" group 
showed a delayed return to spontaneous ventilation of 11 compared to 7 minutes post 
termination of anaesthesia. 
Kan gave a remifentanil infusion, at a rate of 0.1 microgram I kg I minute, to nineteen 
mothers during caesarean section under epidural anaesthesia. He found a sedative and 
respiratory depressant effect on the mothers but no adverse effects on the babies. 
Jones reported the successful use of patient-controlled analgesia using remifentanil in a 
labouring woman with thrombocytopenia and concluded that good analgesia without 
maternal or foetal side effects was possible, provided that the woman could anticipate the 
contraction and that bolus doses were of appropriate size (0.5 Jlg I kg). 
Thus, little work has, as yet, been done on the use of remifentanil in paediatrics. This is the 
first big study including neonates and preterm babies. Further work is required. The studies 
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to date suggest that remifentanil is safe and effective in children, including term and 
preterm babies, but that the usual side effects of hypotension and respiratory depression are 
of concern due to the babies limited physiological reserve. 
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1. THE AIM OF THE STUDY 
The tunnelling phase of ventriculoperitoneal shunt insertion has traditionally not received optimal 
analgesic cover, for fear of the predictable dose-dependant side effects of opioids in small children 
(Kart, Bhat) with an already compromised cerebral perfusion. Known side effects of opioids include 
hypotension, delayed recovery and post-operative respiratory depression. There is a high risk of.post-
operative respiratory depression and a delayed recovery is likely in sick neonates with poorly 
developed respiratory drive, especially when there is a depressed level of consciousness 
preoperatively due to intracranial pathology. The resultant hypercarbia may compromise cerebral 
perfusion further by increasing intracranial volume or pressure. 
Inadequate analgesia in this setting, however, may predispose to multiple complications, including 
intraventricular haemorrhage (Mullart). 
The aim of the study is to see if remifentanil could usefully attenuate the signs of pain and stress 
caused by tunnelling without causing any dangerous side effects. 
It is not the intention of the study to assess remifentanil as the "ideal opioid", as it is considered to be 
in some of the work quoted in chapter 3. It is difficult, as discussed in chapter 1, to assess the stress 
response in the very young. It is even harder to assess what constitutes a clinically significant 
attenuation of that stress response, where statistical and clinical significance are not the same. Much 
work has been published on the value or otherwise of the stress response and it's attenuation. Little 
hard evidence exists in the literature, but perceived wisdom is that an uncontrolled stress response is 
damaging and that careful attenuation can improve outcome (Anand). Each individual clinical 
situation, however, is multi-factorial and outcome studies on one group cannot be assumed to be 
relevant to another. I have therefore set out to assess whether a statistically significant attenuation of 
the degree of stress response is demonstrable with the use of remifentanil, when compared to 
placebo. Further work is then required to assess the relevance of the findings in terms of outcome. It 
has been assumed for the purposes of this study that an increase from baseline of 15 - 20% or more 
in the parameters that mark stress can be taken to represent clinically significant stress, and an equal 
degree of attenuation in these parameters can be taken to represent clinically relevant suppression of 
the response. I have also set out to examine if any evidence exists that the use of remifentanil in this 
scenario causes a statistically significant increase in the degree and duration of the well documented 
side effects of opioids, in particular hypotension, delayed recovery and post-operative respiratory 
depression. 
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Thus we set out to compare remifentanil with placebo in order to see whether remifentanil' s unique 
kinetic profile makes it suitable for use in this group of patients. We chose not to include an 
additional opioid, such as alfentanil, as a third group because remifentanil appears to have significant 
advantages over the other opioids and because having three different treatment options would have 
decreased the sample sizes and therefore decreased the likelihood of achieving valuable statistical 
results. 
2.SUMMARY 
We have studied 62 children (13 neonates (8 "x-premies"), 24 infants and 25 older children), 
undergoing the insertion of a cerebrospinal fluid drainage shunt under general anaesthesia for the 
relief of hydrocephalus. Patients were allocated randomly to one of two groups: group R (n=33) 
received remifentanil 1 microgram per kilogram and group S (n=29) who received saline just prior to 
the tunnelling phase of shunt insertion, in a double blind, prospective study. We compared the 
cardiovascular responses to the agent, the stress response to tunnelling, the recovery profiles, the 
post-operative respiratory depression and the side effects in the two groups. 
Patient characteristics such as ASA status, age, sex, height, weight and baseline cardiovascular 
parameters were similar in both groups within each age category. Surgical characteristics such as 
technique and associated procedures were similar and anaesthesia characteristics, such as total 
duration and the duration from drug administration to the end of anaesthesia were generally similar in 
both groups. A standardised anaesthetic protocol was followed for each patient, details of which are 
given below. 
Group S (control) demonstrated a significantly greater stress response to the stimulus of tunnelling, 
with a greater degree and duration of rise in heart rate and blood pressure, and a significant rise in 
plasma catecholamines compared to group R (remifentanil). Some group S patients, in fact, showed a 
reduction in stress levels in spite of tunnelling. The differences were generally consistent across the 
different age groups. 
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There was no evidence that remifentanil causes a delayed recovery, there being no prolongation, in 
the remifentanil group, in the time required from the end of surgery to fulfilling the criteria for 
extubation, discharge to recovery and discharge to the ward, in all age groups. In fact, the 
remifentanil group appeared to recover slightly faster than the control group. 
There was some evidence of post-operative respiratory depression and increased oxygen 
requirements in both groups, but with no difference between the two groups, at all ages. 
There was some evidence of cardiovascular depression in the remifentanil group, with some children 
exhibiting a degree of bradycardia and hypotension, either before or even during the tunnelling. 
There was no difference between term babies and ex-premies of similar post conceptual age in their 
overall response to remifentanil. 
There was no difference between groups in post-operative analgesic requirements, in blood loss and 
there were no other significant side effects in either group. 
We conclude that remifentanil is an appropriate and safe analgesic to provide balanced anaesthesia to 
cover the tunnelling phase of cerebrospinal fluid shunt insertion and patients show a good recovery 
profile. There was no evidence of additional postoperative respiratory depression or of major 
complications, in children of all ages, including ex-premature babies. 
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3. STUDY PROTOCOL -PATIENTS AND METHODS 
The Research Ethics Committee of the University of Cape Town approved the study. At the time of 
the trial the drug was unregistered in South Africa. The Medicines Control Council thus granted 
permission for the trial. Full explanation was given to and written consent was obtained from the 
parents or guardians. 
Of the 91 patients presenting during the trial period, we studied 62 patients: 8 x-premies, 13 neonates, 
24 infants and 25 children over the age of one year. These groups were identified at the start of the 
trial. Power analysis, based on the assumption that a 20% increase in heart rate or blood pressure 
would represent clinically important stress responses, and with an assumed standard deviation of 
such an increase of approximately 15 mrnHg or beats per minute indicated that a minimum of 8 
subjects in each age group and drug group should be included to establish reasonable statistical 
power, with a beta error of 0.1. The "x-premies" group was made up of patients from both the 
neonate and infant groups, who were born before 35 weeks of post conceptual age and were still less 
than 56 weeks of post conceptual age. All patients were ASA 2 or 3 and were undergoing the 
insertion or revision of a cerebrospinal fluid shunt. Exclusion criteria included severe 
cardiorespiratory disease, guardian refusal, logistical problems (i.e. time constraints) or protocol 
violations. 
Patients were allocated randomly to one of two groups by the opening of a sealed envelope by a non-
participating clinician. Inside each envelope was either the letter "A" or "B", the random sequence 
having been generated by a "random number generation computer programme". Remifentanil or 
saline were then prepared and handed to the trial worker (myself, the author, only) who remained 
blinded until completion of the trial, when the codes were broken and the results analysed. 
Standard pre-operative fasting intervals were applied. If required, premedication was with 
midazolam, 0.5 mglkg. In fact, no patient received premedication. Caffeine (1 0 mg/kg) was given as 
a respiratory stimulant to premies and ex- premies (up to 60 weeks of post conceptual age), as is our 
usual practise according to the Red Cross Hospital protocol. 
On arrival in theatre a full set of observations were performed as a pre-induction baseline. These 
· were: heart rate, non invasive blood pressure, respiratory rate, oxygen saturation on room air and 
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transcutaneous carbon dioxide partial pressure. These measurements were to be compared to post-
operative parameters to assess post-operative respiratory depression and analgesic requirements. 
Inhalational induction was then performed with nitrous oxide, oxygen and either sevoflurane or 
halothane. Only halothane was actually used for the inhalational induction, although sevoflurane was 
also allowable by protocol, should it have been indicated clinically (i.e. for a difficult airway). It was 
felt that the differing rates of elimination of the two agents were immaterial, considering that the 
overall duration of anaesthesia is about 2 hours. 
Isoflurane, at 1-% end tidal concentration using a calibrated agent monitor, was then immediately 
substituted to maintain anaesthesia with nitrous oxide and 30 % 02. The vocal cords were sprayed 
with lignocaine and oral endotracheal intubation performed (minimal apparatus dead space ensured). 
Intermittent positive pressure ventilation to an end tidal carbon dioxide partial pressure of 3.5 to 4.5 
kPa was achieved. 
Intravenous access was obtained by the femoral vein. Atracurium (0.5 mg/kg), cloxacillin (25 mg/kg) 
plus further antibiotics were administered at the surgeon's request. 
The intravenous fluid regime was modified Ringers Lactate with 2 % added glucose, giving an initial 
rehydration bolus of 8 ml/kg and then maintenance at a rate of 4 ml/kg/hr, with challenges of 4 ml/kg 
if indicated clinically. 
Temperature was maintained above 35.5°C by both active and passive manoeuvres, to exclude 
temperature changes as a source of post-operative respiratory depression or delayed recovery. 
The patient was then turned, positioned, cleaned, draped and given. Bupivacaine and por 8 to scalp 
and abdominal sites was given (bupivacaine 3 mg/kg and por 8, 5IU in 50 ml, max 4 mllkg). Skin 
incision and surgery followed. 
"Steady state" observations were then recorded and serum catecholamine levels were taken just prior 
to remifentanil/placebo administration. These observations were heart rate, blood pressure, oxygen 
saturation, transcutaneous carbon dioxide partial pressure and rectal temperature. The remifentanil or 
control was then given as a bolus over 1 minute, with full sets of the above measurements being 
recorded during this minute and for one further minute, to detect adverse cardiovascular responses to 
the drug, immediately prior to tunnelling. 
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Tunnelling was then performed and full sets of the same measurements were taken mid - tunnelling 
and then at one minute intervals for ten minutes and then at five minute intervals until the end of 
surgery. From these readings, the maximal deviations from the "steady state" cardiovascular 
parameters were subsequently compared, as were the durations of time for a return to within 5 % of 
these "steady state" cardiovascular parameters. The degree of these cardiovascular deviations from 
"steady state" and the duration of these deviations were taken as markers of the stress response to 
tunnelling. The tunnelling stage generally lasted about four minutes. 
A second venous blood sample for serum catecholamines was taken just after tunnelling, for 
comparison with the "steady state" serum catecholamine levels. 
The catecholamine samples were immediately placed into cooled ( 4 degrees Celcius ), heparinised 
tubes and spun down, the plasma separated and frozen at -70°C. The samples were then analysed at 
the University of Cape Town Anaesthetics Laboratory by electrochemical detection after separation 
with reverse phase high-performance liquid chromatography using dihydrobenzylamine as the 
internal standard. The coefficient of variation of the method is 7.9% for noradrenaline and 8.7% for 
adrenaline; the lower limit of sensitivity was 20 pg.ml-1. 
On application of the wound dressing, reversal was given. This was subject to adequate spontaneous 
reversal of neuromuscular blockade as assessed by a peripheral nerve stimulator and therefore 
incomplete reversal of neuromuscular blockade as a factor in post-operative respiratory depression 
was excluded. Anaesthetic gases were turned off and weaning from the ventilator commenced. 
The time intervals from the end of surgery to extubation, to moving to recovery, to readiness for 
discharge were compared between the two groups. Specific criteria had to be achieved for each stage. 
A Red Cross Hospital modification of Steward's criteria was used (see table attached table). 
Table of criteria used to assess post-operative recovezy 
RED X MODIFIED STEWARDS' CRITERIA: 
Criteria for extubation: 
Spontaneous breathing, Sats >95% on Fi02 40 %, normothermic, cardiovascularly uncompromised. 
Criteria for movinLt to Recovery: 
Maintaining airway, Sats >95% with added Fi02 
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Criteria for Discharee to ward: 
Respiratory: can breath deeply or cough, Sats >95% on room air, normal respiratory pattern 
Cardiovascular: HR and SBP within 10% of pre-op value, warm peripherally. 
8 
Neurological: pain free, moving all 4 limbs, opening eyes, responding to commands or painful 
stimulus 
Temperature: >35. 5 axillary 
Adverse events, blood loss, and additional comments were recorded and the patients were kept in 
recovery for two hours post administration of the drug for full monitoring including respiratory rate, 
transcutaneous carbon dioxide partial pressure, oxygen requirements (added oxygen was given if 
peripheral oxygen saturation< 95% on room air) and analgesic requirements (see table). 
Table of criteria used to assess post-operative analgesia requirements 
Criteria for administration of analeesia: 
Restless, crying, heart rate or blood pressure > 10% above pre-induction baseline (having first been 
given "Tender Loving Care" including comforting and handling by the recovery room nursing staff and 
I or Y2 Darrows Dextrose or feed to babies to exclude hunger). 
The degree and duration of changes in the respiratory parameters from pre-operative baseline were 
recorded. In addition, the time in minutes until transcutaneous C02 levels decreased to (1) a steady 
state and (2) 6.0 kPa and then to (3) 5.3 kPa, was recorded, along with (4) any rebound respiratory 
depression. 
To assess evidence of intra-operative cardiovascular depression due to remifentanil, we looked at 
heart rate and blood pressure, just before and just after administration of the "drug" and looked at the 
percentage changes in these parameters. No other variable was involved during this period. Thus if at 
p =0.05 the cardiovascular changes in the two groups were different, a statistically significant degree 
of cardiovascular depression could be implied. 
To assess the signs of pain and stress we looked at the changes in heart rate, blood pressure and 
plasma catecholamine levels with tunnelling. Measurements were made just before, during and after 
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tunnelling and percentage changes from the "before" readings in control and remifentanil groups 
were compared. These findings were compared within different age groups and with all ages grouped 
together. Statistical analysis was performed to assess possible differences existed between the 
remifentanil and the control group. Thus if at p =0.05 the two groups were different, a statistically 
significant attenuation of the stress response could be concluded. 
To assess whether any delay in recovery was caused, we measured the time in minutes from the end 
of surgery until specific criteria were fulfilled. These criteria assessed whether the patient was ready 
to be extubated, to be taken to recovery and to be discharged to the ward. Thus if at p = 0.05 the 
times taken to achieve these criteria two groups were different, a statistically significant delay in 
recovery could be implied. 
To assess post-operative respiratory depression we looked at post-operative respiratory rate, post-
operative oxygen requirements (added oxygen was given until the peripheral saturation stayed above 
95%) and transcutaneous carbon dioxide measurements. Transcutaneous carbon dioxide readings and 
measurements of respiratory rate were taken pre-induction and post-operative recordings were then 
compared. These comparisons included the maximum percentage deviation from the pre-operative 
baseline, the time in minutes taken to descend to 6.0 kPa, the time in minutes taken to descend to 
5.3kPa and the time taken in minutes until the readings became steady. Thus if at p = 0.05 the two 
groups differ, a statistically significant degree of post-operative respiratory depression could be 
implied. 
Transcutaneous carbon dioxide (C02) partial pressure was measured using a Novametrix C02 meter 
manufactured by Medtronics. The sensor consists basically of a modified pH electrode bathed in an 
electrolyte solution covered by a thin membrane across which C02 can diffuse. 
Changes in C02 concentration cause pH changes according to the Henderson-Hasselbalch equation, 
leading to the generation of a voltage. The sensor incorporates a warming device that heats skin to 45 
degrees Celsius, causing superficial tissue vasodilatation and a decreased distance for tissue C02 to 
diffuse towards the sensor. A digital graphical display of tissue C02 level then monitors changes 
with a lag time of approximately one minute. 
Transcutaneous carbon dioxide measurement is often used as a research tool to monitor tissue levels 
both in adults and in children. However, there have been problems with the use of transcutaneous 
measurement in the past and the literature over the last two decades has reflected this. 
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McLellan in 1981 compared arterial and transcutaneous carbon dioxide levels in healthy volunteers 
given varying concentrations of inspired gas. He found that the cutaneous capnograph accurately and 
consistently reflected the arterial levels with only a small time lag in these healthy adults. 
Kost in 1983 monitored transcutaneous levels of carbon dioxide in premature babies with. respiratory 
distress syndrome. While he found that although there was good correlation with arterial levels, he 
found there to be a significant calibration drift and thus recommended that it calibration be repeated 
at three hourly intervals. 
Rome in 1984 demonstrated the relative inaccuracy of the earlier models and advised caution in the 
interpretation of their data. He found that in nine ex-premature infants with bronchopulmonary 
dysplasia the transcutaneous partial pressure consistently overestimated the arterial pressur~ by 9 
kPa. 
Wimberley in 1985 also pointed out the problem of electrode drift, stating that although a valuable 
tool, transcutaneous monitoring should not be regarded as a replacement for arterial sampling. In 
addition, Wimberley pointed out that with increasing electrode temperature, transcutaneous readings 
increase by a factor similar to the anaerobic temperature coefficient of PC02 in blood. He found that 
transcutaneous measurements of carbon dioxide to be more accurate that measurements of oxygen. 
Geven in 1987 concluded that the transcutaneous meter gives reasonably good correlation with 
arterial levels in sick newborns. He felt that the meter could not replace arterial sampling, but may 
decrease the frequency of arterial samples required. 
Kavanagh in 1992, however, found that the transcutaneous carbon dioxide readings correlated poorly 
with arterial levels in 30 post-operative, spontaneously breathing adults. 
Binder in 1994 tested transcutaneous carbon dioxide readings in very low birth weight infants at 
different sensor temperatures (43 and 40 degrees Celsius) and found good correlation with umbilical 
arterial measurements. Thus he recommended the use of the lower temperature sensor. This work 
was done in the light of the decreasing use of transcutaneous blood gas monitoring following the 
advent of pulse oximetry. Thus he found that transcutaneous carbon dioxide levels do in fact give 
accurate readings and he suggested that this mode of monitoring should continue to have a place. 
Tobias in 1997 demonstrated that transcutaneous carbon dioxide measurements were a more accurate 
reflection of arterial partial pressures than were end tidal measurements in infants and toddlers under 
48 months of age being ventilated for respiratory failure. He found that the transcutaneous level 
correlated well with the arterial reading. He compared end-tidal, transcutaneous and arterial levels. 
The ETC02 to PaC02 difference was 6.8 +/- 5.1 mm Hg, while the TC-C02 to PaC02 difference 
was 2.3 +/- 1.3 mm Hg (P < 0.0001). The absolute difference ofthe TC-C02 and PaC02 was 4 mm 
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Hg or less in 96 of the 100 values, while the ETC02 to PaC02 difference was 4 rnm Hg or less in 38 
ofthe 100 values (P < 0.0001). 
Arsowa in 1997 pointed out the problems of using end-tidal carbon dioxide readings in 61 ventilated 
neonates to assess the adequacy of ventilation and suggested the use of transcutaneous monitoring. 
He found a good correlation (r=0.72) between end-tidal and transcutaneous readings but a significant 
discrepancy between the two. Thus he concluded that transcutaneous measurement is more accurate 
in this age group due to ventilation-perfusion mismatch causing inaccuracy in the end-tidal readings 
(12mmHg difference). In addition, there is the problem of apparatus dead space further decreasing 
the accuracy of end-tidal assessments. 
Drummond also in 1997 reported his use of the transcutaneous meter to assess post-operative 
hypercarbia in 64 adults, post-craniotomy patients following extubation. He compared the levels 
recorded with arterial samples and found them to correlate well. He also found that post operative 
transcutaneous hypercarbia is a good predictor of post operative seizures, lower post-operative 
Glasgow coma scale, re-intubation and correlates well with the degree of intra-operative brain 
disturbance. 
Lang in 1998 used continuous transcutaneous monitoring to assess tissue carbon dioxide levels in 
patients undergoing brain stem death apnoea tests. He showed a good correlation with arterial levels. 
O'connor in 1998 recommended the use of the transcutaneous monitor for the long distance transport 
(greater than 30 miles) of ventilated neonates. He found in his prospective trial that monitored 
neonates were more likely to arrive with normal blood gases and experience lower peak airway 
pressures than non-monitored neonates. He also found that pre-transport stabilization times were not 
different between the two groups. 
There were reports of burns being caused by the early transcutaneous gas monitors in addition to the 
reports of inaccuracy. The risk ofburns has now been eradicated through design changes. The advent 
of pulse oximetry, with its ease of use, also caused a decrease in the use of the transcutaneous meter. 
There are areas of the world where its use is reduced or not available because of economic reasons, 
but it is considered a standard of care in many leading centres. However, most level three intensive 
care units in North America today use transcutaneous monitoring on their critical neonates. In the 
ICUs in the Children's Hospital at the University College of Los Angeles, very few blood gases are 
taken, almost all gas partial pressures being monitored transcutaneous. 
The accuracy and clinical applicability of the transcutaneous monitor have been questioned but more 
recent studies generally agree that it has a place both for research and clinical purposes. Rauch 
showed that in a paediatric intensive care unit there was significant correlation between the 
intermittently taken arterial and transcutaneous carbon dioxide levels in neonates and infants with a 
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variety of underlying pathologies. There was, however, a consistent difference between the arterial 
and transcutaneous readings. He recommended further refinement of the technology to produce 
greater accuracy. 
Transcutaneous readings depend not only on blood gases, but also local perfusion, site preparation 
and skin density. Skill is required in its application and interpretation. Transcutaneous readings are 
thus reflections of blood gas values. Blood gas values hopefully reflect organ values. 
During the time that studies on the usefulness or otherwise of the transcutaneous meter have been 
reported, the companies making them have created newer, improved versions as a response to the 
problems and criticisms. Thus the early problems of user unfriendliness with problematic sensors, 
inaccuracy, poor repeatability, baseline sensor electrode drift, lack of compensation for temperature 
or atmospheric pressure, heat related skin injuries etc. have been largely attended to. In addition 
smaller, lighter sensors are more easily and safely applied to the neonatal chest wall, where larger, 
heavier sensors may cause compression, twisting or even ischaemia of the relatively less perfused 
neonatal tissue. It should be noted that it is important to change measurement sites on a regular basis. 
In this study we used the Novametrix 860 meter. The Novametrix 860 transcutaneous carbon dioxide 
meter is the most recent model manufactured by Novametrix. Its advantages over older versions 
include more reliable and durable sensors. The sensor is a Stow-Severinghaus pH I Clark-type 
polargraphic variety. It is small and light and has a fast response time and can be easily re-
membraned when required. 
The monitor demonstrates real time analysis with a 45 second response time, rapid automatic two-
point calibration procedures against known gases with built-in barometric pressure compensation for 
increased accuracy. Stability is quoted at "better than 2mmHglhr". 
An automatic skin timer enhances patient safety and comfort. 
Technically, the displayed carbon dioxide partial pressure is compensated for metabolic factors 
related to the temperature effect and carbon dioxide production. It has limit alerts that are adjustable 
and retainable. It has the facility to select different sensor temperatures to accommodate differing 
diffusion distances due to differing skin and subcutaneous tissue thickness, i.e. for neonates or adults. 
There is an automatic power shutdown to the sensor heater to prevent burns if temperature limit is 
reached. Also the duration of sensor activity at one given site is monitored and limited to prevent 
InJury. 
Local power is the amount of energy required to heat the tissue to the appropriate temperature. This 
is also monitored and displayed. 
To monitor trends this monitor has a digital, continuous display with a memory. 
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We also looked for other side effects or differences such as chest wall rigidity, post-operative 
analgesic requirements and bleeding. 
During this study, within patient changes, represented as a percentage of the baseline readings are 
compared between control and remifentanil groups. Absolute values have not been used because of 
the huge variation of baselines and changes with age. 
Thus the control group represents the "usual" levels of stress response, the "usual" recovery profile 
and the "usual" post-operative respiratory patterns. Against this standard the remifentanil group can 
be compared, using standard statistical analysis. Any significant differences found between the two 
groups thus demonstrate a significant difference in stress level, recovery profile or post-operative 
respiratory profile. 
It is the intention of this trial to compare the response to remifentanil versus control within each 
separate age group as well as looking at all ages combined. It is beyond the scope of this study to 
compare age groups with each other, although the data and mode of statistical analysis does allow 
inter-age group comparisons to be made. This is an area for further study. 
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4. RESULTS: 
This section consists of a classification of the parameters analysed, a description of the modes of 
statistical analyses used and then the individual results sections. 
Classification of the parameters analysed 
14 
There were 33 patients in group R (remifentanil) and 29 patients in group S (control). Within each 
treatment group, the patients were then divided into "x-premies", neonates, infants, over 1 year olds 
and all ages combined. The following parameters are assessed statistically: 
Patient Characteristics: 
An analysis is performed to compare the patient profiles (age, weight, height, baseline cardiovascular 
parameters) in the remifentanil and control groups, both overall and within each age bracket, to 
ensure statistical comparability. 
Anaesthesia Characteristics: 
An analysis is performed to ensure that a comparable duration of anaesthesia was received by the 
remifentanil and the control groups, both overall and within each age bracket. 
Response To Drug: 
An analysis is performed to compare the haemodynamic response to administration of remifentanil 
and control, both overall and within each age bracket. 
Response To Tunnelling: 
An analysis is performed to compare the degree and duration of changes in autonomic and endocrine 
markers of stress, in the remifentanil and control groups, both overall and within each age bracket. 
Recovery Profile: 
An analysis is performed to compare the rates of recovery from anaesthesia in the remifentanil and 
control groups, both overall and within each age bracket. 
Respiratory Depression: 
An analysis is performed to compare the degree of post-operative respiratory depression in the 
remifentanil and control groups, both overall and within each age bracket. 
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Explanation of statistical analyses used. including definitions of patient groups: 
Age categories 
The age groups that have been looked at are x-premies, neonates, infants, older children and all ages 
combined. 
X-premies are babies born before 35 weeks of post conceptual age and who are still less than 56 
weeks of post conceptual age. This group is made up of patients from both the neonate and infant age 
brackets. They have been analysed separately because premature babies may represent a group that is 
distinct from term babies. 
Neonates are babies during their first 28 days of extra-uterine life. 
Infants are babies between the ages of one month and one year. 
Older children are children over the age of one year. 
Treatment Groups 
The patients have all been allocated randomly to receive either remifentanil (R) or saline (S) as 
control 
Abbreviations 
ANOVA =Analysis ofVariance 
Statistical Tests 
The modes of analysis were chosen by an independent body at the Medicines Research Council and 
were part of the original design protocol. Tests were used for parametric data and for non-parametric 
data. 
Tests for parametric data 
For the parametric data, tables include basic statistical data, using number of patients in sample, 
mean and standard deviation. 
Several different types of statistical analysis have then been applied to this data. The use of different 
types of analysis can increase the amount of statistical evidence available from which to make final 
conclusions. 
The tests applied to this parametric data include analysis of variance, which uses pooled data to test 
each age group. This increases the power of the result when all ages together are considered, because 
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of the increased numbers involved, but it decreases the accuracy of result within each specific age 
category. 
The ANOVA tables suggest the statistical likelihoods ofthe following: 
In the first column, first row "Code" refers to remifentanil or control grouping. The p value in this 
row suggests the statistical likelihood that the means in the remifentanil and control groups are the 
same, when all age groups are combined. 
In the second row "agecode" refers to age groupings. The p value in this row suggests the statistical 
likelihood that the means in each age category are the same (this is unrelated to remifentanil or 
control groupings). 
In the third row "code#agecod" refers to the effect of age on the response to remifentanil or control. 
The p value in this row suggests whether the conclusion reached by the p value in row one is also 
applicable to each individual age group as well. A "p" value of< 0.05 is regarded as significant. 
95% confidence intervals for the means are given. If one interval overlaps with the other, there is 
considered to be no statistically significant difference between the means of the remifentanil and 
control groups. 
95% confidence intervals for the difference between the means. This assesses the difference between 
remifentanil and control group means and gives the 95% confidence limits of this difference. If one 
limit is a positive figure and the other limit is negative, the difference includes the number zero, i.e. 
the means are considered not statistically different. 
T tests between the means. This is a standard 2 sample T test that gives a p value which if< 0.05 
suggests that the means are statistically different and if> 0.05 suggests that they are not significantly 
different. 
Box and whisker charts. These are reader friendly charts that give an easy visual representation of 
the means or medians and their 95% confidence intervals. If the intervals overlap with each other, 
there is no statistically significant difference. 
The conclusions that can be drawn from each individual test have been stated in bold, 
immediately underneath the test. 
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Tests for non-parametric data 
For the non parametric data, ie where "censored" data (arbitrary cut off values) have been used, the 
tables include medians and 95% confidence intervals. 
The tests applied to this data include cox regression tests, which is comparable to the analysis of 
variance test for parametric data. As with analysis of variance tables the p value in the first row 
suggests the statistical difference between the remifentanil and control groups when all age groups 
are combined. The p value in the second row suggests age differences, unrelated to remifentanil or 
control groupings. The p value in the third row suggests whether the conclusions reached by the p 
value in row one are applicable equally to all age groups. 
Log rank tests give a p value for each individual age category that suggests the statistical likelihood 
that the medians are the same. 
Wilcox and -2LR test results are also included, although no conclusions have been drawn from them 
due to the decreased accuracy of these tests. 
Box and whisker charts are presented as either the mean and the 95% confidence interval of the mean 
for parametric data, or as the median and the 95% confidence interval of the median for non-
parametric data. 
Generally speaking there should be good correlation between the results of the various tests. This is 
not always the case, however, because of differences between the tests, i.e. analysis of variance 
testing uses pooled variances using data from all age groups together and thus conclusions are not as 
accurate for individual age categories as a conclusions made from a two sample T test or a 95% 
confidence interval. On occasions the box and whisker confidence interval graphs are at odds with 
the comparable confidence interval figures; this is due to the use of slightly different statistical 
computer programmes. Usually there is good agreement between these different types of statistical 
analysis, but in borderline cases, results may differ slightly. 
Final conclusions are ~iven at the end of each section, using all the data from all the tests. 
Again, conclusions are written in bold. 
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Individual Results for each parameter 
Patient Characteristics 
Age, weight, height and baseline cardiovascular parameters are compared in the remifentanil and 
control groups, within each age group, using box and whisker charts, analysis of variance, T tests and 
95% confidence intervals, at p = 0.05. They are found to be similar. Thus differences found during 
the trial between the groups can be interpreted as being related purely to the effect of remifentanil or 
control. 
This "All ages " table shows the means. standard errors of the mean and p values testing the null 
hypothesis that the remifentanil and control groups have the same characteristics and are thus 
comparable: 
Age Weight Height Heart rate Systolic Mean Diastolic 
(months) (Kg) (em) Beats/min Pressure Pressure Pressure 
mmHg mmHg mmHg 
Control 34.8 (8.9) 10.5 (1.9) 76.3 (6.2) 106.7 85.6 (3.7) 60.1 (3.3) 50.4 (3.2) 
(4.0) 
Remifent 23.6 (5.8) 8.65 (1.2) 71.8 (4.7) 113.2 83.4 (3.9) 60.4 (3.0) 48.2 (2.6) 
(4.0) 
P value >0.05 > 0.05 > 0.05 > 0.05 >0.05 > 0.05 > 0.05 
On the following pages numbered A to AA are the detailed statistics for each variable within each 
age category 
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Table to show the sex distribution within remifentanil and control groups 
The first column shows the number of females 
The second column shows the number of males 
The third column shows both sexes combined 
The rows show the remifentanil numbers (R) and the control numbers (S) 
f m all 
s 14 15 29 
R 15 18 33 
All 29 33 62 
A 
This shows that both remifentanil and control ~roups have a similar proportions 
of male and female. 
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x-prem neonate infant older all 
Confidence intervals and two sample T test to compare the mean ages, in months, 
between remifentanil and control groups, in each age group: 
X -nrem1e 
N Mean StDev SEMean 95%CI 
s 4 2.112 0.895 0.45 1.48-2.74 
R 4 2.12 1.33 0.67 1.18- 3.06 
Confidence intervals overlap, therefore the mean ages are not significantly 
different 
95% Confidence interval for the difference between the means -2.07 to 2.05 
The difference between the means is therefore not significant 
T test for null hypothesis that the means are the same: 
T= -0.02 P=0.99 DF= 5 
The null hypothesis is proven, thus the mean ages are not significantly different 
B 
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Neonate 
N Mean StDev SEMean 95%CI 
s 5 0.520 0.236 0.11 0.4-0.7 
R 8 0.587 0.243 0.086 0.5- 0.7 
Confidence intervals overlap, therefore the mean ages are not significantly 
different 
95% Confidence interval for the difference between the means -0.38 to 0.247 
The difference between the means is therefore not significant 
T test for null hypothesis that the means are the same: 
T= -0.50 P=0.63 DF= 8 
The null hypothesis is proven, thus the mean ages are not significantly different 
Infant 
N Mean StDev SEMean 95%CI 
s 11 4.77 3.78 1.1 3.2- 6.4 
R 13 5.15 3.68 1.0 3.7- 6.6 
Confidence intervals overlap, therefore the mean ages are not significantly 
different 
95% Confidence interval for the difference between the means -3.6 to 2.8 
The difference between the means is therefore not significant 
T test for null hypothesis that the means are the same : 
T= -0.25 P=0.80 DF= 21 
The null hypothesis is proven, thus the mean ages are not significantly different 
Older Child 
N Mean StDev SEMean 95%CI 
s 13 73.5 48.7 14 54.7-92.2 
R 12 59.0 ,31.9 9.2 46.3- 71.8 
I 
Confidence intervals overlap, therefore the mean ages are not significantly 
different 
95% Confidence interval for the difference between the means -48.5 to 20 
The difference between the means is therefore not significant 
T test for null hypothesis that the means are the same 
T= -0.88 P=0.39 DF= 20 
The null hypothesis is proven, thus the mean ages are not significantly different 
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CONCLUSION 
Notwithstanding the quite large. but not statistically significant. mean age 
difference of the two groups. the distributions into the five age categories of the 
remifentanil and control groups are quite similar. A chi-square test of 
homogeneity of the distributions gives result: observed chi-square = 0.644 on 2 
degrees of freedom. which is not significant. 
There was also no statistical difference. at p= 0.05. between the mean ages in the 
remifentanil and control groups. within each age group. using. 95% confidence 
intervals for the means. 95% confidence intervals for the difference between the 
means , T tests and box and whisker confidence interval charts. 
D 
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x-prem neonate infant older all 
Two sample T test and 95% confidence intervals to compare weights, in kilograms, 
between remifentanil and control groups, in each age group: 
X -nremtes 
N Mean StDev SEMean 95%CI 
s 4 2.875 0.690 0.34 2.4 - 3.35 
R 4 2.42 1.00 0.50 1.72- 3.12 
Confidence intervals overlap, therefore the mean weights are not significantly 
different 
95% Confidence interval for the difference between the mean weights -1.12 to 2.02 
The difference between the mean weights is therefore not significant 
T test for null hypothesis that the mean weights are the same 
T= 0.74 P=0.49 DF= 5 
The null hypothesis is proven, thus the mean weights are not significantly 
different 
E 
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Neonate 
N Mean StDev SEMean 95%CI 
s 5 3.220 0.449 0.20 2.94- 3.50 
R 8 3.283 0.642 0.23 2.97-3.60 
Confidence intervals overlap, therefore the mean weights are not significantly 
different 
95% Confidence interval for the difference between the mean weights -0.74 to 0.61 
The difference between the mean weights is therefore not significant 
T test for null hypothesis that the mean weights are the same 
T= -0.21 P=0.84 DF= 10 
The null hypothesis is proven, thus the mean weights are not significantly 
different 
N Mean StDev SEMean 95%CI 
s 11 5.06 2.49 0.75 4.02-6.11 
R 13 5.54 2.76 0.77 4.48- 6.61 
Confidence intervals overlap, therefore the mean weights are not significantly 
different 
95% Confidence interval for the difference between the mean weights is -2.71 to 1.75 
The difference between the mean weights is therefore not significant 
T test for null hypothesis that the mean weights are the same 
T=-0.45 P=0.66 DF= 21 
The null hypothesis is proven, thus the mean weights are not significantly 
different 
Older Child 
N Mean StDev SEMean 95%CI 
s 13 18.0 11.2 3.1 13.69 - 22.34 
R 12 15.59 6.86 2.0 12.84- 18.34 
Confidence intervals overlap, therefore the mean weights are not significantly 
different 
95% Confidence interval for the difference between the mean weights is -10.1 to 5.3 
The difference between the mean weights is therefore not significant 
T test for null hypothesis that the mean weights are the same 
T= -0.66 P=0.52 DF= 20 
The null hypothesis is proven, thus the mean weights are not significantly 
different 
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CONCLUSION 
There was no difference between wei~hts in the remifentanil and control ~roups , 
within each a~e ~roup. at p=0.05. us in~ 95% confidence intervals of the means. 
95% confidence intervals of the difference between the means. T tests and box 
and whisker charts 
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x-p-em reonate infant older all 
Two sample T test and confidence interval to compare height in centimetres between 
remifentanil and control groups. in each age group: 
X-Premies 
N Mean StDev SEMean 95%CI 
s 4 45.75 4.92 2.5 42.3-49.3 
R 4 44.25 7.14 3.6 39.3-49.3 
Confidence intervals overlap, therefore the mean heights are not significantly 
different 
95% Confidence interval for the difference between the mean heights is -9.6 to 12.6 
The difference between the mean heights is therefore not significant 
T test for null hypothesis that the mean heights are the same 
T= 0.35 P=0.74 DF= 5 
The null hypothesis is proven, thus the mean heights are not significantly 
different 
H 
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Neonate 
N Mean StDev SE Mean 95%CI 
s 5 49.00 4.64 2.1 46.1-51.9 
R 8 47.75 4.30 1.5 45 .6- 49.9 
Confidence intervals overlap, therefore the mean heights are not significantly 
different 
95% Confidence interval for the difference between the mean heights is -4.7 to 7.2 
The difference between the mean heights is therefore not significant 
T test for null hypothesis that the mean heights are the same 
T= 0.49 P=0.64 DF= 8 
The null hypothesis is proven, thus the mean heights are not significantly 
different 
Infant 
N Mean StDev SEMean 95% CI 
s 11 55.6 12.1 3.7 50.5-60.7 
R 13 61.8 16.1 4.5 55.6-68.1 
Confidence intervals overlap, therefore the mean heights are not significantly 
different 
95% Confidence interval for the difference between the mean heights is -18.2 to 5.8 
The difference between the mean heights is therefore not significant 
T test for null hypothesis that the mean heights are the same 
T= -1.07 P=0.29 DF= 21 
The null hypothesis is proven, thus the mean heights are not significantly 
different 
Older Child 
N Mean StDev SE Mean 95%CI 
s 13 104.3 30.8 8.6 92.4- 116.2 
R 12 98.7 22.0 6.3 89.9- 107.6 
Confidence intervals overlap, therefore the mean heights are not significantly 
different 
95% Confidence interval for the difference between the mean heights is -27.7 to 16.6 
The difference between the mean heights is therefore not significant 
T test for null hypothesis that the mean heights are the same 
T= -0.52 P=0.61 DF= 21 
The null hypothesis is proven, thus the mean heights are not significantly 
different 
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CONCLUSION 
There was no difference. at p=0.05, between heiehts in the remifentanil and 
control eroups. within each aee eroup. usine 95% confidence intervals for the 
mean. 95% confidence intervals for the difference between the means. Ttests and 
box and whisker charts. 
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Mean baseline heart rate . in beats per minute & 95% confidence interval, 
remifentanil versus control 
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x-prem neonate infant older all 
Basic statistics 
Rows contain the number, mean and standard deviation of baseline heart rate in 
control (S) or remifentanil (R) 
Columns contain the age categories: neonate, infant,> 1yr old, all ages 
neonate infant > 1yr all ages 
S number 5 11 13 29 
mean 120.20 117.82 92.00 106.66 
sd 15.53 10.08 22.16 21.51 
R number 8 13 12 33 
mean 118.87 124.00 97.58 113.15 
sd 17.48 15.01 26.36 23.17 
all number 13 24 25 62 
mean 119.38 121.17 94.68 110.11 
sd 16.10 13.10 23.92 22.47 
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Analysis of variance for differences between the baseline heart rate in the remifentanil 
and control groups 
The p values in the final column test the null hypothesis that comparative groups are 
the same. The first row (marked "code") compares the remifentanil group baseline 
heart rate against the control. The second row (agecod) compares baseline heart rates 
in different age groups. The third row (code*agecod) assesses whether the 
comparability of remifentanil and control group baseline heart rates, as suggested by 
row one, are consistent amongst the differing age groups. 
Source DF Seq SS Adj SS AdjMS F p 
code 1 651.4 166.9 166.9 0.46 0.501 
agecod 2 9652.1 9728.9 4864.5 13.38 0.000 
code* agecod 2 128.5 128.5 64.2 0.18 0.838 
Error 56 20358.2 20358.2 363.5 
Total 61 30790.2 
Thus the anova table shows that baseline heart rates are different from one a2e 
2roup to the next. as would be expected (p = 0.000). 
It also concludes that there is no statistical difference between the baseline heart 
rates in the remifentanil and control 2roups (p = 0.501) and that this is consistent 
in the different a2e 2roups (p = 0.838). 
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95 % confidence intervals and T tests to compare the baseline heart rates in beats per 
minutes between remifentanil and control groups, in each age group: 
X-Premies 
N Mean StDev SEMean 95%CI 
s 4 119.5 14.0 7.0 109.7- 129.3 
R 4 120.25 3.30 1.7 117.9-122.6 
M 
Confidence intervals overlap, therefore the mean heart rates are not significantly 
different 
95% confidence interval for the difference between the mean heart rates is -23.6 to 
22.1 
The difference between the mean heart rates is therefore not significant 
T test for null hypothesis that the mean heart rates are the same 
T= -0.10 P=0.92 DF= 3 
The null hypothesis is proven, thus the mean heart rates are not significantly 
different 
Neonate 
N Mean StDev SEMean 95%CI 
s 5 120.2 15.5 6.9 110.5- 129.9 
R 8 118.9 17.5 6.2 110.3 - 127.5 
Confidence intervals overlap, therefore the mean heart rates are not significantly 
different 
95% confidence interval for the difference between the mean heart rates is -19.7 to 
22.4 
The difference between the mean heart rates is therefore not significant 
T test for null hypothesis that the mean heart rates are the same 
T= 0.14 P=0.89 DF= 9 
The null hypothesis is proven, thus the mean heart rates are not significantly 
different 
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Infant 
N Mean StDev SEMean 95%CI 
s 11 117.8 10.1 3.0 113.6- 122.0 
R 13 124.0 15.0 4.2 118.2- 129 .. 8 
Confidence intervals overlap, therefore the mean heart rates are not significantly 
different 
95% confidence interval for the difference between the mean heart rates is -16.9 to 
4.5 
The difference between the mean heart rates is therefore not significant 
T test for null hypothesis that the mean heart rates are the same 
T= -1.20 P=0.24 DF= 21 
The null hypothesis is proven, thus the mean heart rates are not significantly 
different 
Older Child 
N Mean StDev SEMean 95%CI 
s 13 92.0 22.2 6.1 83.5- 100.5 
R 12 97.6 26.4 7.6 87.0- 108.2 
Confidence intervals overlap, therefore the mean heart rates are not significantly 
different 
95% confidence interval for the difference between the mean heart rates is -14.8 to 
25.9 
The difference between the mean heart rates is therefore not significant 
T test for null hypothesis that the mean heart rates are the same 
T= 0.57 P=0.57 DF= 21 
The null hypothesis is proven, thus the mean heart rates are not significantly 
different 
CONCLUSION: 
There was no statistical difference, at p=0.05, between the baseline heart rates in 
the remifentanil and control ~:roups , usint: analysis of variance. 95% 
confidence intervals of the means. 95% confidence intervals of the difference 
between the means. T tests and box and whisker charts. in all a~:e ~:roups. 
There was obviously a significant difference in heart rate from one age group to 
the next. 
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Mean baseline systolic blood pressure. in mm Hg. 95% confidence intervals. 
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120 
100 
C) 80 I 
E 
E 60 ..._ 
OSaline 
a_ II Renifentanil 
co 40 (/) 
20 
0 
x -prem neonate infant older all 
Basic statistics 
Rows contain the number, mean and standard deviation of baseline systolic pressure 
in control (S) or remifentanil (R) 
Columns contain the age categories: neonate, infant,> 1 yr old, all ages 
neonate infant > 1 yr all 
s number 5 11 13 29 
mean 65.20 77.00 100.77 85.62 
sd 8.56 17.25 13.13 20.02 
R number 8 13 12 33 
mean 62.50 77.69 103.42 83 .36 
sd 6.37 20.12 13.30 22.23 
all number 13 24 25 62 
mean 63.54 77.38 102.04 84.42 
sd 7.07 18.46 13.01 21.08 
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Analysis of variance for baseline systolic blood pressure in mm Hg. a comparison 
between remifentanil and control groups 
Source DF Seq SS Adj SS AdjMS F 
p 
code 1 78.6 0.6 0.6 0.00 0.958 
agecod 2 14552.6 14190.0 7095.0 31.97 0.000 
code* agecod 2 59.1 59.1 29.5 0.13 0.876 
Error 56 12426.8 12426.8. 221.9 
Total 61 27117.1 
Thus the anova table shows that baseline systolic pressures are different from 
one aee eroup to the next. as would be expected (p = 0.000). 
p 
It also concludes that there is no statistical difference between the baseline 
systolic pressures in the remifentanil and control eroups (p = 0.958) and that this 
is consistent amon2st the different aee eroups (p = 0.876). 
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Confidence intervals and T tests to compare baseline systolic blood pressures in mm 
Hg between remifentanil and control groups, in each age group: 
X-Premies 
N Mean StDev SEMean 95%CI 
s 4 58.25 8.54 4.3 52.2-64.3 
R 4 54.75 6.99 3.5 49.9- 59.7 
Confidence intervals overlap, therefore the mean systolic pressures are not 
significantly different 
95% confidence interval for the difference between the mean systolic pressures is -
10.7 to 17.7 
The difference between the mean systolic pressures is therefore not significant 
T test for null hypothesis that the mean systolic pressures are the same 
T= 0.63 P=0.55 DF= 5 
The null hypothesis is proven, thus the mean systolic pressures are not 
significantly different 
Neonate 
N Mean StDev SEMean 95%CI 
s 5 65.20 8.56 3.8 59.9-70.5 
R 8 62.50 6.37 2.3 59.4- 65.6 
Confidence intervals overlap, therefore the mean systolic pressures are not 
significantly different 
95% confidence interval for the difference between the mean systolic pressures is 
-8.2 to 13.6 
The difference between the mean systolic pressures is therefore not significant 
T test for null hypothesis that the mean systolic pressures are the same 
T= 0.61 P=0.57 DF= 6 
The null hypothesis is proven, thus the mean systolic pressures are not 
si2nificantly different 
Q 
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Infant 
N Mean StDev SEMean 95%CI 
s 11 77.0 17.3 5.2 69.8-84.2 
R 13 77.7 20.1 5.6 69.9- 85.4 
Confidence intervals overlap, therefore the mean systolic pressures are not 
significantly different 
95% confidence interval for the difference between the mean systolic pressur
es is 
-16.6 to 15.2 
The difference between the mean systolic pressures is therefore not significa
nt 
T test for null hypothesis that the mean systolic pressures are the same 
T= -0.09 P=0.93 DF= 21 
The null hypothesis is proven, thus the mean systolic pressures are not 
sig_nificantly different 
Older Child 
N Mean StDev SEMean 95%CI 
s 13 100.8 13.1 3.6 95.7- 105.8 
R 12 103.4 13.3 3.8 98.1 - 108.8 
Confidence intervals overlap, therefore the mean systolic pressures are not 
significantly different 
95% confidence interval for the difference between the mean systolic pressur
es is 
-8.3 to 13.6 
The difference between the mean systolic pressures is therefore not significa
nt 
T test for null hypothesis that the mean systolic pressures are the same 
T= 0.50 P=0.62 DF= 22 
The null hypothesis is proven, thus the mean systolic pressures are not 
sie;nificantly different 
CONCLUSION: 
There was no statistical difference, at p=0.05, between the baseline systolic b
lood 
pressure in the remifentanil and control eroups, in each aee eroup, usine 
analysis of variance. 95% confidence intervals of the mean, 95% confidence
 
intervals of the difference of the means. Ttests and box and whisker charts. 
There was obviously a significant difference in systolic blood pressure from 
one 
age group to the next. 
R 
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Mean baseline mean arterial pressure. in mm Hg. & 95% confidence intervals. 













x-prem neonate infant older all 
Basic statistics 
Rows contain the number, mean and standard deviation of baseline mean arterial 
pressure in control (S) or remifentanil (R) 
Columns contain the age categories: neonate, infant, > 1 yr old, all ages 
neonate infant > 1 yr all ages 
s number 5 11 13 29 
mean 46.000 52.273 72.154 60.103 
sd 7.810 15.389 15.421 17.951 
R number 8 13 12 33 
mean 50.000 54.538 73.917 60.485 
sd 7.728 16.313 14.884 17.277 
all number 13 24 25 62 
mean 48.462 53.500 73.000 60.306 
sd 7.699 15.593 14.874 17.451 
CHAPTER 4- THE TRIAL -RESULTS APPENDIX TO PAGE 18 
Analysis of variance for baseline mean arterial pressure in mmHg. a comparison 
between remifentanil and control groups : 
Source DF Seq SS Adi SS AdiMS F p 
code 1 2.2 98.7 98.7 0.48 0.491 
agecod 2 7050.4 7043.0 3521.5 17.13 0.000 
code*agecod 2 10.5 10.5 5.3 0.03 0.975 
Error 56 11514.0 11514.0 205.6 
Total 61 18577.2 
Thus the anova table shows that baseline mean arterial pressures are different 
from one age group to the next, as would be expected (p = 0.000). 
T 
It also concludes that there is no statistical difference between the baseline mean 
arterial pressures in the remifentanil and control groups (p = 0.491) and that this 
is consistent amongst the different age groups (p = 0.975) 
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Confidence intervals and two sample T test and to compare baseline mean arterial 
pressures in mm Hg between the remifentanil and control groups. in each age group. 
X-Premies 
N Mean StDev SEMean 95%CI 
s 4 37.25 4.99 2.5 33.75-40.8 
R 4 37.50 4.04 2.0 34.7-40.3 
Confidence intervals overlap, therefore the baseline mean arterial pressures are 
not significantly different 
95% confidence interval for the difference between the baseline mean pressures is 
-8.5 to 8.0 
The difference between the baseline mean pressures is therefore not significant 
T test for null hypothesis that the baseline mean pressures are the same 
T= -0.08 P=0.94 DF= 5 
The null hypothesis is proven, thus the baseline mean pressures are not 
sie:nificantly different 
Neonate 
N Mean StDev SEMean 95%CI 
s 5 46.00 7.81 3.5 41.1-50.9 
R 8 50.00 7.73 2.7 46.2- 53.8 
Confidence intervals overlap, therefore the baseline mean arterial pressures are 
not significantly different 
95% confidence interval for the difference between the baseline mean pressures is 
-14.2 to 6.2 
The difference between the baseline mean pressures is therefore not significant 
T test for null hypothesis that the baseline mean pressures are the same 
T= -0.90 P=0.39 DF= 8 
The null hypothesis is proven, thus the baseline mean pressures are not 
sie:nificantly different 
u 
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Infant 
N Mean StDev SEMean 95%CI 
s 11 52.3 15.4 4.6 45.8- 58.7 
R 13 54.5 16.3 4.5 48.2-60.8 
Confidence intervals overlap, therefore the baseline mean arterial pressures are 
not significantly different 
95% confidence interval for the difference between the baseline mean pressures is 
-15.7 to 11.2 
The difference between the baseline mean pressures is therefore not significant 
T test for null hypothesis that the baseline mean pressures are the same 
T= -0.35 P=0.73 DF= 21 
The null hypothesis is proven, thus the baseline mean pressures are not 
si~nificantly different . 
Older Child 
N Mean StDev SEMean 95%CI 
s 13 72.2 15.4 4.3 66.2-78.1 
R 12 73.9 14.9 4.3 67.9-79.9 
Confidence intervals overlap, therefore the baseline mean arterial pressures are 
not significantly different 
95% confidence interval for the difference between the baseline mean pressures is 
-10.8 to 14.3 
The difference between the baseline mean pressures is therefore not significant 
T test for null hypothesis that the baseline mean pressures are the same 
T= 0.29 P=0.77 DF= 22 
The null hypothesis is proven, thus the baseline mean pressures are not 
significantly different 
CONCLUSION: 
There was no statistical difference. at p=O.OS. between the baseline mean arterial 
blood pressure in the remifentanil and control groups, in each age group, using 
analysis ofvariance. 95%confidence intervals of the means. 95% confidence 
intervals of the difference of the means. Ttests and box and whisker charts. 
There was obviously a significant difference in mean arterial pressure from one 
age group to the next. 
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Mean baseline diastolic pressure, in mm H~. & 95% confidence intervals, 













x-p-em raxlate infant older all 
Basic statistics 
Rows contain the number, mean and stand deviation of baseline diastolic pressure in 
control (S) or remifentanil (R) 
Columns contain the age categories: neonate, infant, > 1 yr old, all ages 
neonate infant > 1 yr all ages 
s number 5 11 13 29 
mean 38.800 44.545 59.846 50.414 
sd 7.855 16.464 16.370 17.303 
R number 8 13 12 33 
mean 41.250 41.846 59.667 48.182 
sd 10.110 12.314 13.970 14.970 
all number 13 24 25 62 
mean 40.308 43.083 59.760 49.226 
sd 9.041 14.102 14.948 16.008 
CHAPTER 4- THE TRIAL -RESULTS APPENDIX TO PAGE 18 
Analysis of variance for baseline diastolic blood pressure in mm Hg, a comparison 
between remifentanil and control groups: 
Source DF Seq SS Adj SS AdjMS F p 
code 1 76.9 0.3 0.3 0.00 0.970 
agecod 2 4642.9 4675.8 2337.9 12.06 0.000 
code*agecod 2 56.0 56.0 28.0 0.14 0.866 
Error 56 10855.1 10855.1 193.8 
Total 61 15630.8 
Thus the anova table shows that baseline diastolic pressures are different from 
one aee eroup to the next. as would be expected (p = 0.000). 
It also concludes that there is no statistical difference between the baseline 
diastolic pressures in the remifentanil and control ~:roups (p = 0.970) and that 
this is consistent amon~:st the different a~:e ~:roups (p = 0.866) 
X 
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Confidence intervals and two sample T tests to compare baseline diastolic blood 
pressures in mm Hg between remifentanil and control groups. in each age group 
X-Premies 
N Mean StDev SEMean 95% CI 
s 4 28.50 5.45 2.7 24.7- 32.3 
R 4 28.75 4.27 2.1 25.8- 31.69 
Confidence intervals overlap, therefore the baseline diastolic pressures are not 
significantly different 
95% confidence interval for the difference between the baseline diastolic pressures is 
-9.1 to 8.6 
The difference between the baseline diastolic pressures is therefore not 
significant 
T test for null hypothesis that the baseline diastolic pressures are the same 
T= -0.07 P=0.95 DF= 5 
The null hypothesis is proven, thus the baseline diastolic pressures are not 
sig_nificantly different 
Neonates 
N Mean StDev SEMean 95%CI 
s 5 38.80 7.85 3.5 33.9-43.7 
R 8 41.3 10.1 3.6 36.3-46.2 
Confidence intervals overlap, therefore the baseline diastolic pressures are not 
significantly different 
95% confidence interval for the difference between the baseline diastolic pressures is 
-13.6 to 8.7 
The difference between the baseline diastolic pressures is therefore not 
significant 
T test for null hypothesis that the baseline diastolic pressures are the same 
T=-0.49 P=0.64 DF= 10 
The null hypothesis is proven, thus the baseline diastolic pressures are not 
sh~nificantly different 
y 
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Infants 
N Mean StDev SEMean 95%CI 
s 11 44.5 16.5 5.0 37.6-51.4 
R 13 41.8 12.3 3.4 37.1-46.6 
Confidence intervals overlap, therefore the baseline diastolic pressures are not 
significantly different 
95% confidence interval for the difference between the baseline diastolic pressures is 
-10.0 to 15.4 
The difference between the baseline diastolic pressures is therefore not 
significant 
T test for null hypothesis that the baseline diastolic pressures are the same 
T= 0.45 P=0.66 DF= 18 
The null hypothesis is proven, thus the baseline diastolic pressures are not 
significantly_ different 
Older Child 
N Mean StDev SEMean 95%CI 
s 13 59.8 16.4 4.5 53.5-66.2 
R 12 59.7 14.0 4.0 54.1 - 65.3 
Confidence intervals overlap, therefore the baseline diastolic pressures are not 
significantly different 
95% confidence interval for the difference between the baseline diastolic pressures is 
-12.8 to 12.4 
The difference between the baseline diastolic pressures is therefore not 
significant 
T test for null hypothesis that the baseline diastolic pressures are the same 
T= -0.03 P=0.98 DF= 22 
The null hypothesis is proven, thus the baseline diastolic pressures are not 
significantly different 
CONCLUSION: 
There was no statistical difference. at p=0.05. between the baseline diastolic 
blood pressure in the remifentanil and control &roups, within in each a&e &roup, 
usin& analysis of variance. 95% confidence intervals of the means. 95% 
confidence intervals of the difference of the means. T tests and box and whisker 
charts. 
There was obviously a significant difference in diastolic pressure from one age 
group to the next. 
z 
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OVERALL CONCLUSION: 
The remifentanil and control groups are comparable. within each age group. in 
terms of age. weight. height and baseline cardiovascular parameters. using 
several different forms of statistical analysis. 
Thus differences found between the remifentanil or control groups can be 
interpreted as being related solely to the effect of remifentanil or control. 
AA 
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Anaesthetics Characteristics -
The duration of anaesthesia, in minutes, is compared in remifentanil and control groups, within each 
age group, as is the duration of time from administration of the drug until the end of surgery using 
box and whisker charts, analysis of variance, T tests and 95% confidence intervals, at p = 0.05. 
The duration of anaesthesia is found to be similar in remifentanil and control groups. 
The duration of time between administration ofthe "drug" and the end of surgery was found to be 
similar in the remifentanil and control groups, except in the older child where the control group had a 
longer time interval. (The control group took 57 and the remifentanil group 35 minutes). This, 
presumably, was just a chance occurrence and is discussed later. 
This "All ages combined" table shows the means. standard errors of the mean and p values 
confirming the null hypothesis that the remifentanil and control groups had the same duration of 
anaesthesia: 
Duration of anaesthesia, Duration from drug administration to 
in minutes the end of Surgery, in minutes 
Control 122.1 (5.9) 48.1 (4.4) 
Remifent 116.2 (5.1) 39.7 (4.3) 
P value > 0.05 > 0.05 
I 
On the following pages numbered A to I are the detailed statistics for each variable in each age 
category 
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x-r:rem necmte infall: dder all 
Basic statistics 
Rows contain the number, mean and standard deviation of mean duration of 
anaesthesia, in minutes, in control (S) or remifentanil (R) 
Columns contain the age categories: neonate, infant, > 1 yr old, all ages 
neonate infant > 1 yr old all ages 
s number 5 11 13 29 
mean 116.20 115.09 130.38 122.14 
sd 13.29 17.99 43.42 31.72 
R number 8 13 12 33 
mean 116.50 124.23 107.42 116.24 
sd 17.00 39.15 22.46 29.44 
all number 13 24 25 62 
mean 116.38 120.04 119.36 119.00 
sd 15.08 31.02 36.21 30.42 
CHAPTER 4-THE TRIAL- RESULTS APPENDIX TO PAGE 19 
Analysis of variance for duration of anaesthesia. in minutes: a comparison between 
remifentanil and control groups 
Source DF Seq SS Adj SS AdjMS F p 
code 1 536.5 280.2 280.2 0.30 0.587 
agecod 2 88.0 91.0 45.5 0.05 0.953 
code*agecod 2 3283.5 3283.5 1641.8 1.75 0.183 
Error 56 52526.0 52526.0 938.0 
Total 61 56434.0 
The anova table shows that there is no statistical difference between the 
durations of anaesthesia in the remifentanil and control groups (p = 0.587) and 
that this is consistent amongst the different age groups (p = 0.838). 
B 
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Confidence intervals and two sample T tests to compare the durations of anaesthesia 
in minutes in remifentanil and control groups. in each age group: 
X-Premie 
N Mean StDev SEMean 95%CI 
s 4 121.0 28.2 14 101.4- 140.6 
R 4 137.2 15.3 7.7 126.4- 148.0 
Confidence intervals overlap, therefore the mean durations of anaesthesia are 
not significantly different 
c 
95% confidence interval for the difference between the mean durations of anaesthesia 
is -61 to 28.3 
The difference between the mean durations of anaesthesia is therefore not 
significant 
T test for null hypothesis that the mean durations of anaesthesia are the same 
T= -1.01 P=0.37 DF= 4 
The null hypothesis is proven, thus the mean durations of anaesthesia are not 
significantly different 
Neonate 
N Mean StDev SEMean 95%CI 
s 5 116.2 13.3 5.9 107.9- 124.5 
R 8 116.5 17.0 6.0 108.1 - 124.9 
Confidence intervals overlap, therefore the mean durations of anaesthesia are 
not significantly different 
95% confidence interval for the difference between the mean durations of anaesthesia 
is -19.1 to 18.5 
The difference between the mean durations of anaesthesia is therefore not 
significant 
T test for null hypothesis that the mean durations of anaesthesia are the same 
T= -0.04 P=0.97 DF= 10 
The null hypothesis is proven, thus the mean durations of anaesthesia are not 
significantly different 
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Infant 
N Mean StDev SE Mean 95% CI 
s 11 115.1 18.0 5.4 107.6- 122.6 
R 13 124.2 39.1 11 109.1 - 139.3 
Confidence intervals overlap, therefore the mean durations of anaesthesia are 
not significantly different 
95% confidence interval for the difference between the mean durations of anaesthesia 
is -34.8 to 16 
The difference between the mean durations of anaesthesia is therefore not 
significant 
T test for null hypothesis that the mean durations of anaesthesia are the same 
T= -0.75 P=0.46 DF= 17 
The null hypothesis is proven, thus the mean durations of anaesthesia are not 
sb~nificantly different 
Older Child 
N Mean StDev SEMean 95%CI 
s 13 130.4 43.4 12 113.3- 147.1 
R 12 107.4 22.5 6.5 98.4- 116.4 
Confidence intervals overlap, therefore the mean durations of anaesthesia are 
not significantly different 
95% confidence interval for the difference between the mean durations of anaesthesia 
is -51.7to6 
The difference between the mean durations of anaesthesia is therefore not 
significant 
T test for null hypothesis that the mean durations of anaesthesia are the same 
T= -1.68 P=O.ll DF= 18 
The null hypothesis is proven, thus the mean durations of anaesthesia are not 
sie:nificantly different 
CONCLUSION: 
There is no statistical difference, at p=0.05. between the durations of anaesthesia 
in the remifentanil and control groups. in all age groups. using analysis of 
variance. 95% confidence limits of the means, 95% confidence limits of the 
difference between the means. two sample T tests and box and whisker charts. 
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Mean duration of time in minutes from drug administration until the end of surgery. in 

















x-prem neonate infant older all 
Basic statistics 
Rows contain the number, mean and standard deviation of time from drug 
administration, in minutes, until end of surgery in control (S) or remifentanil (R) 
Columns contain the age categories: neonate, infant, > 1 yr old, all ages 
neonate infant > 1 yr old all ages 
s number 5 11 13 29 
mean 42.800 39.636 57.308 48.103 
sd 10.183 10.308 32.053 23.782 
R number 8 13 12 33 
mean 36.625 45.769 35.167 39.697 
sd 9.117 38.027 9.408 24.817 
all number 13 24 25 62 
mean 39.000 42.958 46.680 43.629 
sd 9.635 28.467 26.110 24.507 
CHAPTER 4-THE TRIAL- RESULTS APPENDIX TO PAGE 19 
Analysis of variance for the duration of time. in minutes. from drug administration 
until the end of surgery: a comparison of remifentanil and control groups 
Source DF Seq SS Adi SS Adi MS F p 
code 1 1090.8 753.5 753.5 1.29 0.261 
agecod 2 383.7 378.6 189.3 0.32 0.725 
code*agecod 2 2448.0 2448.0 1224.0 2.10 0.133 
Error 56 32714.0 32714.0 584.2 
Total 61 36636.5 
The anova table shows that there is no statistical difference between the 
durations of time in minutes from drug administration until the end of surgery 
in the remifentanil and control groups (p = 0.261) and that this is consistent 
amongst the different age groups (p = 0.133). 
F 
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95% confidence intervals and two sample T tests to compare the duration, in minutes, 














SE Mean 95% CI 
7.9 31.9- 54.1 
10 33.2- 61.2 
Confidence intervals overlap, therefore the mean durations from drug 
administration to end are not significantly different 
95% confidence interval for the difference between the mean durations from drug 
administration until the end of surgery is -37.0 to 28 
The difference between the mean durations from drug administration until the 
end of surgery is therefore not significant 
T test for null hypothesis that the mean durations from drug administration until the 
end of surgery are the same 
T= -0.33 P=0.75 DF= 5 
The null hypothesis is proven, thus the mean durations from drug 















36.5 - 49.1 
32.3-41.1 
Confidence intervals overlap, therefore the mean durations from drug 
administration to end of surgery are not significantly different 
95% confidence interval for the difference between the mean durations from drug 
administration until the end of surgery is -7.0 to 19.4 
The difference between the mean durations from drug administration until the 
end of surgery is therefore not significant 
T test for null hypothesis that the mean durations from drug administration until the 
end of surgery are the same 
T= 1.11 P=0.31 DF= 7 
The null hypothesis is proven, thus the mean durations from drug 
administration until the end of surgery are not significantly different 

















Confidence intervals overlap, therefore the mean durations from drug 
administration to end are not significantly different 
95% confidence interval for the difference between the mean durations from drug 
administration until the end of surgery is -29.7 to 1 7 
The difference between the mean durations from drug administration until the 
end of surgery is therefore not significant 
T test for null hypothesis that the mean durations from drug administration until the 
end of surgery are the same 
T= -0.56 P=0.59 DF= 14 
The null hypothesis is proven, thus the mean durations from drug 

















Confidence intervals DO NOT overlap, therefore the mean durations from drug 
administration to end are significantly different. This is probably a chance 
finding in this age group and is at odds with the findings in all other age groups 
and with all ages combined 
95% confidence interval for the difference between the mean durations from drug 
administration until the end of surgery is -42.1 to -2.2 
H 
The difference between the mean durations from drug administration until the 
end of surgery IS THEREFORE significant. As with the above confidence 
interval, it is probably a chance finding and is at odds with the results in all other 
age groups 
T test for null hypothesis that the mean durations from drug administration until the 
end of surgery are the same 
T= -2.38 P=0.032 DF= 14 
The ALTERNATIVE hypothesis is proven, thus the mean durations from drug 
administration until the end of surgery are significantly different. Again, this a 
probably a chance finding, as stated for the above two tests. 
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CONCLUSION: 
Except in the case of the > 1 year olds. there is no difference between 
remifentanil and control ~roups, at p=0.05, in the duration of time between 
administration of the "dru~" until the end of sur~ery. in all a~e ~roups. 
This conclusion is reached by usin~ 95% confidence intervals for the mean. 95% 
confidence intervals for the differences between the means. analysis of variance. 
T tests and box and whisker charts 
In the over 1 year old child. the control ~roup result was 57 minutes and the 
remifentanil ~roup 35 minutes. This was probably a chance occurrence. given 
that this a~e ~roup overall had a mean duration of 46 minutes compared to 43 
minutes in infants and 39 minutes in neonates (no statistical difference) 
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Cardiovascular response to drug 
Cardiovascular responses to the administration of remifentanil and control are compared, using box 
and whisker charts, 95% confidence intervals, T tests and analysis of variance, in each age group. 
There was a decrease in heart rate and blood pressure post remifentanil administration, compared to 
control, which, generally speaking, was statistically significant, across the age groups, at p = 0.05. 
These findings seemed to be even more significant the older the child. 
20 
This "All ages combined" table shows the means. standard errors of the mean and p values testing the 
null hypothesis that the remifentanil and control groups had the same cardiovascular response to the 
drug: 
Percentage Heart Percentage Percentage Percentage 
Rate Change Systolic Pressure Mean Pressure Diastolic Pressure 
Change Change Change 
Control 2.8 (1.4) 5.8 (2.2) 8.2 (3.0) 4.6 (3.9) 
Remifentanil -5.8 (1.0) -2.1 (2.5) -7.9 (2.9) -8.8 (3.6) 
P value p < 0.05 p < 0.05 p < 0.05 p < 0.05 
On the following pages numbered A to S are the detailed statistics for each variable in each age 
category 
CHAPTER 4 -THE TRIAL - RESULTS APPENDIX TO PAGE 20 A 
Mean percentage change in heart rate, in beats per minute, from baseline, & 95% 
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Basic statistics 
Rows contain the number, mean and standard deviation of maximum percentage 
change in heart rate post drug administration in control (S) or remifentanil (R) 
Columns contain the age categories: neonate, infant, > 1 yr old, all ages 
neonate infant > 1 year all ages 
s number 5 11 13 29 
mean 1.4400 0.3818 5.3538 2.7931 
sd 3.5225 3.0649 10.0095 7.3295 
R number 8 13 12 33 
mean -4.0375 -6.8154 -5.7417 -5.7515 
sd 5.3976 5.7798 5.5028 5.5230 
all number 13 24 25 62 
mean -1.9308 -3.5167 0.0280 -1.7548 
sd 5.3688 5.9104 9.7971 7.6900 
CHAPTER 4 -THE TRIAL- RESULTS APPENDIX TO PAGE 20 B 
Analysis of variance for the percentage change in heart rate post drug administration. 
a comparison of remifentanil and control groups 
Source DF Seq SS Adj SS Adj MS F p 
code 1 1126.95 865.16 865.16 21.21 0.000 
agecod 2 116.37 112.76 56.38 1.38 0.259 
code*agecod 2 80.21 80.21 40.10 0.98 0.380 
Error 56 2283.77 2283.77 40.78 
Total 61 3607.29 
Thus the anova table shows that percentage change in heart rate from baseline 
post drug administation is statistically different between remifentanil and 
control groups (p=O.OOO). Remifentanil causing a significant bradycardia when 
compared to control. This finding is consistent amongst the different age groups 
(p = 0.380). 
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Confidence intervals and two sample T tests to compare the percentage change in 



















Confidence intervals DO NOT overlap, therefore the mean percentage changes 
in heart rate after drug administration are significantly different 
95% confidence interval for the difference between the mean percentage changes in 
heart rate post drug administration is 2.2 to 20.1 
The difference between the mean percentage change in heart rate after drug 
administration IS THEREFORE significant 
T test for null hypothesis that the mean percentage changes in heart rate post drug 
administration are the same. 
T= 3.45 P=0.026 DF= 4 
The ALTERNATIVE hypothesis is proven, thus the mean percentage changes in 



















Confidence intervals DO NOT overlap, therefore the mean percentage changes 
in heart rate after drug administration are significantly different 
95% confidence interval for the difference between the mean percentage changes in 
heart rate post drug administration is 0.0 to 11.0 
The difference between the mean percentage change in heart rate after drug 
administration IS THEREFORE significant 
T test for null hypothesis that the mean percentage changes in heart rate post drug 
administration are the same. 
T= 2.21 P=0.05 DF= 10 
The ALTERNATIVE hypothesis is proven, thus the mean percentage changes in 
heart rate are significantly different 
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Infant 
N Mean StDev SEMean 95%CI 
s 11 0.38 3.06 0.92 ( -0.90) - 1.67 
R 13 -6.82 5.78 1.6 (-9.04)- (-4.59) 
Confidence intervals DO NOT overlap, therefore the mean percentage changes 
in heart rate after drug administration are significantly different 
95% confidence interval for the difference between the mean percentage changes in 
heart rate post drug administration is 3.31 to 11.1 
The difference between the mean percentage change in heart rate after drug 
administration IS THEREFORE significant 
T test for null hypothesis that the mean percentage changes in heart rate post drug 
administration are the same. 
T= 3.89 P=O.OOll DF= 18 
The ALTERNATIVE hypothesis is proven, thus the mean percentage changes in 



















Confidence intervals DO NOT overlap, therefore the mean percentage changes 
in heart rate after drug administration are significantly different 
95% confidence interval for the difference between the mean percentage changes in 
heart rate post drug administration is -17.8 to -4.4 
The difference between the mean percentage change in heart rate after drug 
administration IS THEREFORE significant 
T test for null hypothesis that the mean percentage changes in heart rate post drug 
administration are the same. 
T= -3.47 P=0.0027 DF= 18 
The ALTERNATIVE hypothesis is proven, thus the mean percentage changes in 
heart rate are significantly different 
CONCLUSION: 
There is a statistically si~nificant fall, at p=0.05, in the heart rate post 
remifentanil administration. compared to the control ~roup. in all a~e ~roups. 
usin~ 95% confidence intervals of the mean. 95% confidence intervals of the 
difference of the means. analysis of variance tables. T tests and box and whisker 
charts. The mean percentage change in heart rate after remifentanil 
administration was -5.8 (sd= 5.5) and after control was +2.8 ( sd=7.3) when all 
ages are considered. 
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Mean percentage change in systolic pressure post drug administration. in mm Hg. & 














x-prem neonate infant older all 
Rows contain the number, mean and standard deviation of maximum percentage 
change in systolic blood pressure post drug administration in control (S) or 
remifentanil (R) 
Columns contain the age categories: neonate, infant, > 1 yr old, all ages 
neonate infant > 1 year old all ages 
s number 5 11 13 29 
mean 6.860 4.755 6.323 5.821 
sd 12.526 14.933 9.140 11.774 
R number 8 13 12 33 
mean 3.700 -4.369 -3.400 -2.061 
sd 23.778 10.717 8.299 14.197 
all number 13 24 25 62 
mean 4.915 -0.188 1.656 1.626 
sd 19.613 13.358 9.895 13.604 
CHAPTER 4 -THE TRIAL- RESULTS APPENDIX TO PAGE 20 
Analysis of variance for the percentage change in systolic blood pressure post drug 
administration. remifentanil versus control 
Source DF S~g_ SS Adj SS AdiMS F p 
code 1 958.8 741.6 741.6 4.17 0.046 
agecod 2 279.8 213.2 106.6 0.60 0.552 
code*agecod 2 97.7 97.7 48.9 0.27 0.761 
Error 56 9953.7 9953.7 177.7 
Total 61 11289.9 
Thus the anova table shows that percentage change in systolic blood pressure 
from baseline post drug administration is statistically different in the 
remifentanil and control groups (p=0.046). Remifentanil causes a statistically 
significant degree of hypotension (-2.06%) when compared to control (5.8%). 
This finding is consistent amongst the different age groups (p = 0.761): 
F 
CHAPTER 4 -THE TRIAL- RESULTS APPENDIX TO PAGE 20 
Confidence intervals and two sample T test to compare percentage change in systolic 



















Confidence intervals overlap, therefore the mean percentage changes in systolic 
pressure post drug administration are not significantly different 
95% Confidence interval for the difference between the mean percentage changes in 
systolic pressure post drug administration is -42.8 to 25.8 
The difference between the mean percentage changes in systolic pressure post 
drug administration is therefore not significant 
T test for null hypothesis that the mean percentage changes in systolic pressure post 
drug administration are the same 
T= -0.64 P=0.55 DF= 5 
The null hypothesis is proven, thus the mean percentage changes in systolic 



















Confidence intervals overlap, therefore the mean percentage changes in systolic 
pressure post drug administration are not significantly different 
95% Confidence interval for the difference between the mean percentage changes in 
systolic pressure post drug administration is -19.4 to 25.7 
The difference between the mean percentage changes in systolic pressure post 
drug administration is therefore not significant 
T test for null hypothesis that the mean percentage changes in systolic pressure post 
drug administration are the same 
T= 0.31 P=0.76 DF= 10 
The null hypothesis is proven, thus the mean percentage changes in systolic 
pressure post dru2 administration are not si2nificantly different 
G 
CHAPTER 4 -THE TRIAL- RESULTS APPENDIX TO PAGE 20 
Infant 
N Mean StDev SEMean 95%CI 
s 11 4.8 14.9 4.5 (-1.5)- 11.01 
R 13 -4.4 10.7 3.0 (-8.5)- (-0.24) 
Confidence intervals overlap, therefore the mean percentage changes in systolic 
pressure post drug administration are not significantly different 
95% Confidence interval for the difference between the mean percentage changes in 
systolic pressure post drug administration is -2.3 to 20.5 
The difference between the mean percentage changes in systolic pressure post 
drug administration is therefore not significant 
T test for null hypothesis that the mean percentage changes in systolic pressure post 
drug administration are the same 
T= 1.69 P=O.ll DF= 17 
The null hypothesis is proven, thus the mean percentage changes in systolic 













SE Mean 95% CI 
2.5 2.80- 9.85 
2.4 (-6.73)- ( -0.07) 
Confidence intervals DO NOT overlap, therefore the mean percentage changes 
in systolic pressure post drug administration are significantly different 
95% Confidence interval for the difference between the mean percentage changes in 
systolic pressure post drug administration is -17.0 to -2.5 
The difference between the mean percentage changes in systolic pressure post 
drug administration IS THEREFORE significant 
T test for null hypothesis that the mean percentage changes in systolic pressure post 
drug administration are the same 
P=O.Oll DF= 22 
H 
The ALTERNATIVE hypothesis is proven, thus the mean percentage changes in 
systolic pressure post dru2 administration are si2nificantly different 
CHAPTER 4 -THE TRIAL- RESULTS APPENDIX TO PAGE 20 
CONCLUSION: 
Analysis of variance tables suggest that there is a statistically significant fall. at 
p = 0.05. in systolic blood pressure. all age groups. post remifentanil 
administration when compared to control and this is consistent amongst all age 
groups. 
T tests. 95% confidence intervals of the mean. 95% confidence intervals for the 
difference between the means and box and whisker charts confirms this finding 
in older children and all ages together but show no significant differences. at 
p=0.05, in neonate. infant and x-premie groups. 
The mean percentage systolic blood pressure change after control was + 5.8 ( 
sd=11.8) and after remifentanil-2.1 (sd= 14.2), when all ages are considered. 
I 
CHAPTER 4 -THE TRIAL- RESULTS APPENDIX TO PAGE 20 
Mean percentage change of mean arterial pressure post drug administration. in mm 
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x-t:rem necnte infCilt dder all 
Basic statistics 
Rows contain the number, mean and standard deviation of maximum percentage 
change in systolic blood pressure post drug administration in control (S) or 
remifentanil (R) 
Columns contain the age categories: neonate, infant, > 1 yr old, all ages 
neonate infant > 1 year old all ages 
s number 5 11 13 29 
mean 9.520 6.873 8.762 8.176 
sd 24.648 16.403 13.239 16.098 
' 
R number 8 13 12 33 
mean -8.400 -8.385 -7.092 -7.918 
sd 25.884 14.650 12.165 16.683 
all number 13 24 25 62 
mean -1.508 -1.392 1.152 -0.390 
sd 25.994 17.008 14.860 18.179 
J 
CHAPTER 4 -THE TRIAL- RESULTS APPENDIX TO PAGE 20 K 
Analysis of variance for the percentage change from baseline in mean arterial pressure 
post drug administration, remifentanil versus control: 
Source DF Seq SS Adi SS AdiMS F p 
code 1 3998.1 3681.0 3681.0 12.79 0.001 
agecod 2 30.3 33.3 16.7 0.06 0.944 
code*agecod 2 14.7 14.7 7.4 0.03 0.975 
Error 56 16116. 16116.9 287.8 
Total 61 20160.1 
Thus the anova table shows that percentage change in mean blood pressure from 
baseline post drug administration is statistically different between remifentanil 
and control groups (p=O.OOl). Remifentanil causes a statistically significant 
degree of hypotension (-7.9%) when compared to control (8.2%). This finding is 
consistent amongst the different age groups (p = 0.975). 
CHAPTER 4 -THE TRIAL- RESULTS APPENDIX TO PAGE 20 
Confidence intervals and two sample T test for the percentage change from baseline 



















Confidence intervals overlap, therefore the mean percentage changes in mean 
arterial pressure post drug administration are not significantly different 
95% Confidence interval for the difference between the mean percentage changes in 
mean arterial pressure post drug administration is -42.2 to 20.7 
The difference between the mean percentage changes in mean arterial pressure 
post drug administration is therefore not significant 
T test for null hypothesis that the mean percentage changes in mean arterial pressure 
post drug administration are the same 
T= -0.88 P=0.42 DF= 5 
The null hypothesis is proven, thus the mean percentage changes in mean 













SE Mean 95% CI 
11 (-5.80)- 24.84 
9.2 (-21.12)- 4.32 
Confidence intervals overlap, therefore the mean percentage changes in mean 
arterial pressure post drug administration are not significantly different 
95% Confidence interval for the difference between the mean percentage changes in 
mean arterial pressure post drug administration is -15 to 51.0 
The difference between the mean percentage changes in mean arterial pressure 
post drug administration is therefore not significant 
T test for null hypothesis that the mean percentage changes in mean arterial pressure 
post drug administration are the same 
T= 1.25 P=0.25 DF= 8 
The null hypothesis is proven, thus the mean percentage changes in mean 
arterial pressure post dru2 administration are not si2nificantly different 
L 
CHAPTER 4 -THE TRIAL- RESULTS APPENDIX TO PAGE 20 M 
Infant 
N Mean StDev SEMean 95%CI 
s 11 6.9 16.4 4.9 0.00- 13.75 
R 13 -8.4 14.6 4.1 (-14.03)- (-2.74) 
Confidence intervals DO NOT overlap, therefore the mean percentage changes 
in mean arterial pressure post drug administration are significantly different 
95% Confidence interval for the difference between the mean percentage changes in 
mean arterial pressure post drug administration is 1.9 to 28.6 
The difference between the mean percentage changes in mean arterial pressure 
post drug administration IS THEREFORE significant 
T test for null hypothesis that the mean percentage changes in mean arterial pressure 
post drug administration are the same 
T= 2.38 P=0.027 DF= 20 
The ALTERNATIVE hypothesis is proven, thus the mean percentage changes in 
mean arteriall!_ressure post drug administration are significantly_ different 
Older Child 
N Mean StDev SEMean 95%CI 
s 13 8.8 13.2 3.7 3.66- 13.87 
R 12 -7.1 12.2 3.5 (-11.97)- (-2.21) 
Confidence intervals DO NOT overlap, therefore the mean percentage changes 
in mean arterial pressure post drug administration are significantly different 
95% Confidence interval for the difference between the mean percentage changes in 
mean arterial pressure post drug administration is -26.4 to -5.3 
The difference between the mean percentage changes in mean arterial pressure 
post drug administration IS THEREFORE significant 
T test for null hypothesis that the mean percentage changes in mean arterial pressure 
post drug administration are the same 
T= -3.12 P=0.0050 DF= 22 
The ALTERNATIVE hypothesis is proven, thus the mean percentage changes in 
mean arterial pressure post drue: administration are sie:nificantly different 
CHAPTER 4 -THE TRIAL- RESULTS APPENDIX TO PAGE 20 N 
CONCLUSION: 
Anova tables su~~est that there is a statistically si~nificant fall. at p = 0.05. in the 
mean blood pressure. all a~e ~roups. post remifentanil administration, 
compared to control. 
95% confidence intervals of the means. 95% confidence intervals of the 
difference between the means. T tests and box and whisker charts confirm this 
for infants. older children and all a~es to~ether and show no si~nificant 
differences in neonates and x-premies. at p = 0.05 
The mean percentage change in mean arterial pressure after control was + 8.2 ( 
sd=l6.1) and after remifentanil - 7.9 (sd=l6.7) when all ages are included. 
CHAPTER 4 -THE TRIAL-RESULTS APPENDIX TO PAGE 20 0 
Maximum percentage change of diastolic pressure post drug administration, in mm 

















Rows contain the number, mean and standard deviation of maximum percentage 
change in diastolic blood pressure post drug administration in control (S) or 
remifentanil (R) 
Columns contain the age categories: neonate, infant,> 1yr old, all ages 
neonate infant > 1 year old all ages 
s number 5 11 13 29 
mean 11.040 -1.555 7.262 4.569 
sd 26.305 23.037 17.593 21.133 
R number 8 13 12 33 
mean -12.750 -3.469 -11.833 -8.761 
sd 27.012 22.556 13.605 20.807 
all number 13 24 25 62 
mean -3.600 -2.592 -1.904 -2.526 
sd 28.309 22.296 18.286 21.842 
CHAPTER 4 -THE TRIAL- RESULTS APPENDIX TO PAGE 20 
Analysis of variance for the percentage change in diastolic blood pressure post drug 
administration. remifentanil versus control 
Source DF Seq SS Adi SS AdiMS F p 
code 1 2742.5 3073.1 3073.1 6.87 0.011 
agecod 2 0.2 24.0 12.0 0.03 0.974 
code*agecod 2 1320.5 1320.5 660.2 1.48 0.237 
Error 56 25037.5 25037.5 447.1 
Total 61 29100.7 
Thus the anova table shows that percentage change in diastolic blood pressure 
from baseline post drug administration is statistically different between 
remifentanil and control groups (p=O.Oll). Remifentanil causing statistically 
significant degree ofhypotension(-8.8%) when compared to control (+4.6%). 
This finding is consistent amongst the different age groups (p = 0.237). 
p 
CHAPTER 4 -THE TRIAL- RESULTS APPENDIX TO PAGE 20 
Confidence intervals two sample T tests for the percentage change in diastolic 



















Confidence intervals DO NOT overlap, therefore the mean percentage changes 
in diastolic pressure post drug administration are significantly different. In fact, 
the remifentanil group show a paradoxical increase in diastolic pressure when 
compared to control. The numbers involved are small and this is probably a 
chance finding. 
95% Confidence interval for the difference between the mean percentage changes in 
diastolic pressure post drug administration is -59.2 to -1.7 
Q 
The difference between the mean percentage changes in diastolic pressure post 
drug administration IS THEREFORE significant. Again, the remifentanil group 
show a paradoxical increase, presumably due to the small numbers involved and 
chance. 
T test for null hypothesis that the mean percentage changes in diastolic pressure post 
drug administration are the same 
T= -2.94 P=0.042 DF= 4 
The ALTERNATIVE hypothesis is proven, thus the mean percentage changes in 
diastolic pressure post drug administration are significantly different, again with 



















Confidence intervals overlap, therefore the mean percentage changes in diastolic 
arterial pressure post drug administration are not significantly different 
95% Confidence interval for the difference between the mean percentage changes in 
diastolic pressure post drug administration is -11 to 58.7 
The difference between the mean percentage changes in diastolic pressure post 
drug administration is not significant. 
T test for null hypothesis that the mean percentage changes in mean arterial pressure 
post drug administration are the same 
T= 1.57 P=O.l6 DF= 8 
The null hypothesis is proven, thus the mean percentage changes in diastolic 





















Confidence intervals overlap, therefore the mean percentage changes in diastolic 
arterial pressure post drug administration are not significantly different 
95% Confidence interval for the difference between the mean percentage changes in 
diastolic pressure post drug administration is -17.5 to 21.4 
The difference between the mean percentage changes in diastolic pressure post 
drug administration is not significant. 
T test for null hypothesis that the mean percentage changes in mean arterial pressure 
post drug administration are the same 
T= 0.20 P=0.84 DF= 21 
The null hypothesis is proven, thus the mean percentage changes in diastolic 



















Confidence intervals DO NOT overlap, therefore the mean percentage changes 
in diastolic pressure post drug administration are significantly different. 
95% Confidence interval for the difference between the mean percentage changes in 
diastolic pressure post drug administration is -32.1 to -6.1 
The difference between the mean percentage changes in diastolic pressure post 
drug administration IS THEREFORE significant, with the remifentanil group 
showing a fall in pressure when compared to control 
T test for null hypothesis that the mean percentage changes in mean arterial pressure 
post drug administration are the same 
T= -3.05 P=0.0059 DF= 22 
The ALTERNATIVE hypothesis is proven, thus the mean percentage changes in 
diastolic pressure post drug administration are significantly different, with the 
remifentanil group showing a fall in pressure when compared to the control 
group 
CHAPTER 4 -THE TRIAL- RESULTS APPENDIX TO PAGE 20 s 
CONCLUSION: 
Analysis of variance tables su~~est that there is a statistically si~nificant fall, at p 
= 0.05, in diastolic blood pressure, all a~e ~roups. post remifentanil 
administration. 
95% confidence intervals of the means, 95% confidence interval of the 
difference between the means. T tests and box and whisker charts confirm this 
for older children and all a~es to~ether, but show a non si~nificant fall in 
diastolic pressure post remifentanil in neonates and infants. 
Paradoxically, probably by chance and because of small numbers, all forms of 
statistical analysis showed that diastolic blood pressure rises post remifentanil in 
the x-premie ~roup 
The mean percentage change in diastolic blood pressure after control was + 4.6 ( 
sd=21.1) and after remifentanil - 8.8 (sd=20.8) (all ages included). 
OVERALL CONCLUSION: 
There was a decrease in heart rate post remifentanil administration, compared 
to control, which was statistically si~ificant, by all modes of analysis across the 
a~e ~roups. These findin~s seemed to be even more si~ificant the older the 
child. 
There was a decrease in blood pressure in the remifentanil ~roup, when 
compared to control, when all a~es are combined and for the older child. The 
infant and neonate showed a non-si~nificant decrease in blood pressure post 
remifentanil, when compared to control. Greater numbers are required to make 
further conclusions. 
The clinical si~nificance of these findin~s is probably very limited. Normal peri-
operative chan~es in haemodynamics are usually far ~reater than the chan~es, as 
demonstrated here, that are related to remifentanil administration. Due care. 
however, must be taken, therefore careful pre-loadin~ and timin~ of 
administration to coincide with the stimulus is advised. 
Paradoxically the x-premie ~roup was found to show an increase in pressure 
with remifentanil, probably due to the small numbers involved and because of 
chance. Thus real conclusions cannot be drawn about the response by very 
youn~ babies and this is an area that merits further investi~ation in the future. 
CHAPTER 4 - THE TRIAL 
Stress response to tunnelling 
Heart rate, blood pressure and plasma catecholamine level changes following tunnelling are 
compared in remifentanil and control groups, in each age group, using box and whisker charts, 
analysis of variance, T tests and 95% confidence intervals. The control group generally showed a 
statistically greater increase and duration of increase of all these markers of pain and stress post 
tunnelling, when compared to the remifentanil group, in all age groups. Some of the remifentanil 
patients even showed a reduction from baseline in these parameters. These differences were again 
even greater the older the child. 
21 
Plasma adrenaline levels were also measured but quantities assayed were too low to be of clinical 
significance. It should be noted that noradrenaline is primarily a neurotransmitter and plasma 
concentrations reflect the activation of the sympathetic nervous system in general. Adrenaline is 
primarily a hormone, and the concentrations found in anaesthetized subjects are frequently too low 
for detection using the HPLC method. However, the lower limit of sensitivity of the method is below 
the level at which adrenaline becomes active (around 40pg/ml). It is therefore entirely valid to 
exclude the adrenaline data where the majority of the values are below clinically relevant 
concentrations. 
These 3 "All ages combined" tables show the means, standard errors of the mean and p values 
testing the null hypothesis that the remifentanil and control groups had the same response to 
tunnelling (bold, underlined figures are medians, as they used "censored", non-parametric results): 
Percentage Percentage Systolic Percentage Mean Percentage Diastolic 
Heart Rate Blood Pressure Arterial Pressure Blood Pressure 
change change change change 
Control 26.2 (4.9) 33.9(3.1) 41.4 (3.6) 46.3 (5.2) 
Remif -0.7 (2.4) 1.1 (2.9) -1.4 (3.6) -2.8 (4.7) 
P value p < 0.05 p < 0.05 p < 0.05 p < 0.05 
CHAPTER 4 - THE TRIAL 
Duration of Duration of Systolic Duration of Mean Duration of 
Heart Rate Blood Pressure Pressure change in Diastolic Pressure 
change in change in minutes minutes change in minutes 
: 
minutes 
Control 5 10 8 6 
Remif 0 0 0 0 
P value p < 0.05 p < 0.05 p < 0.05 p < 0.05 
Percentage change from baseline 
in plasma noradrenaline 
Control 32.8 (14.5) 
Remif -8.4 (7.5) 
P value p < 0.05 
On the following pages numbered A to FF are the detailed statistics for each variable in each age 
category 
22 
CHAPTER 4 - THE TRIAL -RESULTS APPENDIX TO PAGE 22 A 
Maximum percentage change in heart rate in response to tunnelling. in 














x-prem neonate infant older all 
OSaline 
ll~entanil 
Rows contain the number, mean and standard deviation of maximum percentage 
change in heart rate post tunnelling in control (S) or remifentanil (R) 
Columns contain the age categories: neonate, infant, > 1 yr old, all ages 
neonate infant > 1 year old all ages 
s number 5 11 13 29 
mean 11.380 19.964 36.992 26.117 
sd 6.918 12.334 26.775 21.840 
R number 8 13 12 33 
mean -2.625 -3.454 3.583 -0.694 
sd 11.727 13.978 14.709 13.734 
all number 13 24 25 62 
mean 2.762 7.279 20.956 11.847 
sd 12.102 17.611 27.346 22.356 
CHAPTER 4 - THE TRIAL -RESULTS APPENDIX TO PAGE 22 
Analysis of variance for the maximum percentage change from baseline in heart rate 
post tunnelling. remifentanil versus control 
Source DF Seq SS Adj SS AdjMS F p 
code 1 11095.6 7682.1 7682.1 26.88 0.000 
agecod 2 2565.8 2754.6 1377.3 4.82 0.012 
code*agecod 2 822.6 822.6 411.3 1.44 0.246 
Error 56 16003.1 16003.1 285.8 
Total 61 30487.1 
Thus the anova table shows that percentage change in heart rate from baseline 
post tunnelling is statistically different between remifentanil and control groups 
(p=O.OOO). The control group shows a statistically significant rise in heart rate 
(+26%) when compared to the remifentanil group (-0.7%). This finding is 
consistent amongst the different age groups (p = 0.246). 
B 
CHAPTER 4 - THE TRIAL -RESULTS APPENDIX TO PAGE 22 c 
Confidence intervals and two sample T tests for the maximum perentage change from 
baseline in heart rate post tunneling. remifentanil versus control 
X-Premie 
N Mean StDev SEMean 95%CI 
s 4 12.98 4.76 2.4 9.6- 16.3 
R 4 ( -16.17) 4.12 2.1 (-19.1)- (-13.2) 
Confidence intervals DO NOT overlap, therefore the mean percentage changes 
in heart rate post tunnelling are significantly different 
95% confidence interval for the difference between the mean percentage changes in 
heart rate post tunnelling is 21.1 to 3 7.2 
The difference between the mean percentage changes in heart rate post 
tunnelling IS THEREFORE significant 
T test for null hypothesis that the mean percentage changes in heart rate post 
tunnelling are the same 
T= 9.27 P=0.0002 DF= 5 
The ALTERNATIVE hypothesis is proven, thus the mean percentage changes in 













SE Mean 95% CI 
3.1 7.1- 15.7 
4.1 (-8.4)- 3.1 
Confidence intervals DO NOT overlap, therefore the mean percentage changes 
in heart rate post tunnelling are significantly different 
95% confidence interval for the difference between the mean percentage changes in 
heart rate post tunnelling is 2.5 to 25.5 
The difference between the mean percentage changes in heart rate post 
tunnelling IS THEREFORE significant 
T test for null hypothesis that the mean percentage changes in heart rate post 
tunnelling are the same 
T= 2.71 P=0.022 DF= 10 
The ALTERNATIVE hypothesis is proven, thus the mean percentage changes in 
heart rate post tunnellin~ are si~nificantly different 
CHAPTER 4 - THE TRIAL-RESULTS APPENDIX TO PAGE 22 D 
Infant 
N Mean StDev SEMean 95%CI 
s 11 20.0 12.3 3.7 14.8- 25.1 
R 13 -3.5 14.0 3.9 (-8.8)- 1.9 
Confidence intervals DO NOT overlap, therefore the mean percentage changes 
in heart rate post tunnelling are significantly different 
95% confidence interval for the difference between the mean percentage changes in 
heart rate post tunnelling is 12.2 to 34.6 
The difference between the mean percentage changes in heart rate post 
tunnelling IS THEREFORE significant 
T test for null hypothesis that the mean percentage changes in heart rate post 
tunnelling are the same 
T= 4.36 P=0.0003 DF= 21 
The ALTERNATIVE hypothesis is proven, thus the mean percentage changes in 













SE Mean 95% CI 
7.4 26.7-47.3 
4.2 (-2.3)- 9.5 
Confidence intervals DO NOT overlap, therefore the mean percentage changes 
in heart rate post tunnelling are significantly different 
95% confidence interval for the difference between the mean percentage changes in 
heart rate post tunnelling is -51.4 to -15.4 
The difference between the mean percentage changes in heart rate post 
tunnelling IS THEREFORE significant 
T test for null hypothesis that the mean percentage changes in heart rate post 
tunnelling are the same 
T= -3.91 P=O.OOIO DF= 18 
The ALTERNATIVE hypothesis is proven, thus the mean percentage changes in 
heart rate post tunnellin2 are significantly different 
CONCLUSION: 
Analysis ofvariance. 95% confidence intervals of the means. 95% confidence 
intervals of the difference between the means. T tests and box and whisker 
charts show a si~nificant rise in heart rate in the control ~roup. post tunnellin~ 
compared to the remifentanil ~roup. at p =0.05. in all a~e ~roups. The differences 
were even ~reater in the infant and the older child. 
Taking all age groups together, the increase in heart rate was + 26.2 (sd=21.8) in 
the control group and -0.7 (sd=13.7) in the remifentanil group. 
CHAPTER 4 - THE TRIAL -RESULTS APPENDIX TO PAGE 22 E 
Maximum percentage change in systolic pressure post tunnelling. in mm 
Hg. & 95% confidence intervals 
c 00 
x-pran raJlal:e infant dder all 
Basic statistics 
Rows contain the number, mean and standard deviation of maximum percentage 
change in systolic blood pressure post tunnelling in control (S) or remifentanil (R) 
Columns contain the age categories: neonate, infant, > 1 yr old, all ages 
neonate infant > 1 year old all ages 
s number 5 11 12 28 
mean 33.720 30.791 36.725 33.857 
sd 7.281 19.848 15.790 16.212 
R number 7 13 12 32 
mean 9.357 -2.623 0.283 1.087 
sd 12.521 15.567 18.110 16.186 
all number 12 24 24 60 
mean 19.508 12.692 18.504 16.380 
sd 16.192 24.227 24.950 23.016 
CHAPTER 4 - THE TRIAL -RESULTS APPENDIX TO PAGE 22 F 
Analysis of variance for maximum percentage change from baseline in systolic blood 
pressure. mm Hg. post tunnelling. remifentanil versus control 
Source DF Seq SS Adi SS AdiMS F p 
code 1 16036.2 13105.6 13105.6 49.32 0.000 
agecod 2 578.3 490.9 245.4 0.92 0.403 
code*agecod 2 289.4 289.4 144.7 0.54 0.583 
Error 54 14350.4 14350.4 265.7 
Total 59 31254.2 
Thus the anova table shows that the maximum percentage change in systolic 
pressure from baseline post tunnelling is statistically different between 
remifentanil and control groups (p=O.OOO). The control group shows a 
statistically significant rise in systolic pressure (+33.9%) when compared to the 
remifentanil group ( + 1.1% ). This finding is consistent amongst the different age 
groups (p = 0.583). 
CHAPTER 4 - THE TRIAL -RESULTS APPENDIX TO PAGE 22 
Confidence intervals and two sample T tests for the maximum percentage change in 















(-5.1)- 11.7 6.0 
Confidence intervals overlap, therefore the mean percentage changes in systolic 
pressure post tunnellin2: are not si2:nificantly different 
95% confidence interval for the difference between the mean percentage changes in 
systolic pressure post tunnelling is -25 to 76.4 
The difference between the mean percentage changes in systolic pressure post 
tunnellin2: is therefore not si2:nificant 
T test for null hypothesis that the mean percentage changes in systolic pressure post 
tunnelling are the same 



















Confidence intervals DO NOT overlap, therefore the mean percentage changes 
in systolic pressure post tunnelling are significantly different 
95% confidence interval for the difference between the mean percentage changes in 
systolic pressure post tunnelling is 95% C.I. is 11.4 to 37.4 
The difference between the mean percentage changes in systolic pressure post 
tunnelling IS THEREFORE significant 
T test for null hypothesis that the mean percentage changes in systolic pressure post 
tunnelling are the same 
T= 4.24 P=0.0022 DF= 9 
G 
The ALTERNATIVE hypothesis is proven, thus the mean percentage changes in 
systolic pressure post tunnellin2: are si2:nificantly different 
CHAPTER 4- THE TRIAL -RESULTS APPENDIX TO PAGE 22 H 
Infant 
N Mean StDev SEMean 95%CI 
s 11 30.8 19.8 6.0 22.5-39.1 
R 13 (-2.6) 15.6 4.3 (-8.6)- 3.4 
Confidence intervals DO NOT overlap, therefore the mean percentage changes 
in systolic pressure post tunnelling are significantly different 
95% confidence interval for the difference between the mean percentage changes in 
systolic pressure post tunnelling is 95% C.I. is 17.9 to 48.9 
The difference between the mean percentage changes in systolic pressure post 
tunnelling IS THEREFORE significant 
T test for null hypothesis that the mean percentage changes in systolic pressure post 
tunnelling are the same 
T= 4.53 P=0.0003 DF= 18 
The ALTERNATIVE hypothesis is proven, thus the mean percentage changes in 



















Confidence intervals DO NOT overlap, therefore the mean percentage changes 
in systolic pressure post tunnelling are significantly different 
95% confidence interval for the difference between the mean percentage changes in 
systolic pressure post tunnelling is -50.9 to -22.0 
The difference between the mean percentage changes in systolic pressure post 
tunnelling IS THEREFORE significant 
T test for null hypothesis that the mean percentage changes in systolic pressure post 
tunnelling are the same 
T= -5.25 P=O.OOOO DF= 21 
The ALTERNATIVE hypothesis is proven, thus the mean percentage changes in 
systolic pressure post tunnelling are significantly different 
CHAPTER 4 - THE TRIAL -RESULTS APPENDIX TO PAGE 22 I 
CONCLUSION: 
Analysis of variance. confidence intervals of the mean, confidence intervals of the 
difference between the means. Ttests and box and whisker charts show a 
si2nificant rise in systolic blood pressure post tunnellin2 in the control group. 
compared to the remifentanil 2roup. at p=O.OS. 
These findin2s are consistent in all a2e 2roups except for the x-premie group. 
whose numbers are small and who showed a non significant rise of systolic 
pressure in the control group. 
Combining all age groups, the control group showed a mean increase of+ 33.9 
(sd=l6.2) and the remifentanil group a mean increase of only+ 1.1 (sd=l6.2). 
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Mean percentage change in mean arterial pressure post tunnelling, in mm 
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Basic statistics 
Rows contain the number, mean and standard deviation of maximum percentage 
change in mean arterial pressure post tunnelling in control (S) or remifentanil (R) 
Columns contain the age categories: neonate, infant, >1yr old, all ages 
neonate infant > 1 year old all ages 
s number 5 11 12 28 
mean 38.300 38.336 45.383 41.350 
sd 20.684 19.675 18.774 19.052 
R number 7 13 12 32 
mean 1.571 -6.677 2.717 -1.350 
sd 15.727 18.277 25.388 20.643 
All number 12 24 24 60 
mean 16.875 13.954 24.050 18.577 
sd 25.459 29.453 30.850 29.180 
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Analysis of variance for maximum percentage change in mean arterial pressure post 
tunnelling. remifentanil versus control 
Source DF Seq SS Adj SS A<li_MS F p 
code 1 27227.8 22849.8 22849.8 55.98 0.000 
agecod 2 833.8 808.1 404.0 0.99 0.378 
code*agecod 2 134.9 134.9 67.5 0.17 0.848 
Error 54 22041.9 22041.9 408.2 
Total 59 50238.4 
K 
Thus the anova table shows that percentage change in mean pressure from 
baseline post tunnelling is statistically different between remifentanil and control 
groups (p=O.OOO). The control group shows a statistically significant rise in mean 
pressure (+41.4%) when compared to the remifentanil group (-1.4%). This 
finding is consistent amongst the different age groups (p = 0.848). 
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Two sample T-test and confidence intervals for the maximum percentage change in 



















Confidence intervals DO NOT overlap, therefore the percentage changes in 
mean pressures post tunnelling are significantly different 
95% confidence interval for the difference between the mean percentage changes in 
mean pressure post tunnelling is 5 to 86.3 
The difference between the mean percentage changes in mean pressure post 
tunnelling IS THEREFORE significant 
T test for null hypothesis that the mean percentage changes in mean pressure post 
tunnelling are the same 
T= 3.59 P=0.037 DF= 3 
The ALTERNATIVE hypothesis is proven, thus the mean percentage changes in 



















Confidence intervals DO NOT overlap, therefore the percentage changes in 
mean pressures post tunnelling are significantly different 
95% confidence interval for the difference between the mean percentage changes in 
mean pressure post tunnelling is 10.7to 62.7 
The difference between the mean percentage changes in mean pressure post 
tunnelling IS THEREFORE significant 
T test for null hypothesis that the mean percentage changes in mean pressure post 
tunnelling are the same 
T= 3.34 P=0.012 DF= 7 
The ALTERNATIVE hypothesis is proven, thus the mean percentage changes in 
mean pressure post tunnellin2 are si2nificantly_ different 
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Infant 
N Mean StDev SEMean 95%CI 
s 11 38.3 19.7 5.9 30.1-46.6 
R 13 -6.7 18.3 5.1 (-13.7)- 0.4 
Confidence intervals DO NOT overlap, therefore the percentage changes in 
mean pressures post tunnelling are significantly different 
95% confidence interval for the difference between the mean percentage changes in 
mean pressure post tunnelling is 28.7 to 61.3 
The difference between the mean percentage changes in mean pressure post 
tunnelling IS THEREFORE significant 
T test for null hypothesis that the mean percentage changes in mean pressure post 
tunnelling are the same 
T= 5.77 P=O.OOOO DF= 20 
The ALTERNATIVE hypothesis is proven, thus the mean percentage changes in 



















Confidence intervals DO NOT overlap, therefore the percentage changes in 
mean pressures post tunnelling are significantly different 
95% confidence interval for the difference between the mean percentage changes in 
mean pressure post tunnelling is -61.7 to -23.6 
The difference between the mean percentage changes in mean pressure post 
tunnelling IS THEREFORE significant 
T test for null hypothesis that the mean percentage changes in mean pressure post 
tunnelling are the same 
T= -4.68 P=O.OOOI DF= 20 
The ALTERNATIVE hypothesis is proven, thus the mean percentage changes in 
mean pressure post tunnelline are sienificantly different 
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CONCLUSION: 
Analysis of variance. 95% confidence intervals of the means. 95% confidence 
intervals of the difference between the means. Ttests and box and whisker charts 
show a significant increase at p=0.05. in the mean blood pressure, after 
tunnelling.in the control group compared to the remifentanil group. in all age 
groups. 
Combining all age groups, the control group showed a mean increase of 
+ 41.4 %(sd=l9.1) and the remifentanil group -1.4% (sd=20.6). 
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Maximum percentage change in diastolic blood pressure post tunnelling, in mm Hg, 
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Basic statistics 
Rows contain the number, mean and standard deviation of maximum percentage 
change in diastolic blood pressure post drug administration in control (S) or 
remifentanil (R) 
Columns contain the age categories: neonate, infant, > 1 yr old, all ages 
neonate infant > 1 year old all ages 
s number 5 11 12 28 
mean 44.420 39.873 52.958 46.293 
sd 31.204 26.253 28.058 27.522 
R number 7 13 12 32 
mean 2.429 -6.446 -2.000 -2.837 
sd 18.400 26.826 31.759 26.721 
all number 12 24 24 60 
mean 19.925 14.783 25.479 20.090 
sd 31.722 35.084 40.581 36.506 
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Analysis of variance for maximum percentage change in diastolic blood pressure post 
tunnelling. rnrn Hg. remifentanil versus control: 
Source DF Seq SS Adj SS AdjMS F p 
code 1 36046.0 30303.0 30303.0 39.71 0.000 
agecod 2 976.8 969.0 484.5 0.63 0.534 
code*agecod 2 399.1 399.1 199.5 0.26 0.771 
Error 54 41208.7 41208.7 763.1 
Total 59 78630.6 
Thus the anova table shows that the percentage change in diastolic pressure 
from baseline post tunnelling is statistically different between remifentanil and 
control groups (p=O.OOO). The control group shows a statistically significant rise 
in diastolic pressure(+46.3%) when compared to the remifentanil group (-2.8%). 
This finding is consistent amongst the different age groups (p = 0.771). 
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Confidence intervals and two sample T tests for the maximum percentage change 

















(-25.9)- (-9.9) 5.7 
Confidence intervals DO NOT overlap, therefore the percentage changes in 
diastolic pressures post tunnelling are significantly different 
95% confidence interval for the difference between the mean percentage changes in 
diastolic pressure post tunnelling is 22 to 93.9 
The difference between the mean percentage changes in diastolic pressure post 
tunnelling IS THEREFORE significant 
T test for null hypothesis that the mean percentage changes in diastolic pressure post 
tunnelling are the same 
T= 4.47 P=O.Oll DF= 4 
Q 
The ALTERNATIVE hypothesis is proven, thus the mean percentage changes in 



















Confidence intervals DO NOT overlap, therefore the percentage changes in 
diastolic pressures post tunnelling are significantly different 
95% confidence interval for the difference between the mean percentage changes in 
diastolic pressure post tunnelling is 2 to 82.1 
The difference between the mean percentage changes in diastolic pressure post 
tunnelling IS THEREFORE significant 
T test for null hypothesis that the mean percentage changes in diastolic pressure post 
tunnelling are the same 
T= 2.69 P=0.043 DF= 5 
The ALTERNATIVE hypothesis is proven, thus the mean percentage changes in 
diastolic pressure post tunnellin~ are si~nificantly different 
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Infant 
N Mean StDev SEMean 95%CI 
s 11 39.9 26.3 7.9 28.9-50.9 
R 13 -6.4 26.8 7.4 (-16.8)- 3.9 
Confidence intervals DO NOT overlap, therefore the percentage changes in 
diastolic pressures post tunnelling are significantly different 
95% confidence interval for the difference between the mean percentage changes in 
diastolic pressure post tunnelling is 23.7 to 68.9 
The difference between the mean percentage changes in diastolic pressure post 
tunnelling IS THEREFORE significant 
T test for null hypothesis that the mean percentage changes in diastolic pressure post 
tunnelling are the same 
T= 4.26 P=0.0003 DF= 21 
The ALTERNATIVE hypothesis is proven, thus the mean percentage changes in 

















42.1 - 63.8 
(-14.7)- 10.7 
Confidence intervals DO NOT overlap, therefore the percentage changes in 
diastolic pressures post tunnelling are significantly different 
95% confidence interval for the difference between the mean percentage changes in 
diastolic pressure post tunnelling is -80.4 to -29.5 
The difference between the mean percentage changes in diastolic pressure post 
tunnelling IS THEREFORE significant 
T -test for null hypothesis that the mean percentage changes in diastolic pressure post 
tunnelling are the same 
T= -4.49 P=0.0002 DF= 21 
The ALTERNATIVE hypothesis is proven, thus the mean percentage changes in 
diastolic pressure post tunnelling are significantly different 
CONCLUSION: 
Analysis of variance, 95% confidence intervals of the means. 95% confidence 
intervals of the difference between the means. Ttests and box and whisker charts 
show a si~:nificant increase, at p=0.05, in the diastolic blood pressure after 
tunnellin~: in the control~:roup compared to the remifentanil~:roup. in all a~:es. 
Combining all age groups, the control group showed a mean increase of+ 46.3 
(sd=27.5) and the remifentanil group a mean "increase" of -2.8 (sd=26.7). 
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Median duration of change in heart rate post tunnelling. in minutes. & 
95% confidence intervals. remifentanil versus control: 
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x-prem neonate infant older all 
Basic statistics for the duration. in minutes. of change in heart rate post tunneling. 
remifentanil versus control 
The first column refers to control (S) or remifentanil ( R) . The second column refers 
to the age group. The third column is the median. The fourth column is the 95% 
confidence intervals. 
TABLES: 
code agecod median +-1.4(se) 
s x-p 4 1.0-# 
s neonate 3 0.9-4.4 
s infant 5 3.6-7.8 
s > 1 yr 7 4.2- 13.4 
s all 5 3-7 
R xp 0 0-# 
R neonate 0 0 - 1.4 
R infant 0 0 - 1.4 
R > 1 yr 0.5 0.3- 1.4 
R all 0 0-1 
This data includes "censored" figures, thus non-parametric tests are applied. 
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COX REGRESSION ANALYSIS FOR "CENSORED" DATA. for the duration of 
change in heart rate post tunnelling. in minutes, remifentanil versus control 
This is similar to an analysis of variance test, but for non-parametric data 
T 
In the first column, second row, "code" refers to effect of remifentanil vs control, in 
the third row "agecode" refers to effect of age category and in the fourth row 
"code\agecode" refers to the consistency of remifentanil vs control results amongst all 
age categories 
Parameter Estimate S.E. t-ratio p-value 
code -0.290 0.142 -2.033 0.042 
agecode 0.379 0.216 1.758 0.079 
code\agecode -0.317 0.194 -1.640 0.101 
Thus the cox regression table shows that there is a significant difference in the 
duration of change in heart rate post tunnelling between remifentanil(O minutes) 
and control groups (5 minutes) (p=0.042) and that this is consistent for all ages 
(p=0.101) 
\ NON PARAMETRIC LOG-RANK ANALYSIS, for the duration of change in heart 
rate post tunnelling, in minutes, remifentanil versus control 
Test Af!e Chi So DF D 
L-Rank x-premie 4.20 1 0.04 
neonate 4.44 1 0.035 
infant 3.27 1 0.071 
> 1 yr old 15.15 1 0.0001 
Wilcox x-p 4.31 1 0.038 
neonate 7.61 1 0.005 
infant 14.17 1 0.0002 
-2LR x-p 7.73 1 0.005 
neonate 3.94 1 0.047 
infant 44.36 1 0.0001 
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CONCLUSION: 
Cox regression tables and log rank tests show that there was a significantly 
increased duration of change in heart rate post tunnelling in the control group. 
compared to the remifentanil group. at p=0.05. in all age groups. 
u 
The 95% confidence interval box and whisker charts confirm this for the infant. 
the older child and all ages together and show a non significant difference in the 
neonate and x-premie. 
All ages included. the control groups increase averaged 5 minutes and the 
remifentanil group had no increase for any duration. 
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Basic statistics for the duration. in minutes. of change in systolic blood pressure post 
tunnelling, remifentanil versus control 
The first column refers to control (S) or remifentanil ( R). The second column refers 
to the age group. The third column is the median. The fourth column is the 95% 
confidence intervals. 
Code Agecod Median 1.4 (se) 
s x-premie 9.5 1.0- 4.5 
s neonate 5 4.3- 8.5 
s infant 9 5.5- 27.2 
s > 1 yr old 36 24.8-52.8 
s all ages 10 7-35 
R x-premie 5 0- 16.0 
R neonate 2 0.6- 2.7 
R infant 0 0- 1.4 
R > 1 yr old 0 0.3-4.2 
R all ages 0 0-2 
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NON PARAMETRIC LOG-RANK ANALYSIS for duration of change in systolic 
pressure. post tunnelling. remifentanil versus control: 
Test Ae:e Chi Sa DF D 
L-Rank x-premie 0.42 1 0.52 
neonate 10.36 1 0.0013 
infant 11.03 1 0.0009 
> 1 yr old 18.39 1 0.0001 
Wilcox neonate 8.84 1 0.003 
infant 12.79 1 0.0003 
> 1 yr old 16.05 1 0.0001 
-2LR neonate 5.31 1 0.021 
infant 22.89 1 0.0001 
> 1 yr old 32.78 1 0.0001 
CONCLUSION: 
Log rank tables and 95% confidence interval box and whisker charts show a 
statistically greater duration of increase in systolic blood pressure in the control 
group compared to the remifentanil group. at p = 0.05. in all age groups except 
x-premies who show a non significant increase. 
All ages included. the control group's increase averaged ten minutes and the 
remifentanil group had no increase of any duration. 
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Median duration of the change in mean arterial pressure post tunnelling. in minutes. & 
95% confidence intervals 
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Basic statistics for the duration. in minutes. of change in mean arterial pressure post 
tunnelling. remifentanil versus control 
The first column refers to control (S) or remifentanil ( R) . The second column refers 
to the age group. The third column is the median. The fourth column is the 95% 
confidence intervals 
Code Agecod Median 1.4 (se) 
s x-premie 6 1.0- 15.0 
s neonate 5 3.6- 6.4 
s infant 8 5.2-9.0 
s > 1 yr old 15 8.7- 18.5 
s all ages 8 6- 11 
R x-premie 0 0-# 
R neonate 1.5 0.5- 1.9 
R infant 0 0.0- 1.4 
R > 1 yr old 0.5 0.5- 1.9 
R all ages 0 0-2 
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NON PARAMETRIC LOG-RANK ANALYSIS. for the duration, in minutes, of 
change in mean arterial pressure post tunnelling, remifentanil versus control 
Test A!!e Chi Sa DF D 
L-Rank x-premie 0.03 1 0.85 
neonate 1.485 1 0.223 
infant 18.03 1 0.0001 
> 1 yr old 16.43 1 0.0001 
Wilcox x-premie 4.865 1 0.027 
neonate 15.77 1 0.0001 
infant 13.5 1 0.0002 
-2LR x-premie 0.913 1 0.339 
neonate 31.06 1 0.0001 
infant 25.14 1 0.0001 
CONCLUSION: 
y 
95% confidence interval box and whisker charts show that there is a 
significantly longer duration of change in mean arterial pressure post tunnelling, 
in the control group. at p=0.05. compared to the remifentanil group. in all age 
groups except x-premies who show a non significant increase in duration. 
Log rank tests show a significant increase in duration in the control group. in 
infants and older children and a non significant increase in neonates and x-
premies. 
All ages included. the control group's increase averaged eight minutes and the 
remifentanil's group had no increase of any duration. 
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Mean duration of change in diastolic pressure post tunnelling. in minutes. 
& 95% confidence intervals: 
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x-prem neonate infant older all 
Basic statistics for the duration. in minutes, of change in diastolic blood pressure post 
tunnelling, remifentanil versus control 
The first column refers to control (S) or remifentanil ( R) . The second column refers 
to the age group. The third column is the median. The fourth column is the 95% 
confidence intervals. 
Code Agecode Median 1.4(se) 
s x-premie 2.5 1.0- 6.0 
s neonate 5 3.6- 6.4 
s infant 4 1.9-5.4 
s > 1 yr old 7 6.3- 12.6 
s all ages 6 4-7 
R x-premie 0 0-# 
R infant 1 0.3- 3.8 
R infant 0 0.0- 0.7 
R > 1 yr old 0 0.0- 0.7 
R all ages 0 0- 1 
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NON PARAMETRIC LOG-RANK ANALYSIS. for the duration, in minutes, of 
change in diastolic blood pressure post tunnelling, remifentanil versus control 
Test A!!e Chi So DF D 
L-Rank x-premie 0.06 1 0.81 
neonate 0.813 1 0.367 
infant 10.69 1 0.0011 
> 1 yr old 22.59 1 0.0001 
Wilcox neonate 3.378 1 0.066 
infant 11.86 1 0.0006 
> 1 yr old 17.658 1 0.0001 
-2LR neonate 1.014 1 0.3141 
infant 18.20 1 0.0001 
> 1 yr old 34.67 1 0.0001 
CONCLUSION: 
95% confidence interval box and whisker charts and log rank tests show a 
significantly greater duration of change in diastolic blood pressure, at p = 0.05. 
in the control group post tunnelling compared to the remifentanil group in all 
age groups except neonates and x-premies who show a non significant increase. 
All ages included. the control groups' increase averaged six minutes and the 
remifentanil groups had no increase of any duration. 
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Basic statistics for the percentage change from baseline in plasma noradrenaline 
levels in response to tunnelling, remifentanil versus control 
Rows contain the number, mean and standard deviation of percentage change from 
baseline in plasma noradrenaline levels post tunnelling in control (S) or remifentanil 
(R) 
Columns contain the age categories: neonate, infant, >1yr old, all ages 
neonate infant > 1 yr old all ages 
s number 5 11 13 29 
mean 23.960 26.645 41.346 32.772 
sd 49.495 68.872 96.748 78.220 
R number 8 13 11 32 
mean -10.825 -32.731 22.000 -8.441 
sd 23.814 36.130 42.219 42.262 
all number 13 24 24 61 
mean 2.554 -5.517 32.479 11.152 
sd 38.179 60.471 75.865 64.874 
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Analysis of variance for percentage change in plasma noradrenaline post tunnelling. 
remifentanil versus control : 
Source DF SeqSS Adj SS AdjMS F p 
code 1 25840 19501 19501 5.18 0.027 
agecod 2 14840 14949 7474 1.99 0.147 
code*agecod 2 4825 4825 2413 0.64 0.531 
Error 55 207014 207014 3764 
Total 60 252519 
Thus the anova table shows that percentage change in plasma noradrenaline 
levels from baseline post tunnelling is statistically greater in the control group 
than in the remifentanil group (p=0.027). The control group shows a statistically 
significant rise in plasma noradrenaline at + 32.7% when compared to the 
remifentanil group at- 8.4%. 
This finding is consistent amongst the different age groups (p = 0.531). 
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Confidence intervals and two sample T tests for the percentage change in plasma 
noradrenaline due to tunneling. remifentanil versus control 
X-Premie 
N Mean StDev SEMean 95%CI 
s 4 35.8 72.4 36 (-14.6)- 86.2 
R 4 (-21.8) 38.4 19 (-48.4)- 4.8 
Confidence intervals overlap, therefore the percentage changes in plasma 
catecholamines post tunnelling are not significantly different 
95% confidence interval for the difference between the mean percentage changes in 
plasma noradrenaline post tunnelling is -56 to 171 
The difference between the mean percentage changes in plasma noradrenaline 
post tunnelling is therefore not significant 
T test for null hypothesis that the mean percentage changes in plasma catecholamines 
post tunnelling are the same 
T= 1.41 P=0.23 DF= 4 
The null hypothesis is proven, thus the mean percentage changes in plasma 













SE Mean 95% CI 
22 (-6.8)- 54.7 
8.4 ( -22.5) - 0.9 
Confidence intervals overlap, therefore the percentage changes in plasma 
catecholamines post tunnelling are not significantly different 
95% confidence interval for the difference between the mean percentage changes in 
plasma noradrenaline post tunnelling is -26 to 95.7 
The difference between the mean percentage changes in plasma noradrenaline 
post tunnelling is therefore not significant 
T test for null hypothesis that the mean percentage changes in plasma catecholamines 
post tunnelling are the same 
T= 1.47 P=0.20 DF= 5 
The null hypothesis is proven, thus the mean percentage changes in plasma 
noradrenaline post tunnellin2 are not si2nificantly different 
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Infant 
N Mean StDev SEMean 95%CI 
s 11 26.6 68.9 21 (-2.2)- 55.5 
R 13 -32.7 36.1 10 (-46.7)- (-18.8) 
Confidence intervals DO NOT overlap, therefore the percentage changes in 
plasma catecholamines post tunnelling are significantly different 
95% confidence interval for the difference between the mean percentage changes in 
plasma noradrenaline post tunnelling is 1 0 to 1 09 
The difference between the mean percentage changes in plasma noradrenaline 
post tunnelling IS THEREFORE significant 
T test for null hypothesis that the mean percentage changes in plasma catecholamines 
post tunnelling are the same 
T= 2.58 P=0.022 DF= 14 
The ALTERNATIVE hypothesis is proven, thus the mean percentage changes in 













SE Mean 95% CI 
27 4.1-78.6 
13 5.1-38.9 
Confidence intervals overlap, therefore the percentage changes in plasma 
catecholamines post tunnelling are not significantly different 
95% confidence interval for the difference between the mean percentage changes in 
plasma noradrenaline post tunnelling is -82 to 44 
The difference between the mean percentage changes in plasma noradrenaline 
post tunnelling is therefore not significant 
T test for null hypothesis that the mean percentage changes in plasma catecholamines 
post tunnelling are the same 
T= -0.65 P=0.52 DF= 16 
The null hypothesis is proven, thus the mean percentage changes in plasma 
noradrenaline post tunnellin2 are not si2nificantly different 
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CONCLUSION: 
Analysis ofvariance suggests a significant rise in plasma noradrenaline levels in 
the control group. compared to the remifentanil group. at p = 0.05. post 
tunnelling, in all age groups. 
95% confidence intervals of the mean. 95% confidence intervals of the difference 
between the means, box and whisker charts and T tests confirm this in the infant 
and all ages together and showed a non significant increase in noradrenaline in 
the x-premie. neonate and older child. 
All ages included, the controls groups' average change in noradrenaline was 
+ 33.8 % and the remifentanil group - 8.4 % 
Plasma adrenaline levels were also measured but guantities assayed were too low 
to be regarded of any significance. i.e. the levels were less than than the High 
Performance Liguid Chromatogram's degree of accuracy. 
OVERALL CONCLUSIONS: 
The control group eenerally showed a statistically greater deeree and duration of 
increase in heart rate and blood pressure and increase in plasma catecholamines 
post tunnelling than the remifentanil group. in all age groups. 
The heart rate changes were greater the older the child, as were the durations of 
all the changes. Analysis of variance. with it's use of pooled data and it's greater 
power. sugeests that the resnonses are the same in all age groups. The individual 
Ttests and confidence intervals were less conclusive in the younger age groups. I 
would suggest that greater numbers in each group would confirm the anova 
findings. It may be. however. that the neonate or young infant respond 
differently to both stress and to remifentanil when compared to the older child. 
Further work is warranted in these age groups. 
Haemodynamic measurements and catecholamine levels increased by 30 - 45% 
in the control group for between 5- 10 minutes. 
The remifentanil showed almost no change from the baseline. In the youn& brain 
with immature autoregulation and compromised cerebral perfusion this is likely 
to be clinically very significant, for the reasons discussed in the chapter one. 
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Recovery profiles 
Recovery profiles are compared in the remifentanil and control groups, in each age group, using box 
and whisker charts, analysis of variance, T tests and 95% confidence intervals. Recovery criteria 
were time from end of surgery, in minutes, until fulfilling the criteria for extubation, the criteria for 
transfer to recovery and the criteria for discharge to the ward. 
There was no delay in recovery in the remifentanil group, in all age groups, when compared to 
control. In fact, times to fitness for transfer to recovery and for discharge to the ward appeared to be 
faster in the remifentanil group. This unexpected finding is discussed below. 
This "All ages combined" table shows the means. standard errors of the mean and p values testing the 
null hypothesis that the remifentanil and control groups had the same recovery profile: 
Time from end of surgery Time from end of surgery Time from end of 
to extubation in minutes till fit for transfer to surgery till fit for 
recovery area in minutes discharge to ward in 
minutes 
Saline 4.4 (0.7) 6.6 (0.7) 15.4 (1.5) 
Remifentanil 3.1 (0.3) 4.7 (0.3) 10.6 (0.9) 
P value p > 0.05 p < 0.05 p < 0.05 
On the following pages numbered A to N are the detailed statistics for each variable in each age 
category 
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Mean duration between "end of surgery" and "fulfilling criteria for 






















Rows contain the number, mean and standard deviation oftime, in minutes, from the 
end of surgery until fullfilling criteria for extubation in control (S) or remifentanil (R) 
Columns contain the age categories: neonate, infant, > 1 yr old, all ages 
neonate infant > 1 yr all ages 
s number 5 11 13 29 
mean 3.6000 4.6364 4.6154 4.4483 
sd 4.2778 3.9312 3.4044 3.6409 
R number 8 13 12 33 
mean 3.0000 3.3077 3.0000 3.1212 
sd 1.0690 1.8879 1.6514 1.5960 
all number 13 24 25 62 
mean 3.2308 3.9167 3.8400 3.7419 
sd 2.6190 3.0060 2.7791 2.8048 
CHAPTER 4- THE TRIAL- RESULTS APPENDIX TO PAGE 23 
Analysis of variance for time to extubation. in minutes. remifentanil versus control: 
Source DF Seq SS Adi SS AdiMS F p 
code 1 27.183 19.232 19.232 2.41 0.126 
agecod 2 2.963 3.727 1.863 0.23 0.793 
code*agecod 2 2.133 2.133 1.067 0.13 0.875 
Error 56 447.592 447.592 7.993 
Total 61 479.871 
Thus the anova table shows that there is no significant difference between the 
time from the end of surgery to extubation in the remifentanil (3.1 minutes) and 
control groups (4.4 minutes) (p=0.126). This finding is consistent amongst the 
different age groups (p = 0.875). 
B 
CHAPTER 4- THE TRIAL- RESULTS APPENDIX TO PAGE 23 
Confidence intervals and two sample tests for the time. in minutes. from the end of 
surgery to extubation. remifentanil versus control 
X-Premie 
N Mean StDev SEMean 95%CI 
s 4 8.25 4.57 2.3 5.0 - 11.5 
R 4 5.50 1.73 0.87 4.3-6.7 
Confidence intervals overlap, therefore the mean times to extubation are not 
significantly different 
95% confidence interval for the difference between the mean times to extubation is 
-5.0 to 10.53 
The difference between the mean times to extubation is therefore not significant 
T test for null hypothesis that the mean times to extubation are the same 
T= 1.12 P=0.34 DF= 3 
The null hypothesis is proven, thus the mean times to extubation are not 
significantly_ different 
Neonate 
N Mean StDev SE Mean 95% CI 
s 5 3.60 4.28 1.9 0.9-6.3 
R 8 3.00 1.07 0.38 2.5- 3.5 
Confidence intervals overlap, therefore the mean times to extubation are not 
significantly different 
95% confidence interval for the difference between the mean times to extubation is 
-4.8 to 6.02 
The difference between the mean times to extubation is therefore not significant 
T test for null hypothesis that the mean times to extubation are the same 
T= 0.31 P=O. 77 DF= 4 
The null hypothesis is proven, thus the mean times to extubation are not 
sh!:nificantly different 
c 
CHAPTER 4- THE TRIAL- RESULTS APPENDIX TO PAGE 23 
Infant 
N Mean StDev SEMean 95%CI 
s 11 4.64 3.93 1.2 3.0- 6.3 
R 13 3.31 1.89 0.52 2.6-4.0 
Confidence intervals overlap, therefore the mean times to extubation are not 
significantly different 
95% confidence interval for the difference between the mean times to extubation is 
-1.5 to 4.13 
The difference between the mean times to extubation is therefore not significant 
T test for null hypothesis that the mean times to extubation are the same 
T= 1.03 P=0.32 DF= 13 
The null hypothesis is proven, thus the mean times to extubation are not 
significantly different 
Older Child 
N Mean StDev SEMean 95%CI 
s 13 4.62 3.40 0.94 3.3-5.9 
R 12 3.00 1.65 0.48 2.3-3.7 
Confidence intervals overlap, therefore the mean times to extubation are not 
significantly different 
95% confidence interval for the difference between the mean times to extubation is 
-3.85 to 0.62 
The difference between the mean times to extubation is therefore not significant 
T test for null hypothesis that the mean times to extubation are the same 
T=-1.53 P=O.l5 DF= 17 
The null hypothesis is proven, thus the mean times to extubation are not 
sienificantly different 
CONCLUSION: 
Analysis of variance. confidence intervals of the means and confidence intervals 
of the difference between the means. Ttests and box and whisker charts show 
that there is no statistical difference, at p= O.OS,in the time from the end of 
surgery to extubation. between remifentanil and control groups. in all age 
groups. 
In fact, there was a non-significant tendency for extubation to be faster in the 
remifentanil group. All ages included, the mean time for the remifentanil group 
was 3.1 min (sd=1.6) and the control group 4.4 (sd=3.6). Possible explanations 
include chance, observer bias or altered depth of anaesthesia due to the 
haemodynamic surge. This is discussed further in the conclusion. 
D 
CHAPTER 4- THE TRIAL- RESULTS APPENDIX TO PAGE 23 
Mean duration of time from "end of surgery" to "fulfilling criteria for discharge to 


















Rows contain the number, mean and standard deviation of time taken, in minutes, to 
fulfil criteria for moving to recovery, in control (S) or remifentanil (R) 
Columns contain the age categories: neonate, infant, > 1 yr old, all ages 
neonate infant > 1 yr old all ages 
s number 5 11 13 29 
mean 6.2000 6.7273 6.6923 6.6207 
sd 3.8341 4.2448 3.7055 3.8024 
R number 8 13 12 33 
mean 5.2500 4.7692 4.3333 4.7273 
sd 1.8323 2.1274 1.5570 1.8418 
all number 13 24 25 62 
mean 5.6154 5.6667 5.5600 5.6129 
sd 2.6627 3.3449 3.0697 3.0534 
E 
CHAPTER 4- THE TRIAL- RESULTS APPENDIX TO PAGE 23 F 
Analysis of variance for time to recovery. in minutes, remifentanil versus control 
Source DF Seq SS Adj SS AdjMS F p 
code 1 55.337 42.477 42.477 4.68 0.035 
agecod 2 1.042 0.769 0.384 0.04 0.959 
code*agecod 2 4.106 4.106 2.053 0.23 0.798 
Error 56 508.225 508.225 9.075 
Total 61 568.710 
The anova table shows that there is a statistically significant difference in the 
time taken to fulfil criteria for moving to recovery between remifentanil and 
control groups (p = 0.035) and that this is consistent amongst the different age 
groups (p = 0.798). Surprisingly, the remifentanil (4.7 minutes) group appeared 
to fulfil the criteria for moving to recovery faster than the control group (6.6 
minutes). Possible explanations for this phenomenon are mentioned below, in the 
conclusion. 
CHAPTER 4- THE TRIAL- RESULTS APPENDIX TO PAGE 23 
Confidence intervals and two sample T tests for the time taken. in minutes, to fulfill 
criteria for moving to recovery, remifentanil versus control 
X-Premie 
N Mean StDev SEMean 95%CI 
s 4 10.00 5.35 2.7 6.2- 13.8 
R 4 7.25 1.89 0.95 5.9- 8.6 
Confidence intervals overlap, therefore the mean times to recovery are not 
significantly different 
95% confidence interval for the difference between the mean times to recovery is 
-6.3 to 11.79 
The difference between the mean times to recovery is therefore not significant 
T test for null hypothesis that the mean times to recovery are the same 
T= 0.97 P=0.40 DF= 3 
The null hypothesis is proven, thus the mean times to recovery are not 
si!!nificantly different 
Neonate 
N Mean StDev SE Mean 95% CI 
s 5 6.20 3.83 1.7 3.8-8.6 
R 8 5.25 1.83 0.65 4.4-6.2 
Confidence intervals· overlap, therefore the mean times to recovery are not 
significantly different 
95% confidence interval for the difference between the mean times to recovery is 
-3.8 to 5.66 
The difference between the mean times to recovery is therefore not significant 
T test for null hypothesis that the mean times to recovery are the same 
T= 0.52 P=0.63 DF= 5 
The null hypothesis is proven, thus the mean times to recovery are not 
sie:nificantly different 
G 
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Infant 
N Mean StDev SEMean 95%CI 
s 11 6.73 4.24 1.3 5.0- 8.5 
R 13 4.77 2.13 0.59 4.0-5.6 
Confidence intervals overlap, therefore the mean times to recovery are not 
significantly different 
95% confidence interval for the difference between the mean times to recovery is 
-1.1 to 4.98 
The difference between the mean times to recovery is therefore not significant 
T test for null hypothesis that the mean times to recovery are the same 
T= 1.39 P=O.l9 DF= 14 
The null hypothesis is proven, thus the mean times to recovery are not 
significantly different 
Older Child 
N Mean StDev SEMean 95%CI 
s 13 6.69 3.71 1.0 5.3 - 8.1 
R 12 4.33 1.56 0.45 3.7-5.0 
Confidence intervals DO NOT overlap, therefore the mean times to recovery are 
significantly different 
95% confidence interval for the difference between the mean times to recovery is 
-4.74 to 0.0 
The difference between the mean times to recovery is therefore not significant 
T test for null hypothesis that the mean times to recovery are the same 
T= -2.10 P=0.052 DF= 16 
The null hypothesis is proven, thus the mean times to recovery are not 
significantly different 
CHAPTER 4- THE TRIAL- RESULTS APPENDIX TO PAGE 23 
CONCLUSION: 
Analysis of variance surprisin2ly su22est that early recovery is actually faster in 
the remifentanil 2roup. in all a2es ( 4. 7 versus 6.6 minutes) 
T tests and 95% confidence intervals of the difference between the means 
however. show no si2nificant difference. in all a2e 2roups. 
I 
The 95% confidence intervals of the means show no difference in the x-premie, 
neonate and infant. but the remifentanil 2roup show a si2nificantly faster 
recovery in the older child and in all a2e 2roups to2ether 
The analysis of variance test has a higher power than the individual T tests due 
to the use of increased numbers and pooled data. 
In these > one year olds, the mean time required for patients in the control group 
to fulfill criteria for transfer to recovery was 6.6 (sd= 3.8) minutes and the 
remifentanil group 4. 7 minutes (sd= 1.8) 
Possible explanations for this surprising phenomenon include observer bias, 
chance or increased depth of anaesthesia in the control group due to the 
increased cardiac output after tunnelling, although this seems very unlikely (see 
discussion section-chapter 4). 
The clinical significance of theses findings are very limited due to the small times 
involved, when compared to the overall duration of surgery (approximately 2 
hours) 
CHAPTER 4- THE TRIAL - RESULTS APPENDIX TO PAGE 23 
Mean duration of time from "end of surgery" to "fulfilling criteria for 
discharge to the ward". in minutes. & 95% confidence intervals. 
remifentanil versus control 
25 
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Rows contain the number, mean and standard deviation of the time, in minutes, from 
the end of surgery intil fulfilling criteria for discharge to the ward in control (S) or 
remifentanil (R) 
Columns contain the age categories: neonate, infant, > 1 yr old, all ages 
neonate infant > lyr old all ages 
s number 5 11 13 29 
mean 11 .600 13.364 18.538 15.379 
sd 3.578 5.446 10.138 8.077 
R number 8 13 12 33 
mean 9.500 10.846 11.167 10.636 
sd 2.777 7.358 4.282 5.361 
all number 13 24 25 62 
mean 10.308 12.000 15.000 12.855 
sd 3.146 6.541 8.597 7.122 
J 
CHAPTER 4- THE TRIAL- RESULTS APPENDIX TO PAGE 23 
Analysis of variance for time required. in minutes to fulfill dischar2e criteria, 
remifentanil versus control: 
Source DF Seq SS Adj SS AdjMS F p 
code 1 347.23 220.10 220.10 4.96 0.030 
agecod 2 167.63 178.18 89.09 2.01 0.144 
code*agecod 2 92.50 92.50 46.25 1.04 0.360 
Error 56 2486.34 2486.34 44.40 
Total 61 3093.69 
K 
The anova table shows that there is a statistically significant difference in the 
time taken to fulfil criteria for discharge to the ward between remifentanil and 
control groups (p = 0.030) and that this is consistent amongst the different age 
groups (p = 0.360). Surprisingly, the remifentanil group (10.6 minutes) appeared 
to fulfil the criteria for discharge faster than the control group (15.4 minutes). 
Possible explanations for this phenomenon are mentioned below, in the 
conclusion. 
CHAPTER 4- THE TRIAL- RESULTS APPENDIX TO PAGE 23 
Confidence intervals and two sample T tests for the time. in minutes. to fulfill 
discharge criteria. remifentanil versus control 
X-Premie 
N Mean StDev SEMean 95% CI 
s 4 15.50 5.92 3.0 11.3- 19.7 
R 4 16.2 10.9 5.4 8.6-23.8 
Confidence intervals overlap, therefore the mean times to discharge are not 
significantly different 
95% confidence interval for the difference between the mean times to discharge is 
-17.9 to 16.4 
The difference between the mean times to discharge is therefore not significant 
T test for null hypothesis that the mean times to discharge are the same 
T= -0.12 P=0.91 DF= 4 
The null hypothesis is proven, thus the mean times to discharge are not 
si2:nificantly different 
Neonate 
N Mean StDev SEMean 95%CI 
s 5 11.60 3.58 1.6 9.4- 13.8 
R 8 9.50 2.78 0.98 8.1- 10.9 
Confidence intervals overlap, therefore the mean times to discharge are not 
significantly different 
95% confidence interval for the difference between the mean times to discharge is 
-2.3 to 6.54 
The difference between the mean times to discharge is therefore not significant 
T test for null hypothesis that the mean times to discharge are the same 
T= 1.12 P=0.30 DF= 7 
The null hypothesis is proven, thus the mean times to discharge are not 
significantly different 
L 
CHAPTER 4- THE TRIAL- RESULTS APPENDIX TO PAGE 23 M 
Infant 
N Mean StDev SE Mean 95%CI 
s 11 13.36 5.45 1.6 11.1-15.7 
R 13 10.85 7.36 2.0 8.0- 13.7 
Confidence intervals overlap, therefore the mean times to discharge are not 
significantly different 
95% confidence interval for the difference between the mean times to discharge is 
-2.9 to 8.0 
The difference between the mean times to discharge is therefore not significant 
T test for null hypothesis that the mean times to discharge are the same 
T= 0.96 P=0.35 DF= 21 
The null hypothesis is proven, thus the mean times to discharge are not 
si~nificantly different 
Older Child 
N Mean StDev SEMean 95%CI 
s 13 18.5 10.1 2.8 14.6- 22.4 
R 12 11.17 4.28 1.2 9.5 - 12.9 
Confidence intervals DO NOT overlap, therefore the mean times to discharge 
are significantly different 
95% confidence interval for the difference between the mean times to discharge is 
-13.9to -0.9 
The difference between the mean times to discharge is therefore significant 
T test for null hypothesis that the mean times to discharge are the same 
T=-2.40 P=0.029 DF= 16 
The ALTERNATIVE hypothesis is proven, thus the mean times to discharge are 
sienificantly different 
CHAPTER 4- THE TRIAL- RESULTS APPENDIX TO PAGE 23 
CONCLUSION: 
Analysis of variance aa:ain surprisina:ly shows a faster time to fulfillina: criteria 
for dischara:e in the remifentanil ~:roup. at p = 0.05. in all aa:e a:roups. when 
compared to control. 
T tests show no difference except in the older child. 
N 
95% confidence intervals of the means. 95% confidence intervals of the 
difference between the means and box and whisker charts show no difference in 
the x-premie. neonate and infant, but a faster time to dischara:e in the older child 
in the remifentanil ~:roup. 
Mean times for all ages combined was 10.6 (sd=5.4) minutes in the remifentanil 
group and 15.4 ( sd=8.1) minutes in the control group. 
Again observer bias, chance or altered depth of anaesthesia appear to be the 
likely explanations. 
OVERALL CONCLUSIONS 
The times involved are all small in relation to the overall duration of sura:ery. 
thus any small differences have limited clinical sia:nificance. The surprisina: 
fin dina: of the slia:htly faster recovery in certain aa:e a:roups receivina: 
remifentanil is discussed in the discussion section. 
There is certainly no delay in recovery caused by the use of remifentanil in this 
clinical scenario. 
CHAPTER 4 - THE TRJAL 24 
Respiratory Depression 
Post-operative respiratory depression is compared in the remifentanil and control groups, in each age 
group, using box and whisker charts, analysis of variance, T tests and 95% confidence intervals. 
The respiratory parameters looked at were the maximum percentage change post-operatively of the 
transcutaneous carbon dioxide partial pressure from the pre-operative baseline; the time in minutes 
for the transcutaneous carbon dioxide partial pressure, in kPa, to return to< 6.0 kPa post-operatively; 
the time for the transcutaneous carbon dioxide to return to < 5.3 kPa post-operatively; the time for 
carbon dioxide partial pressure to become steady; the amount of time, in minutes, that additional 
oxygen is required to keep the oxygen saturation above 95%; the maximum percentage change from 
pre-operative baseline of respiratory rate post-operatively. 
This "All ages combined" table shows the means. standard errors of the mean and p values testing the 
null hypothesis that the remifentanil and control groups had the same degree of post-operative 
respiratory depression (bold. underlined figures are medians. as they used censored results): 
Percentage change Time till C02 Time till C02 Time till C02 
m C02, post-op, returns to baseline decreases post -op to decreases post-op 
from pre-operative post-op, in minutes < 6 kPa, in minutes to < 5.3 kPa, in 
baseline minutes 
Control 43 (7.0) 32 7 22 
Remi 43.1 (6.1) 60 4 17 
P value > 0.05 >0.05 > 0.05 > 0.05 
Time till C02 Maximum Time till resp rate Time till room air 
steady post-op, in percentage change returns to baseline, sufficient to keep 
minutes in resp rate post op, post-op, in minutes sats> 95% post op, 
frompre-op in minutes 
baseline 
Control 17 24.3 (7.1) 0.2 (0.2) 15.9 (3.6) 
Remi 17 33.2 (7.3) 0.2 (0.1) 13.6 (2.8) 
P value > 0.05 > 0.05 > 0.05 > 0.05 
On the following pages numbered A to W are the detailed statistics for each variable in each age 
category 
CHAPTER 4-THE TRIAL-RESULTS APPENDIX TO PAGE 24 
Maximum percentage change in transcutaneous carbon dioxide partial 
pressure post operatively, in kPa, & 95% confidence intervals, 
remifentanil versus control 
N 






















x-p-em reonate infant older all 
Rows contain the number of patients, mean and standard deviation of the maximum 
percentage change in transcutaneous carbon dioxide partial pressure post-operatively 
in control (S) or remifentanil (R) 
Columns contain the age categories: neonate, infant,> 1yr old, all ages 
neonate infant > 1 yr old all ages 
s number 5 11 13 29 
mean 39.460 48.064 40.177 43.045 
sd 7.272 49.917 34.132 37.587 
R number 8 13 12 33 
mean 50.875 57.900 21.867 43 .094 
sd 44.610 30.693 23.301 35.333 
all number 13 24 25 62 
mean 46.485 53.392 31.388 43 .071 
sd 34.813 39.999 30.307 36.103 
A 
CHAPTER 4-THE TRIAL- RESULTS APPENDIX TO PAGE 24 B 
Analysis of variance for the maximum percentage change from pre-operative baseline 
in transcutaneous carbon dioxide partial pressure post operatively. remifentanil versus 
control 
Source DF Seq SS Adi SS AdiMS F p 
code 1 0 13 13 0.01 0.919 
agecod 2 6148 5994 2997 2.39 0.101 
code*agecod 2 3042 3042 1521 1.21 0.306 
Error 56 70317 70317 1256 
Total 61 79507 
The anova table concludes that there is no statistical difference between the 
maximum percentage changes in transcutaneous carbon dioxide partial pressure 
post operatively. in remifentanil (43 minutes) and control groups (43 minutes) 
(p = 0.919) and that this is consistent amongst the different age groups (p = 
0.306). 
CHAPTER 4-THE TRIAL- RESULTS APPENDIX TO PAGE 24 c 
Confidence intervals and two sample T tests for the maximum percentage change 
from pre-operative baseline of transcutaneous carbon dioxide partial pressure, in kPa. 

















Confidence intervals overlap, therefore the maximum percentage changes in 
carbon dioxide partial pressure are not significantly different 
95% confidence interval for the difference between maximum percentage changes in 
carbon dioxide partial pressure is -97 to 3 7 
The difference between the maximum percentage changes in carbon dioxide 
partial pressure is therefore not significant 
T test for null hypothesis that the maximum percentage changes in carbon dioxide 
partial pressures are the same 
T= -1.14 P=0.31 DF= 5 
The null hypothesis is proven, thus the maximum percentage changes in carbon 













SE Mean 95% CI 
3.3 34.9 - 44.0 
16 29.0- 72.8 
Confidence intervals overlap, therefore the maximum percentage changes in 
carbon dioxide _l!_artial pressure are not significantly different 
95% confidence interval for the difference between maximum percentage changes in 
carbon dioxide partial pressure is -49.5 to 27 
The difference between the maximum percentage changes in carbon dioxide 
partial pressure is therefore not significant 
T test for null hypothesis that the maximum percentage changes in carbon dioxide 
partial pressures are the same 
T= -0.71 P=0.50 DF= 7 
The null hypothesis is proven, thus the maximum percentage changes in carbon 
dioxide partial pressure are not significantly different 
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Infant 
N Mean StDev SEMean 95%CI 
s 11 48.1 49.9 15 27.1 - 69.0 
R 13 57.9 30.7 8.5 46.1-69.7 
Confidence intervals overlap, therefore the maximum percentage changes in 
carbon dioxide partial pressure are not si2nificantly different 
95% confidence interval for the difference between maximum percentage changes in 
carbon dioxide partial pressure is -4 7 to 26.8 
The difference between the maximum percentage changes in carbon dioxide 
partial pressure is therefore not si2nificant 
T test for null hypothesis that the maximum percentage changes in carbon dioxide 
partial pressures are the same 
T= -0.57 P=0.58 DF= 16 
The null hypothesis is proven, thus the maximum percentage changes in carbon 
dioxide partial pressure are not si2nificantly different 
Older Child 
N Mean StDev SEMean 95 %CI 
s 13 40.2 34.1 9.5 27.0-53.3 
R 12 21.9 23.3 6.7 12.5- 31.2 
Confidence intervals overlap, therefore the maximum percentage changes in 
carbon dioxide partial pressure are not si2nificantly different 
95% confidence interval for the difference between maximum percentage changes in 
carbon dioxide partial pressure is -42.5 to 5.8 
The difference between the maximum percentage changes in carbon dioxide 
partial pressure is therefore not significant 
T test for null hypothesis that the maximum percentage changes in carbon dioxide 
partial pressures are the same 
T= -1.58 P=O.l3 DF= 21 
The null hypothesis is proven, thus the maximum percentage changes in carbon 
dioxide partial pressure are not si2nificantly different 
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CONCLUSION: 
Analysis of variance. T tests. 95% confidence intervals of the means. 95% 
confidence intervals of the difference between the means and box and whisker 
charts show no statistical difference, at p=0.05, between remifentanil and control 
2roups. in the percenta2e increase in transcutaneous carbon dioxide partial 
pressure post-operatively. in all a2e 2roups. 
There is a tendency, as seen in the box and whisker charts, for higher carbon 
dioxide partial pressures to be reached in the x-premie group. This was not 
significant, but if sample numbers were larger, a more conclusive result could be 
achieved. 
All ages together, the remifentanil group percentage change of transcutaneous 
carbon dioxide partial pressure was + 43.1% ( sd=35) and the control + 43.0% 
(sd=37). 
CHAPTER 4-THE TRIAL- RESULTS APPENDIX TO PAGE 24 
Median duration of time until transcutaneous carbon dioxide partial 
pressure falls to within 5 % of pre-op baseline. in minutes. & 95% 
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Basic statistics for the duration of time post-operatively. in minutes. until the 
transcutaneous carbon dioxide partial pressure falls to within 5 % of pre-op baseline. 
remifentanil versus control 
The first column refers to control (S) or remifentanil ( R) . The second column refers 
to the age group. The third column is the median. The fourth column is the 95% 
confidence interval. 
Code Agecod Median 95% cr 
s x-premie 7.5 1 - 35 
s neonate 25 11.7-70 
s infant 35 13.4- 70 
s < 1 yr old 32 18.0-70 
s all ages 32 17-60 
R x-premie 29 3-# 
R neonate 33 11.0- 70 
R infant 47 36.4- 72.2 
R > 1 yr old 60 0-70 
R all ages 60 44-60 
The confidence intervals overlap in each age group overlap, showing no 
statistical difference. 
CHAPTER 4-THE TRIAL- RESULTS APPENDIX TO PAGE 24 G 
NON PARAMETRIC LOG-RANK ANALYSIS for the duration of time post-
operatively until transcutaneous carbon dioxide partial pressure falls to within 5 % of 
pre-op baseline: 
Test A!!e Chi Sa DF D 
L-Rank xp 1.81 1 0.18 
1 0.313 1 0.576 
2 0.548 1 0.459 
3 0.635 1 0.426 
Wilcox 1 0.424 1 0.515 
2 1.09 1 0.296 
3 0.955 1 0.329 
-2LR 1 0.182 1 0.670 
2 0.47 1 0.492 
3 0.428 1 0.513 
Thus in each individual age group, there is no statistical difference, at p = 0.05, 
between the remifentanil and control groups in the time taken for the 
transcutaneous carbon dioxide partial pressure to fall to within 5% of pre-
operative baseline, post-operatively. 
CONCLUSION: 
Loe rank tests. 95% confidence intervals of the medians and box and whisker 
charts show no statistical difference, at p = 0.05. between remifentanil (60 
minutes) and control eroups (32 minutes). in the time taken for transcutaneous 
carbon dioxide partial pressure to return to baseline post operatively. in all aee 
eroups. 
CHAPTER 4-THE TRIAL- RESULTS APPENDIX TO PAGE 24 
Median duration of time post-operatively. in minutes. until the 
transcutaneous carbon dioxide partial pressure decreases to< 6.0 kpa. & 
95% confidence intervals. remifentanil versus control 
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Basic statistics for the duration of time post-operatively. in minutes. until the 
transcutaneous carbon dioxide partial pressure falls to within< 6.0 kPa. remifentanil 
versus control 
The first column refers to control (S) or remifentanil ( R) . The second column refers 
to the age group. The third column is the median. The fourth column is the 95% 
confidence interval 
Code Age cod Median 95% conf. limits 
s x-premie 3.5 0 - 8 
s neonate 6 0 - 25 
s infant 7 0 - 10 
s > 1 yr old 3.5 0 - 13 
s all ages 7 0- 10 
R x-premie 4.5 0- 14 
R neonate 5.5 2 - 13 
R infant 6 0 - 16 
R > 1 yr old 0 0 - 6 
R all ages 4 0-9 
Confidence intervals overlap in each age group, thus there is no statistical 
difference. 
CHAPTER 4-THE TRIAL- RESULTS APPENDIX TO PAGE 24 
Non parametric tests to assess the duration of time post-operatively, in 
minutes, until the transcutaneous carbon dioxide partial pressure falls to 
< 6.0 kPa., remifentanil versus control: 
Test A!!e Chi Sa DF D 
L-Rank x-premie 0.13 1 0.72 
neonate 0.003 1 0.958 
infant 0.059 1 0.808 
> 1 yr old 0.159 1 0.689 
Wilcox neonate 0.005 1 0.942 
infant 0.031 1 0.860 
> 1 yr old 0.865 1 0.352 
-2LR neonate 0.096 1 0.757 
infant 0.069 1 0.793 
> 1 yr old 0.277 1 0.599 
Thus in each individual age group, there is no statistical difference, at p = 0.05, 
between the remifentanil ( 4 minutes) and control groups (7 minutes) in the time 
taken for the transcutaneous carbon dioxide partial pressure to fall to < 6.0 kPa, 
post-operatively. 
CONCLUSION: 
Lo2 rank tests. 95% confidence intervals of the medians and box and whisker 
charts show no statistical difference, at p= 0.05. between remifentanil and 
control 2roups. in the duration of time until the transcutaneous carbon dioxide 
partial pressure falls to < 6.0 kPa post operatively. in all a2e 2roups. 
The control 2roup had a median of seven minutes and the remifentanil 2roup 
four minutes. till carbon dioxide levels fell to < 6.0 kPa 
I 
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Median duration of time post-operatively. in minutes. until the 
transcutaneous carbon dioxide partial pressure falls to< 5.3 kPa. & 95% 
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x-prem neonate infant older all 
Basic statistics for the duration of time post-operatively. in minutes. until the 
transcutaneous carbon dioxide partial pressure falls to< 5.3 kPa. remifentanil versus 
control 
The first column refers to control (S) or remifentanil ( R) . The second column refers 
to the age group. The third column is the median. The fourth column is the 95% 
confidence interval 
Code Agecod Median 95%CI 
s x-premie 7.5 0-35 
s neonate 25 7.5-70 
s infant 8 3.8- 33.9 
s > 1 yr old 22 6.6- 29.0 
s all ages 22 2-32 
R x-premie 29 3-# 
R neonate 17.5 4.4-70.0 
R infant 17 14.9- 35.9 
R > 1 yr old 19.5 5.9-35.2 
R all ages 17 13-29 
Confidence intervals overlap, therefore there is no statistical difference between 
remifentanil and control. 
J 
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Non parametric tests to assess the duration of time post-operatively. in 
minutes, until the transcutaneous carbon dioxide partial pressure falls to 
< 5.3 kPa., remifentanil versus control: 
Test A!!e Chi So DF D 
L-Rank x-premie 1.81 1 0.18 
neonate 0.007 1 0.935 
infant 0.300 1 0.584 
> 1 yr old 0.044 1 0.835 
Wilcox neonate 0.000 1 1.000 
infant 0.626 1 0.429 
> 1 yr old 0.049 1 0.824 
-2LR neonate 0.002 1 0.965 
infant 0.274 1 0.601 
> 1 yr old 0.121 1 0.728 
Thus in each individual age group, there is no statistical difference, at p = 0.05, 
between the remifentanil and control groups in the time taken for the 
transcutaneous carbon dioxide partial pressure to fall to < 5.3 kPa, post-
operatively. 
CONCLUSION: 
Non-parametric tests, 95% confidence intervals of the medians and box and 
whisker charts show no statistical difference. at p= 0.05. between remifentanil 
and control &roups. in the duration of time until transcutaneous carbon dioxide 
partial pressures fall to < 5.3 kPa post operatively. in all a&e &roups. Overall the 
control &roup avera&ed 22 minutes and the remifentanil &roups 17 minutes 
K 
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Median duration of time post-operatively. in minutes. until the 
transcutaneous carbon dioxide partial pressure reaches steady state & 
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Basic statistics for the duration of time post-operatively. in minutes. until the 
transcutaneous carbon dioxide partial pressure reaches a steady state. remifentanil 
versus control 
The first column refers to control (S) or remifentanil ( R). The second column refers 
to the age group. The third column is the median. The fourth column is the 95% 
confidence interval 
Code Agecod Median 95%CI 
s x-premie 32.5 6-# 
s neonate 14 5.6-70 
s infant 8 6.6- 35.3 
s > 1 yr old 22 15 - 36.7 
s all 17 10-33 
R x-premie 23.5 2-38 
R neonate 32 20.8-70 
R infant 17 14.9-30.3 
R > 1 yr old 8 3.8- 41.6 
R all 17 12-36 
Confidence intervals overlap, therefore there is no statistical difference between 
remifentanil and control. 
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Non parametric tests to assess the duration of time post-operatively, in 
minutes, until the transcutaneous carbon dioxide partial pressure reached 
a steady state, remifentanil versus control: 
Test A!!e Chi Sa DF D 
L-Rank x-premie 0.89 1 0.35 
neonate 0.524 1 0.469 
infant 0.659 1 0.417 
> 1 yr old 0.149 1 0.699 
Wilcox neonate 0.975 1 0.323 
infant 0.718 1 0.397 
> 1 yr old 1.868 1 0.172 
-2LR neonate 0.331 1 0.561 
infant 0.614 1 0.433 
> 1 yr old 0.048 1 0.826 
Thus in each individual age group, there is no statistical difference, at p = 0.05, 
between the remifentanil and control groups in the time taken for the 
transcutaneous carbon dioxide partial pressure to reach a steady state, post-
operatively. 
CONCLUSION: 
Non-parametric tests. 95% confidence intervals of the medians and box and 
whisker charts show no statistical difference. at p= 0.05. between remifentanil 
and control groups. in the duration of time until the transcutaneous carbon 
dioxide partial pressure reaches a steady state post operatively. in all age groups. 
The average time for the both the remifentanil and control groups was 17 
minutes. 
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Mean percentage change in the respiratory rate post operatively. when 
compared to pre-op baseline. in breaths per minute. & 95% confidence 
intervals, remifentanil versus control 
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Rows contain the number of patients, mean and standard deviation of the maximum 
percentage change in respiratory rate post-operatively in control (S) or remifentanil 
(R) 
c 1 0 h o umns contam t e age categones: neonate, 1 1 ld 11 ant, > l yr o ., a ages 
neonate infant > 1yr all ages 
s number 5 11 13 29 
mean 2.980 25.182 31.677 24.266 
sd 11.576 39.184 43.270 38.427 
R number 8 13 12 33 
mean 22.763 41.908 30.683 33.185 
sd 25.609 54.648 36.582 42.235 
all number 13 24 25 62 
mean 15.154 34.242 31.200 29.013 
sd 22.969 47.939 39.367 40.419 
N 
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Analysis of variance for the maximum percentage change in respiratory rate post -
operatively. when compared to pre-operative baseline. remifentanil versus control 
Source DF Seq SS Adj SS AdjMS F p 
code 1 1228 1931 1931 1.16 0.287 
agecod 2 3604 3792 1896 1.14 0.329 
code*agecod 2 1318 1318 659 0.39 0.676 
Error 56 93504 93504 1670 
Total 61 99654 
0 
The anova table suggests that there is no statistically significant difference in the 
post-operative changes in respiratory rate between the remifentanil and control 
groups (p = 0.287) and that this is consistent amongst the different age groups (p 
= 0.676). 
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95% Confidence intervals and two sample T tests for the maximum percentage 
changes in respiratory rate post-operatively 
X-Premie 
N Mean StDev SEMean 95%CI 
s 4 25.0 50.0 25 0-60 
R 4 23.12 8.03 4.0 17.5- 28.5 
Confidence intervals overlap, therefore the mean percentage changes in 
respiratory rate are not significantly different 
95% confidence interval for the difference between the mean percentage change in 
respiratory rates is -79 to 82.5 
The difference between the mean percentage changes in respiratory rate is 
therefore not significant 
T test for null hypothesis that the mean changes in respiratory rate are the same 
T= 0.07 P=0.95 DF= 3 
The null hypothesis is proven, thus the mean percentage changes in respiratory 
rate are not si~nificantly different 
Neonate 
N Mean StDev SEMean 95%CI 
s 5 3.0 11.6 5.2 (-4.2)- 10.2 
R 8 22.8 25.6 9.1 10.2- 35.4 
Confidence intervals overlap, therefore the mean percentage changes in 
respiratory rate are not significantly different 
95% confidence interval for the difference between the mean percentage change in 
respiratory rates is -43.0 to 3.5 
The difference between the mean percentage changes in respiratory rate is 
therefore not significant 
T test for null hypothesis that the mean changes in respiratory rate are the same 
T= -1.90 P=0.087 DF= 10 
The null hypothesis is proven, thus the mean percentage changes in respiratory 
rate are not sie:nificantly different 
p 
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Infant 
N Mean StDev SEMean 95%CI 
s 11 25.2 39.2 12 8.8-41.6 
R 13 41.9 54.6 15 20.8- 63.0 
Confidence intervals overlap, therefore the mean percentage changes in 
respiratory rate are not significantly different 
95% confidence interval for the difference between the mean percentage change in 
respiratory rates is -57 to 23 
The difference between the mean percentage changes in respiratory rate is 
therefore not significant 
T test for null hypothesis that the mean changes in respiratory rate are the same 
T= -0.87 P=0.39 DF= 21 
The null hypothesis is proven, thus the mean percentage changes in respiratory 
rate are not sie;nificantly different 
Older Child 
N Mean StDev SEMean 95%CI 
s 13 31.7 43.3 12 15.0- 48.4 
R 12 30.7 36.6 11 16.0- 45.4 
Confidence intervals overlap, therefore the mean percentage changes in 
respiratory rate are not significantly different 
95% confidence interval for the difference between the mean percentage change in 
respiratory rates is -34 to 32 
The difference between the mean percentage changes in respiratory rate is 
therefore not significant 
T test for null hypothesis that the mean changes in respiratory rate are the same 
T= -0.06 P=0.95 DF= 22 
The null hypothesis is proven, thus the mean percentage changes in respiratory 
rate are not sie:nificantly different 
CONCLUSION: 
Analysis of variance. 95% confidence intervals. T tests and box and whisker 
charts show no statistical difference. at p= 0.05. between remifentanil and 
control groups in the maximum percentage change in respiratory rate post 
operatively. in all age groups. 
All ages included, the remifentanil group had a maximum percentage change of 
+33.2 (sd=42.2) and the control group +24.3 (sd=38.4). 
Q 
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Mean time for the respiratozy rate to return to baseline post-operatively. 
in minutes. remifentanil versus control. 
Basic statistics 
R 
Rows contain the number of patients, mean and standard deviation of the time taken 
post-operatively, in minutes, for the respiratory rate to return to pre-operative baseline 
in control (S) or remifentanil (R) 
Columns contain the age categories: neonate, infant, >lyr old, all ages 
neonate infant > 1 yr old all ages 
s number 5 11 13 29 
mean 0.0000 0.4545 0.1538 0.2414 
sd 0.0000 1.5076 0.5547 0.9876 
R number 8 13 12 33 
mean 0.0000 0.4615 0.0000 0.1818 
sd 0.0000 1.1266 0.0000 0.7269 
all number 13 24 25 62 
mean 0.0000 0.4583 0.0800 0.2097 
sd 0.0000 1.2847 0.4000 0.8519 
Analysis of variance for time. in minutes. till post-operative respiratory rate returns to 
baseline. remifentanil versus control 
Source DF Seq SS Adi SS AdiMS F p 
code 1 0.0548 0.0330 0.0330 0.04 0.834 
agecod 2 2.4763 2.4511 1.2256 1.65 0.202 
code*agecod 2 0.0928 0.0928 0.0464 0.06 0.940 
Error 56 41.6503 41.6503 0.7438 
Total 61 44.2742 
The anova table suggests that there is no statistically significant difference in the 
time taken for the respiratory rate to return to baseline between the remifentanil 
and control groups (p = 0.834) and that this is consistent amongst the different 
age groups (p = 0.940). 
CONCLUSION: 
Analysis of variance show no statistical difference. at p= 0.05, in the time taken 
for the respiratory rate to return to baseline post operatively, between 
remifentanil and control groups (p=0.834). 
This was consistent amongst all age groups (p=0.940). 
All ages included, the remifentanil group took 0.2 (sd=0.7) and the control group 
0.2 (sd=l.O) minutes. 
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Mean time required. in minutes. until room air alone is sufficient to 
maintain peripheral oxygen saturation above 95% post operatively & 
95% confidence intervals. remifentanil versus control: 
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Basic statistics 
Rows contain the number of patients, mean and standard deviation of the time 
required post-operatively, until room air alone is sufficient in control (S) or 
remifentanil (R) 
Columns contain the age categories: neonate, infant, > 1 yr old, all ages 
neonate infant > lyr old all a_g_es 
s number 5 11 13 29 
mean 9.800 22.636 12.538 15.897 
sd 8.729 26.834 13.283 19.323 
R number 8 13 12 33 
mean 21.250 15.615 6.333 13.606 
Sd 22.070 16.520 6.485 16.107 
all number 13 24 25 62 
mean 16.846 18.833 9.560 14.677 
sd 18.524 21.639 10.840 17.573 
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Analysis of variance for the time required post-operatively. in minutes. until room air 
alone is sufficient to maintain peripheral oxygen saturation above 95%. remifentanil 
versus control. 
Source DF Seq SS Adj SS AdjMS F p 
code 1 81.0 4.8 4.8 0.02 0.899 
agecod 2 1183.9 1162.8 581.4 1.94 0.153 
code*agecod 2 802.9 802.9 401.4 1.34 0.270 
Error 56 16769.8 16769.8 299.5 
Total 61 18837.5 
The anova table concludes that there is no statistically significant difference in 
the time required until air alone is sufficient to maintain peripheral oxygen 
saturations above 95% between the remifentanil (13.6 minutes) and control 
groups (15.9 minutes) (p = 0.899) and that this is consistent amongst the different 
age groups (p = 0.270). 
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Confidence intervals and two sample tests to assess the time required post-operatively 
until room air alone is sufficient, remifentanil versus control 
X-Premie 
N Mean StDev SEMean 95%CI 
s 4 16.5 19.5 9.8 2.8-30.2 
R 4 40.3 20.2 10 26.3-54.3 
Confidence intervals overlap, therefore the times required for air alone to be 
sufficient are not significantly different 
95% confidence interval for the difference between the times required for air to be 
sufficient is -59.9, to 12 
The difference between the times required for air to be sufficient is therefore not 
si2:nificant 
T test for null hypothesis that the times required for air to be sufficient are the same 
T= -1.69 P=0.15 DF= 5 
The null hypothesis is proven, thus the times required for air to be sufficient are 
not sil!nificantly different 
Neonate 
N Mean StDev SEMean 95%CI 
s 5 9.80 8.73 3.9 4.4- 15.2 
R 8 21.2 22.1 7.8 10.4- 32.1 
Confidence intervals overlap, therefore the times required for air alone to be 
sufficient are not significantly different 
95% confidence interval for the difference between the times required for air to be 
sufficient is -31.2 to 8.3 
The difference between the times required for air to be sufficient is therefore not 
significant 
T test for null hypothesis that the times required for air to be sufficient are the same 
T= -1.31 P=0.22 DF= 9 
The null hypothesis is proven, thus the times required for air to be sufficient are 
not significantly different 
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Infant 
N Mean StDev SEMean 95%CI 
s 11 22.6 26.8 8.1 11.4- 33.9 
R 13 15.6 16.5 4.6 9.3-22.0 
Confidence intervals overlap, therefore the times required for air alone to be 
sufficient are not significantly different 
95% confidence interval for the difference between the times required for air to be 
sufficient is -12.7 to 26.7 
The difference between the times required for air to be sufficient is therefore not 
significant 
T test for null hypothesis that the times required for air to be sufficient are the same 
T= 0.76 P=0.46 DF= 16 
The null hypothesis is proven, thus the times required for air to be sufficient are 
not si~nificantly different 
Older child 
N Mean StDev SEMean 95%CI 
s 13 12.5 13.3 3.7 7.4- 17.7 
R 12 6.33 6.49 1.9 3.7- 8.9 
Confidence intervals overlap, therefore the times required for air alone to be 
sufficient are not significantly different 
95% confidence interval for the difference between the times required for air to be 
sufficient is -14.9 to 2.5 
The difference between the times required for air to be sufficient is therefore not 
significant 
T test for null hypothesis that the times required for air to be sufficient are the same 
T=-1.50 P=0.15 DF= 17 
The null hypothesis is proven, thus the times required for air to be sufficient are 
not significantly_ different 
CONCLUSION: 
Analysis ofvariance, 95% confidence intervals of the means. 95% confidence 
intervals of the difference between the means, T tests and box and whisker 
charts show no statistical difference, at p= 0.05. between remifentanil and 
control ~roups. in the time taken for room air to be sufficient post-operatively to 
maintain peripheral oxy~en saturation > 95%, in all a~e ~roups. 
All ages included, the remifentanil group required 13.6 (sd=16.1) and the control 
group 15.9 (sd=19.3) minutes. 
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OVERALL CONCLUSIONS: 
There is some degree of respiratory depression exhibited in patients of all ages 
post-operatively. as assessed by the degree and duration of changes in 
transcutaneous carbon dioxide partial pressures. respiratory rate and oxygen 
requirements. but no difference between the patients receiving remifentanil and 
the control. 
This is consistent amongst all age groups. It does appear that x-premies receiving 
remifentanil may require oxygen for longer than older children, but numbers are 
too small and further work is required in this age group to make definitive 
conclusions. 
This "routine" post-operative respiratory depression is predictable. temporary 
and is usually of very limited clinical significance in both the remifentanil and 
control groups. providing basic standards of monitoring and care are applied in 
the recovery area. 
Pre-operative respiratory parameters are returned to 15 - 60 minutes post-
operatively. 
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Analgesia. Blood Loss. Chest Wall Rigidity: 
Only two patients out of 62 required analgesia in the immediate recovery period. 
Blood loss was minimal in all patients. 
There was no evidence of chest wall rigidity in any patient. 
25 
Thus there is no evidence that remifentanil causes any difference m these parameters, when 
compared to control. 
5. DISCUSSION & CONCLUSIONS 
The aim of the study was to see if remifentanil is an appropriate analgesic to cover the tunnelling 
phase of ventriculoperitoneal shunt insertion in children of all ages, including x-premies and 
neonates. Present day practice is to either give nothing, to briefly increase the inspired isoflurane 
concentration or to give a short acting opioid. 
As has been extensively discussed in the preceding chapters, it is now understood that young children 
experience a heightened response to a wide variety of noxious stimuli, that their metabolic stability is 
harder to maintain, that uncontrolled stress responses can possibly worsen outcome and that good 
analgesia may improve outcome. The dangers of an uncontrolled stress response are of particular 
importance in this scenario due to the risks of intracranial haemorrhage in the face of immature 
cerebral autoregulation. It is thus imperative that we look to providing the best cover for such events. 
As has also been discussed, we know that young children and babies are at greater risk of respiratory 
depression from the use of opioids. This means that attention to kinetic and dynamic factors of agents 
used is of utmost importance. This is particularly true in the neurosurgical patient, where respiratory 
depression and sedation may compromise postoperative recovery and vital signs monitoring. 
Remifentanil is a new agent, still finding its' place in the clinicians' armoury, as a rapidly titratable 
analgesic,, with more work required both in neurosurgical patients and in the paediatric population. 
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In this study, the administration of remifentanil to cover the tunnelling phase of shunt insertion in 
children caused good attenuation of haemodynamic and endocrine markers of stress, no delay in 
recovery and no additional post operative respiratory depression in all age groups, including x-
premies and neonates. 
There was some degree of respiratory depression exhibited in patients of all ages post operatively, 
but no difference between the patients receiving remifentanil and patients receiving control, in all age 
groups. This is probably the normal level of respiratory depression that routinely occurs post-
operatively, due to predictable effects of the volatile agents. There is always a depression of the 
hypoxic and hypercarbic ventilatory drive, due to a. direct effect of the volatile agent on the 
respiratory centre. In addition, lying supine, general anaesthesia, endotracheal intubation and positive 
pressure ventilation all causes temporary changes in other respiratory parameters such as functional 
residual capacity, respiratory rate and tidal volume, gas exchange, dead space and ciliary function. 
These changes are predictable and readily reversible and usually not of concern to an otherwise 
healthy patient. The x-premie group is, of course, at the greatest risk of this and special care is 
required, with the use of respiratory stimulants and more intensive post-operative monitoring. 
In this study, other reasons for respiratory depression were excluded by vigilantly maintaining 
normothermia, by achieving full reversal of neuromuscular blockade using a peripheral nerve 
stimulator and by maintaining an inspired isofl.urane partial pressure of lkPa in all patients, using a 
calibrated agent monitor. The same inspired partial pressure of isoflurane was given to all age groups, 
in spite of the changing minimal alveolar concentration for isoflurane with age. This was felt 
appropriate, because the same concentration was being given to both remifentanil and control groups 
and comparisons were being made within individual age groups. Altering the levels for each age 
group could have confused and complicated the study. There was no rebound respiratory depression 
in either group (defined for the purposes of the study as an increase in transcutaneous C02 partial 
pressure of> 1 kPa from the post operative steady state value). 
There was some evidence of cardiovascular depression; thus attention to correct dosage, to preload 
and to timing of dose to coincide with the noxious stimulus would appear to be prudent. 
There was no evidence of adverse effects, such as muscle rigidity (the patients were all paralysed, of 
course). There was also no difference in postoperative analgesic requirements or intraoperative blood 
loss between the two groups. 
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Thus the agent remifentanil appears to have an appropriate kinetic and dynamic profile to be safe an
d 
effective in this setting, in children of all ages. 
The use of percentage changes of parameters from baseline was used to compare certain the respons
e 
of parameters in the remifentanil and control groups. Although it was not the mandate of this study t
o 
compare one age group with another, this mode of comparison does at least allow some sort of cros
s 
age group comparison. Hard data changes of course are not comparable across age groups due to th
e 
differing baselines of different age groups. 
Why did remifentanil patients recover faster? - Could the increased delivery of isoflurane to the bra
in 
in the control group due to cardiovascular stimulation have caused a significant deepening o
f 
anaesthesia and thus a slower recovery? Was it just chance, or observer bias? Observer bias is alway
s 
a possibility, but the study was specifically designed to minimise this risk. The anaesthesia wa
s 
rigidly standardised, the partia 
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Thus the agent remifentanil appears to have an appropriate kinet
ic and dynamic profile to be safe and 
effective in this setting, in children of all ages. 
The use of percentage changes of parameters from baseline was
 used to compare certain the response 
of parameters in the remifentanil and control groups. Although i
t was not the mandate of this study to 
compare one age group with another, this mode of comparison 
does at least allow some sort of cross 
age group comparison. Hard data changes of course are not com
parable across age groups due to the 
differing baselines of different age groups. 
Why did remifentanil patients recover faster? - Could the increa
sed delivery of isoflurane to the brain 
in the control group due to cardiovascular stimulation have
 caused a significant deepening of 
anaesthesia and thus a slower recovery? Was it just chance, or obse
rver bias? Observer bias is always 
a possibility, but the study was specifically designed to min
imise this risk. The anaesthesia was 
rigidly standardised, the partial pressure of the volatile anaes
thetic controlled against an end-tidal 
monitor, and the anaesthetist blinded as to the agent given 
(saline or remifentanil). However, 
remifentanil produced a consistent bradycardia, and this partiall
y confounded the attempted blinding. 
There is therefore a possibility that subconscious bias may ha
ve contributed to the apparent faster 
wakening in the remifentanil group. 
Thus further work is required, especially in small and unwel
l children, whose physiology is that 
much more brittle, in other surgical areas. 
6. OTHER COMMENTS OR POINTS ARISING FROM 
THE STUDY THAT MERIT 
FURTHER CONSIDERATION 
1. The study looked at children of all ages receiving a shunt. Alt
hough the overall numbers in the 
remifentanil and control group afford good power to the study a
nd credible statistical analysis has 
been made, it is not possible to group neonates and older children t
ogether as they represent disparate 
groups. Thus the individual age groups were looked at to see if c
onclusions could be applied equally 
to different. age groups. The sample sizes for each age group we
re quite small, however, particularly 
in the neonate and x-premie groups. This means that the chances
 of making sound statistically 
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significant conclusions are less good for individual age groups as for conclusio
ns for all children 
overall. When all ages are combined, the numbers are sufficient to reveal very
 obvious and 
significant differences between remifentanil and control groups, with very real
 implications for 
clinical practise. There are strong scientific reasons to suspect that the very yo
ung may react 
differently to older children and it is therefore of import to view each group as
 separate, even if this 
diminishes sample sizes. In spite of the small numbers, trends were evident an
d perhaps further work 
is necessary within each age group, particularly the x-premies and neonates. In
 addition, further work 
could look at a comparison of one age group with another; again, larger numb
ers of patients are 
required. 
2.If tunnelling is prolonged (i.e .. > 3 - 5 minutes) or complicated, then a fur
ther bolus dose of 
remifentanil may be required, due to the short half life of remifentanil. This m
ay be of relevance if an 
inexperienced surgeon is operating, or in older children when longer conduits 
are required. 
3.Remifentanil patients generally had a bimodal haemodynamic response to 
the bolus dose and the 
stimulus - initially a depression, followed by a smaller degree of stimulation. 
This knowledge means 
that timing and dosage of remifentanil may need adapting to the individual cli
nical situation. 
4. What about the ethics of doing such a trial with some patients being provid
ed with no "cover" for 
the tunnelling phase? Most authorities would usually recommend an increase
 the level of isoflurane 
to cover the cardiovascular surge associated with tunnelling. However, severa
l units make no attempt 
to cover this phase, and therefore it was considered ethical to take this cours
e. There was, also, no 
way of standardising an increase in volatile partial pressure in the control 
group and thus it was 
deemed acceptable by the involved parties and the ethics committee to use s
aline only as a control 
group. Perhaps patients receiving higher inspired concentrations throughout
 would have responded 
quite differently in both remifentanil and control groups. Further work may b
e indicated, comparing 
remifentanil or control with differing levels of baseline anaesthesia. This tri
al, however, compared 
responses in patients receiving remifentanil and control only at this partic
ular baseline depth of 
anaesthesia, which was standardized and equal in each group. 
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addendum-raw data 
Heart Rate Changes for Neonates Heart Rate Changes for Children > 1 yr 
Ex-Prem base hr HR post Drg Max HR dur hr base hr HR post Drg Max HR dur hr 
Control 130 136 141 3 Control 69 60 87 7 
104 103 116 2 103 107 119 11 
110 113 133 5 116 112 139 3 
115 120 131 5 104 100 126 5 
142 137 145 0 106 125 119 3 
120.2 121.8 133.2 3.0 98 103 144 16 
15.5 14.7 11.2 2.1 103 100 110 2 
59 69 108 111 
Remifentanil Ex-Prem 118 106 96 0 92 108 114 7 
160 144 146 0 132 139 162 5 
114 117 131 3 61 68 106 129 
113 107 107 0 72 71 107 2 
114 111 126 2 81 94 146 49 
102 106 107 0 92.0 96.6 122.1 26.9 
120 117 114 0 22.2 23.7 20.6 43.3 
110 101 95 0 
118.9 113.6 115.2 0.6 Remifentar 82 78 89 2 
17.5 13.5 17.8 1.2 77 65 66 0 
90 88 110 1 
Heart Rate Changes for Infants 72 70 63 0 
Control Ex-Prem 115 111 127 3 123 117 132 1 
Ex-Prem 106 105 117 33 65 59 61 0 
Ex-Prem 118 121 131 1 122 119 136 5 
Ex-Prem 139 143 167 5 105 97 101 0 
107 109 112 5 93 84 110 4 
107 110 146 6 135 130 129 0 
115 108 159 3 122 116 151 3 
115 113 130 1 69 61 58 0 
122 123 166 5 139 147 161 2 
123 127 138 9 99.5 94.7 105.2 1.4 . ·~ 
129 132 164 35 26.2 28.7 35.7 1.7·· .. ·.~· .. · 
117.82 118.359636 141.523 9.6364 
10.078 11.9328885 20.0275 12.266 ., 
Remifentanil Ex-Prem 124 103 100 0 
Ex-Prem 122 106 102 0 
Ex-Prem 117 113 105 0 
151 131 127 0 
115 103 109 0 
128 118 114 0 
141 129 132 0 
135 130 147 2 
123 129 135 35 
115 113 150 15 
130 126 123 0 
88 82 78 0 
124.1 115.3 118.5 4.3 
15.7 15.0 21.1 10.6 
addendum-raw data 
Mean Arterial Pressure Changes for Neonates Mean Arterial Pressure Changes for Children >1 yr 
Ex-Prem base map MAP post DG Max MAP dur map Ex-Prem base map MAP post DG Max MAP dur map 
Control 47 51 56 3 Control 65 88 100 11 
57 61 74 6 93 90 97 0 
49 35 84 5 90 92 91 32 
39 50 50 4 56 54 82 6 
38 51 55 7 65 77 80 6 
46.0 49.9 64.1 5.0 46 52 73 39 
7.8 9.0 14.4 1.6 71 74 111 34 
70 86 105 20 
Remifentanil Ex-Prem 43 59 43 55 86 86 120 6 
65 30 72 2 98 92 131 8 
39 34 44 2 70 76 112 15 
49 45 52 1 69 90 116 20 
54 46 56 0 59 64 98 15 
51 49 48 0 72.2 78.3 101.0 16.3 
48 52 56 2 15.4 14.0 16.9 12.2 
51 45 37 0 
50.0 45.0 51.1 7.8 Remifentanil 72 68 79 2 
7.7 9.5 10.8 19.1 81 62 66 0 
58 54 73 1 
Mean Arterial Pressure Changes for Infants 88 70 68 0 
Control Ex-Prem 44 43 51 4 76 67 84 3 
Ex-Prem 38 40 49 8 69 67 55 0 
Ex-Prem 34 43 59 15 103 78 79 0 
Ex-Prem 33 27 42 1 86 83 102 5 
49 59 69 4 66 75 82 7 
47 49 79 9 80 75 63 0 
56 56 72 8 49 54 71 9 
83 81 97 4 60 57 57 0 
64 73 97 35 75 78 103 2 
62 87 93 8 74.1 68.1 75.3 2.2 
65 62 83 3 14.3 9.4 15.0 3.0 
52.3 56.4 72.0 9.0 
15.4 18.2 19.5 9.4 
Remifentanil Ex-Prem 38 39 35 0 
Ex-Prem 35 37 31 0 
Ex-Prem 34 37 31 0 
61 53 60 0 
48 37 36 0 
44 27 26 0 
65 60 51 0 
68 75 61 0 
44 36 53 2 
56 53 65 2 
53 44 45 0 
87 95 104 2 
52.8 49.4 49.9 0.5 
15.7 19.2 21.3 0.9 
